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Today, upwards of 10 million people—approximately 9 500 of whom reside in 
New Zealand—are living with Parkinson’s disease (PD). Yet, the means of 
diagnosing PD remain somewhat similar to those available to James Parkinson in 
1817. Recently, however, there has been an increasing interest in the role of 
biomarkers in PD; these, in turn, are hoped to provide the necessary means by 
which PD can be diagnosed earlier, treated better and—ultimately—altogether 
prevented and/or cured. 
 
Given the multifaceted nature of the aetiology underlying PD, a “multi-system” 
approach to biomarkers is more likely to yield fruitful results. Thus, the 
overarching aim of this study was to explore several biomarkers (within two 
realms—biological and behavioural) that may be used at different time-points as 
the disease progresses. 
 
In the biological markers trials, biofluid samples (i.e., cerebrospinal fluid ‘CSF’ and 
plasma) were obtained from 11 patients with PD. Analyses of these samples did 
not detect any blackcurrant anthocyanins either before or after oral 
supplementation with blackcurrant concentrate for four weeks. Consumption of 
blackcurrant concentrate, however, significantly increased the CSF concentration 
of cyclic glycine-proline. This led to the hypothesis of an indirect mechanism 
underlying the putative benefit of berry-fruit consumption on the risk of 
developing PD—perhaps through modulating the peripheral resistance to insulin-
like growth factor-1 otherwise observed in patients with PD. CSF concentrations of 
the aminoterminal fragment of C-type natriuretic peptide were significantly lower 
in PD patients than the reported range from a group of pre-operative orthopaedic 
patients. Finally, the obtained samples were utilised to characterise the profile of 
exosomes present in the CSF and plasma of PD patients. The three patients with 
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the highest plasma exosome concentrations also had the lowest scores on the 
Montreal Cognitive Assessment.  
 
The behavioural markers study investigated biomarkers in patients with 
established PD—a stage when cognition may become involved. The emphasis was 
to obtain an in-depth evaluation of novel eye movement-performance associations. 
In general, no remarkable differences in eye movement parameters were noted 
among the three study groups (n = 16 per group): PD with normal cognition (PD-
N), PD with mild cognitive impairment (PD-MCI) and matched controls (NC) in 
natural and laboratory-based neuropsychological tasks. This indicates a relatively 
preserved organisation of neuropsychological task performance as evident from 
eye movements among the participants. In addition, some insights into human 
behaviour on several tasks were gained. In the animal naming task, participants 
from all three groups tended to fixate on the animal’s head in order to name it. 
Participants also fixated on the distal ends of lines when attempting the 
Judgement of Line Orientation task. PD-MCI participants were found to make 
significantly more vertical saccades when searching the Where’s Wally?™ Maze 
task in comparison with NC and PD-N participants. On the Symbol Digit 
Modalities Test, PD-MCI participants scored significantly lower than NC and PD-
N participants. Finally, task organisation of the tea-making task was mostly 
consistent among the study participants; PD participants (of both groups) 
executed the task significantly slower than NC participants. 
 
Given the relatively small sample sizes, an exploratory approach was generally 
taken. To gain confidence in the results of individual findings, further research 
ought to be carried out in order to exclude the possibility of sampling variability 
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1.1   Parkinson’s disease 
 
1.1.1  Clinical definition 
 
Parkinson’s disease (PD) is a degenerative disorder that primarily affects the nervous 
system. Whilst the pathophysiology underlying idiopathic PD has long been elusive 
to pinpoint, mounting evidence is implicating neuroinflammation as a central 
precipitating and perpetuating culprit (i.e., Braak’s hypothesis; Barnum & Tansey, 
2012). 
 
In the central nervous system (CNS), this neuroinflammatory process manifests as 
neuronal degeneration particularly involving the dopamine-releasing cells (i.e., 
dopaminergic neurons); and when a patient starts exhibiting symptoms of PD, 50 to 
70% of these dopaminergic cells will have been lost, with a resultant reduction in 
dopamine neurotransmitter stores of about 80% (Fearnley & Lees, 1991). This state of 
‘dopamine deficiency’ is the basis of the motor symptoms experienced by PD 
patients. Non-motor symptoms (e.g., constipation and mood disorders; see review by 
Alamri, 2015 for the latter) are likely the result of degenerative processes extending to 
other non-dopaminergic systems (e.g., cholinergic pathways; Chaudhuri, Healy, & 
Schapira, 2006). 
 
Even though there are a number of diagnostic criteria for PD (e.g., Queen Square 
Brain Bank clinical diagnostic criteria, Hughes, Daniel, Kilford, & Lees, 1992; and the 
Movement Disorders Society clinical diagnostic criteria, Postuma et al., 2015), there 
are essentially three cardinal features of PD: muscular rigidity, resting tremor and 
bradykinesia. Postural instability is also a common feature, but does not present until 
later in the course of the disease, and was hence deemphasised in the clinical criteria 
by Postuma et al (2015). Each of these symptoms varies in its time of onset, severity 
and rate of progression along the course of the disease. Figure 1-1 shows a schema of 
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Muscular rigidity is defined as the resistance that muscles exert to passive movement 
across all ranges (Jankovic, 2008)—this form of rigidity exhibited by PD patients is 
referred to as “lead-pipe” rigidity. When lead-pipe rigidity is combined with 
parkinsonian tremor, it is termed “cogwheel” rigidity. It is sometimes accompanied 
by joint stiffness, joint pain or both, and these symptoms sometimes constitute the 
earliest complaints in PD patients (Riley, Lang, Blair, Birnbaum, & Reid, 1989). 
 
Resting tremor, also called parkinsonian tremor, is characterised by slow (4-6 cycles 
per second), involuntary rhythmic muscle movements that occur at rest, and is nearly 
always more prominent in the distal part of a limb (Jankovic, 2008). However, it can 
also involve the lips, tongue, jaw, chin and trunk, but rarely the head, neck or voice 
(Jankovic, 2008; Lees, Hardy, & Revesz, 2009). It may be described as ‘pill-rolling’ in 
nature, pointing to its resemblance to the voluntary manipulation of small objects or 

















Figure 1-1. Classification of idiopathic Parkinson's disease (PD) according to Leventoglu and Baysal (2008). 
Whilst useful to highlight the clinical heterogeneity of the initial presentation of idiopathic PD, the 
classification remains controversial as most patients possibly eventually converge to an akinetic/rigid-type. 
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pills with fingers (Elble, 2008). It usually starts unilaterally, and is one of the most 
easily identifiable symptoms of PD (Jankovic, 2008). 
 
Bradykinesia refers to the slowness of movements. PD is, by far and away, the most 
common cause of bradykinesia (Jankovic, 2008; Lees et al., 2009). Newly-diagnosed 
PD patients have been shown to have a prolongation of reaction times upon motor-
task testing. This indicates that the slowness is not only related to executing the 
movement, but also to planning it—a feature sometimes referred to as 
“bradyphrenia” (Cooper, Sagar, Tidswell, & Jordan, 1994). In addition, bradykinesia 
was found to be the cardinal feature that best correlates with the extent of dopamine 
deficiency in PD patients. It is, hence, the most characteristic and important of the 
three cardinal features (Lees et al., 2009; Vingerhoets, Schulzer, Calne, & Snow, 1997), 
and the only necessary one—along with at least one of tremor or rigidity—for 
diagnosis (Postuma et al., 2015). 
 
One of the later manifesting symptoms of PD is postural instability which is chiefly 
due to the loss of postural reflexes. Such instability leads to frequent falls, loss of 
confidence and secondary traumatic injuries (Williams, Watt, & Lees, 2006).  
 
1.1.2  Epidemiology 
 
1.1.2.1 General remarks 
 
PD is the second most common neurodegenerative disease in the elderly after 
Alzheimer’s disease (AD; Mehta et al., 2007). Since PD is an age-related disorder, it is 
expected that PD incidence will increase in the future, as there are far more people 
surviving beyond 65 years of age than there ever used to be (Joseph et al., 1999). This 
increase may not be continuous, however, as PD incidence may start to decline in 




Even though PD is often quoted to have a global prevalence rate of 0.1%, this figure 
increases substantially when populations are age-stratified (Tanner, 2003). For 
example, Tanner (2003) estimated that PD affects around 3% of persons over 65 years 
and 4-5% of people over 85 years, while patients under 40 year of age represent only 5 
to 10% of all PD patients. As evident from the literature, prevalence rates can vary 
considerably according to, for example, the diagnostic criteria used in a particular 
study or the methodology of screening. Although the studies published in the 
literature on the epidemiology of PD are aplenty, it was of interest to me to examine 




In the latest of studies looking at the prevalence of PD in Australian populations, 
Mehta et al reported PD prevalence rate to be around 460 per 100 000 persons 49 years 
or older (2007). This rate increased to as high as 820 per 100 000 in persons aged 70 to 
79 years, but declined again to 560 per 100 000 in persons aged 80 year and over. 
Other reported prevalence rates (not age-stratified) varied according to the 
community studied. For example, the estimated prevalence of PD in urban 
Queensland was 145 per 100 000 persons (Hely et al., 1999), meanwhile rural 
Queensland was reported to have an estimated prevalence of 415 per 100 000 persons 
(McCann et al., 1998).  
 
Studies from New Zealand have been less numerous. In 1962, the prevalence of PD 
was examined in Wellington’s residents. This was estimated to be 106 per 100 000 
persons (Pollock & Hornabrook, 1966). Almost 30 years later, a similar cross-sectional 
study of Dunedin’s population was conducted and showed a PD prevalence of 91 per 
100 000 persons aged 55 to 64 years and 476 per 100 000 persons aged 65 to 74 years 
(Caradoc-Davies, Weatherall, Dixon, Caradoc-Davies, & Hantz, 1992). In contrast to 
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the decline in prevalence seen in Australian population aged 80 years or more, the 
prevalence in the Dunedin study kept increasing to reach 1 995 per 100 000 persons 84 
years or older. However, this New Zealand study is more than 25 years old now and 
originates from a single city in New Zealand. 
 
More recent national estimates from New Zealand started appearing in the literature. 
In 2013, the age-standardised prevalence rate of PD was 245 per 100 000 persons in 
New Zealand Europeans (also known as Pākehā), and 104 per 100 000 person in New 
Zealand Māori (Pitcher et al., 2016). In the ageing population, the prevalence of PD 
peaked at 2 200 per 100 000 in persons aged 85-89, gradually decreasing to 640 per 
100 000 in the 100+ age-group (Myall et al., 2016). These latter findings are more or 
less in line with trends observed in Australia (Mehta et al., 2007). 
 
1.1.2.3 Arab World 
 
Arabic-speaking countries, sometimes referred to as the Arab World, stretch over two 
continents (i.e., Asia and Africa); they include countries from Oman in the East to 
Morocco and Mauritania in the West. Arab families tend to be large units with a high 
rate of consanguineous marriage, raising the risk of genetic disorders (Tadmouri et 
al., 2009). With the help of globalisation and oil-discovery, there has been a recent 
improvement in health services in the Arab World (Benamer, de Silva, Siddiqui, & 
Grosset, 2008). This accounts for the expected increase in life-expectancy, invariably 
leading to an increase in the incidence of PD as the population ages. 
 
Only a handful of studies have looked at the prevalence of PD specifically. In a 
Libyan population, PD had a prevalence rate of 285 per 100 000 persons aged more 
than 50 years (Ashok, Radhakrishnan, Sridharan, & Mousa, 1986). Another study 
from Saudi Arabia reported a prevalence rate of 27 per 100 000 persons (al Rajeh et al., 
1993). Compared with Australasian populations, these prevalence rates—especially in 
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Saudi Arabia—are much lower, even after accounting for the differences in national 
age averages and life expectancies (Alamri, MacAskill, Anderson, & Benamer, 2015). 
 
Even within the Arab World, North African Arabs seem to have a much higher 
prevalence rate of PD than those that of other Arab populations (reviewed by Alamri 
et al., 2015). This may be attributable to a relatively large contribution of genetic cases 
of PD (e.g., LRRK2 G2019S mutations) in Arabs of North African origin (Benamer & 
de Silva, 2010). However, the comparability of the results in Arab populations may be 
limited since these studies were conducted two to three decades ago. 
 
 
1.2   Biomarkers in PD 
 
1.2.1  Definitions and characteristics 
 
Various definitions exist in the literature for biomarkers. In medicine, a biomarker 
may refer to an indicator upon which an inference about the person’s health can be 
made. The National Health Institute’s Biomarkers Definitions Working Group (2001) 
defines a biomarker as “a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes or pharmacological 
responses to a therapeutic intervention”. 
 
A biomarker need not necessarily be a direct indicator for a disease process. In other 
words, a biomarker may act as a substitute for an often difficult-to-quantify clinical 
end-point. For example, a general practitioner may monitor the patient’s blood 
pressure to get an estimate of their risk of developing a cerebrovascular accident 
(Hansson et al., 1998). This subset of biomarkers is appropriately termed surrogate 
biomarkers. Whilst not always ideal, they often provide easy and useful proxies for 
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the disease in question, and are based on epidemiological, pathophysiological, 
therapeutic or other scientific evidence. 
 
The ideal biomarker is simple to obtain, validated by rigorous studies and 
inexpensive. In fact, Michell and colleagues (2004) suggested eight characteristics for 
the ideal biomarker for disease “X”: 
 
1. Close (first-degree) association with X without relying on intermediate 
variables, thereby minimising the risk of dissociation. 
2. It must sensitively reflect even small changes in X. 
3. Treatment has no direct effect on the biomarker; it only changes with a true 
change in X. 
4. The biomarker changes linearly (either negatively or positively) in response 
to a change in X. 
5. Measurements are reproducible at a different time or in a different centre. 
6. The biomarker should ideally capture all changes in X so that no 
information is lost. 
7. The optimal clinical biomarker should be cheap, non-invasive and quick to 
measure by untrained staff. 
8. Appropriately thorough validation of the above (depends upon the use of 
the biomarker and implications of error). 
 
Evidently not many biomarkers—and none in the case of PD (see discussion below)—
fulfil all these criteria. Still, available biomarkers in other diseases have proved useful 
for disease prevention, early diagnosis, disease monitoring, therapeutic target 
identification and assessment of drug response. A single biomarker is unlikely to 
provide all pertinent information, and often multiple biomarkers of different types 




1.2.2  Classification of biomarkers 
 
There are many methods by which biomarkers have been classified and typified in 
the literature—even more numerous than there are biomarker definitions. Trying to 
capture all classifications of biomarkers in the literature can be overwhelming. 
However, ordering the different biomarkers into categories and types can the make 
the task more manageable. A classification scheme is suggested below. 
 
At the most basic level, biomarkers pertaining to a particular disease process can be 
categorised according to the disease stage. In asymptomatic persons, biomarkers may 
be pre-pathological (e.g., screening the population at risk), pre-symptomatic (i.e., 
persons with a confirmed disease process who have not yet displayed any symptoms) 
and pre-clinical (i.e., patients whose symptoms are so mild that they do not warrant 
visiting the doctor). 
 
Once patients manifest symptoms, the purpose of biomarkers shifts. They can now be 
utilised to confirm the patient’s diagnosis (i.e., diagnostic biomarkers), monitor 
disease progression (i.e., progress biomarkers), evaluate response to treatment and 
sometimes monitor levels of medication (i.e., monitoring biomarkers). 
 
Finally, especially if the disease is incurable, patients may then be interested in their 
outlook (i.e., prognostic biomarkers). Towards the terminal stages of their illness, 
patients may be offered comfort cares (i.e., ‘palliative’ and ‘end-of-life’ biomarkers 
become applicable). 
 
At a higher echelon, the basic categories of disease biomarkers can be divided into 
several types. In other words, several modalities (e.g., clinical examination, blood 
tests or imaging studies) may be employed as biomarkers for each stage of the 
patient’s journey with the illness. Findings on one type of biomarker (e.g., an imaging 
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study) may differ as the patient progresses from one category of disease (e.g., pre-
pathological) to another (e.g., diagnostic). 
 
Starting at the patient’s bedside, clinical examination manoeuvres are routinely 
elicited by clinicians in an attempt to determine the patient’s disease stage. Pen-and-
paper neuropsychological tests may also be administered. Physiological testing (e.g., 
electromyography) is sometime quintessential to making certain diagnoses and 
monitoring progress or resolution. Biochemical analyses may then be performed by 
obtaining bio logical fluid  ‘biofluid’ samples (e.g., blood or cerebrospinal fluid, ‘CSF’) 
from the patient; they can also be obtained from a larger healthy sample (e.g., genetic 
testing of a family or population screening studies). The patient may also need to 
undergo specialised radiological imaging or functional (e.g., eye movement) 
assessments. Finally, post-mortem examination may also be undertaken to elucidate 
the exact cause of demise or evaluate the presence of co-pathologies (e.g., concomitant 
AD and PD; Hughes, Daniel, Blankson, & Lees, 1993). 
 




There has been an increasing interest in finding biomarkers for PD; this is evident 
from the number of “Parkinson’s disease biomarker” articles indexed by the 
MEDLINE® database over the years (see Figure 1-2). Given the complexity 
underpinning PD’s pathological processes, a useful single biomarker is unlikely to 
encompass the plethora of disease facets. However, the diverse features of PD’s 
aetiological process and manifestations make it particularly suited to have a number 
of biomarkers (of different categories and types) that serve distinct purposes at 





Figure 1-2. Increasing numbers of PD biomarker-related articles, as indexed by MEDLINE®, are appearing in 
the literature. 
 
First, PD may be argued to be sufficiently prevalent in certain populations (e.g., 
patients with REM sleep behaviour disorder; Chahine et al., 2016) to justify screening 
(i.e., pre-pathological biomarkers). The disease has genetic forms as well as familial 
clustering of the idiopathic form, both of which allow for the use of pre-symptomatic 
biomarkers in, for example, twin-siblings of affected patients (Piccini, Burn, Ceravolo, 
Maraganore, & Brooks, 1999). Furthermore, because the neuronal loss in PD extends 
beyond the dopaminergic system, patients almost always develop non-motor 
symptoms, some of which predate the classical motor symptoms of PD (Chaudhuri & 
Naidu, 2008).  This often persuades patients to seek medical attention, at which point 
an astute physician may also elect to use pre-clinical biomarkers to uncover an early 
PD diagnosis. 
 
If the patient eventually displays ‘parkinsonian’ features, the treating doctor, 
especially if not a movement disorders specialist, may be faced with the conundrum 
of trying to confirm if the underlying pathology is indeed due to PD and not another 
cause of parkinsonism (e.g., multiple system atrophy). In such situations, a diagnostic 
biomarker would prove invaluable. Once PD is confirmed, clinical progression (e.g., 
























monitoring biomarkers. Aware of their decline, patients may be interested in their 
prognosis (i.e., end-of-life biomarkers), and what they can be offered if end-stage 
disease develops (e.g., end-of-life biomarkers). Table 1-1 illustrates the multitude of 
examples of biomarkers currently or previously used in PD. 
 
1.2.3.2 Challenges facing PD biomarker research 
 
As with other neurodegenerative disorders, several hurdles face biomarker discovery 
in PD. Such challenges include the general complexity of the human CNS, limited 
access to and availability of tissue for histological diagnosis during the patient’s 
lifetime and the relative lack of validated techniques for disease diagnosis (Dunckley, 
Coon, & Stephan, 2005). Added to these general obstacles are the diagnostic 
uncertainties surrounding PD, including disease heterogeneity and the potential for 
atypical parkinsonian syndromes. 
 
As alluded to earlier, the multiplicity of disease aspects of PD make it difficult for a 
single multi-purpose biomarker to ever exist. This is evident from the current lack of 
such a ‘Holy Grail’ biomarker to date. By the same token, “reductionist”-type 
biomarkers focussing on single aspects of PD molecular neuropathology are unlikely 
to be overly clinically useful in the general schema of disease (Mielke & Maetzler, 
2014). It seems, therefore, that several biomarkers of different types may need to be 
utilised in conjunction. 
 
Taking PD diagnosis as an example, no one single biomarker to date has 
demonstrated perfect sensitivity and specificity; even post-mortem pathological 
examinations can be inconclusive at times (Berg et al., 2013; Lees et al., 2009). Instead, 
a tier-based system of different types of biomarkers (e.g., clinical assessment by a 
specialist, biofluid analysis, genetic testing and/or imaging studies) used in concert is 
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much more likely to yield the much needed diagnostic accuracy (Schlossmacher & 




Table 1-1. Examples of different PD biomarkers most of which had only limited or modest success. 
         Category 
Type 





Family history of 
PD (Barrett, Hac, 
Yan, Harrison, & 
Wooten, 2015) 
Olfactory dysfunction 






Cardinal triad of PD: 
bradykinesia with 
rigidity and/or tremor 
(Postuma et al., 2015)  




N/A Subtle executive 
dysfunction (J. A. 
Cooper, Sagar, Jordan, 




(Buttner et al., 1995) 
Surface EMG (Valls-Sole 
& Valldeoriola, 2002) 
MoCA (Dalrymple-
Alford et al., 2010) 
Biochemical 
tests 
Genetic analyses (Polymeropoulos et al., 
1997) 
Platelet CoQ10 (Gotz et 
al., 2000) 
CSF and serum 8-
hydroxyguanosine (Abe, 
Isobe, Murata, Sato, & 
Tohgi, 2003) 




N/A Dopaminergic deficits 
on PET (Laihinen et al., 
2000) 
Reduced dopamine 
transporter binding on 
[I-123]IPT SPECT 
(Schwarz et al., 2000) 
Diminished putamen 
uptake on 18F-dopa PET 
(Burn, Sawle, & Brooks, 
1994) 
18F-dopa PET (Whone et 
al., 2003) 
Aβ1-42 = amyloid β1-42; CSF = cerebrospinal fluid; CoQ10 = coenzyme Q10; [I-123]IPT = cocaine analogue; MDS-UPDRS = Movement 
Disorders Society-Unified Parkinson’s Disease Rating Scale; MoCA = Montreal cognitive assessment; N/A = not available; PD = 
Parkinson’s disease; PET = positron emission tomography; SPECT = single photon emission computed tomography. 
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1.2.3.3 Progress and monitoring biomarkers 
 
Of particular relevance to my biological markers study were progress and monitoring 
biomarkers. Given the protracted prodrome of PD, significant efforts have 
understandably been put into researching the potential use of biomarkers before the 
PD diagnosis is made (i.e., pre-pathological, pre-symptomatic and pre-clinical). 
Progress and monitoring biomarkers, on the other hand, have not until recently 
enjoyed as much attention (Michell et al., 2004). The importance of such biomarkers, 
however, cannot be underestimated. 
 
First, the effect size of current PD treatments is rather arduous to quantify objectively. 
This stems from two reasons: PD symptoms exhibit modest fluctuations over time 
making it difficult to gauge improvement using clinical assessment alone (Clarke & 
Guttman, 2002); also, most such assessments tend to be subjective. Existing 
quantitative measures, such as the MDS-UPDRS, focus on motor deficits (Goetz et al., 
2007) rather than providing a more holistic picture of the disease status. 
 
Second, even if symptomatic fluctuation was discounted, relief of symptoms does not 
necessarily equate to a halted pathological process. In other words, PD symptoms do 
not make ideal surrogate biomarkers. For example, dopamine agonists, which possess 
proven neuroprotective properties (Nutt, Carter, Lea, & Sexton, 2002), also provide 
symptomatic relief. This symptomatic relief, in turn, confounds assessment of their 
underlying neuroprotective action. A better monitoring biomarker ought to detect 
retarded pathological progression independent of the patient’s symptomatology. 
 
Finally, appropriate progress biomarkers are needed to monitor the gradually 
deteriorating clinical course experienced by most PD patients. Whilst motor 
symptoms worsen over the course of the disease, it is the non-motor symptoms that 
often take the heaviest toll on the patient’s quality of life (Schrag, Jahanshahi, & 
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Quinn, 2000). Cognitive impairment, in particular, places the greatest strain on PD 
patients (see review by Aarsland, Beyer, & Kurz, 2008), their caregivers and the wider 
society (Vossius, Larsen, Janvin, & Aarsland, 2011). In fact, even in non-PD patients, 
fear of dementia has far surpassed that of fear of any other disease (including cancer) 
and death (Benbow & Jolley, 2012). Therefore, there is an important need for a 
suitable progress biomarker that would serve as a surrogate end-point in future 
studies concerning PD-related dementia. 
 
1.2.3.4 Future directions 
 
Much research has gone into obtaining new prospectively-collected data (e.g., the 
Parkinson Progression Marker Initiative; Marek & PPMI Collaborators, 2011), as well 
as examining archived biofluid and tissue samples (e.g., Honolulu Asian Aging 
Study; Abbott et al., 2016). These efforts intend to make large datasets and 
standardised resources publicly available. The next major step, however, is properly 
utilising such data mines. This would manifest as using current bioinformatics and 
technological advances (i.e., “-omics”) to thoroughly evaluate the data, as well as 
making use of integration models which can capture the interplay between 
biomarkers that would have otherwise been hidden (Azuaje, 2011). 
 
 
1.3   Blackcurrant anthocyanin trial 
 




The pathogenesis of neurodegenerative diseases, such as PD, has not been fully 
understood as yet. It appears to be complex and multifactorial; and to encompass 
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both genetic and non-genetic causes. Since sporadic (i.e., non-genetic) cases of PD are 
the majority, this section will examine some of the proposed mechanisms of the 
pathogenesis of PD that have been reviewed in the medical literature. 
 
1.3.1.2 RNA damage, protein misfolding and lipid peroxidation 
 
A growing body of evidence is now indicating that PD perhaps arises from reactive 
oxygen species (ROS)-induced dysfunction of subcellular structures. Shan et al have 
shown that oxidation of ribonucleic acid (RNA) is an incident occurring prior to 
neuronal cell death (2007). This damaged RNA leads to a decline in protein 
expression and is associated with neural deterioration seen in neurodegenerative 
disease, such as AD and PD. Likewise, oxidative damage to RNA can result in 
misfolding of proteins, initiating a cascade of abnormal protein production. In PD, 
this protein is α-synuclein, and has been shown to aggregate to form Lewy bodies—
which were found to be toxic to neurons (Spillantini et al., 1997). Lastly, lipid 
peroxidation was reported to account for some of the neural changes seen in 
neurodegenerative disorders. Lipid peroxidation results from damage to neural cell 
membranes induced by ROS. Cell membranes become more susceptible to ROS-
induced damages as a result of a decrease in fluidity of these membranes due to 
increased dietary lipid consumption as well as aging (Tacconi, Lligona, Salmona, 
Pitsikas, & Algeri, 1991). RNA damage, protein misfolding and lipid peroxidation are 
in part due to ROS and the oxidative stress (OS) experienced by neuronal cells, which 
is the subject of the following section in the chapter. 
 
1.3.1.3 Disruption of cerebral microcirculation 
 
In a study led by Farkas et al, it was found that there was a severe disruption of limbic 
cingulate cortex microvasculature in patients with PD and AD (2000). The cingulate 
gyrus is a very important region of the brain in the study of neurodegenerative 
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disease pathogenesis as it displays characteristic pathological features, such as 
neurofibrillary tangles and Lewy bodies, seen in patients with AD and PD, 
respectively. The authors of the study attributed the microanatomical disruption of 
the vessels (e.g., capillary basement membrane thickening) to an alteration of the 
internal metabolism of the endothelium. This metabolic change was due to the toxic 
influence that ROS had on the production of basement membrane constituents of 
these microvessels. 
 
1.3.1.4 Decreased cerebral perfusion 
 
Another suggested cause in the aetiology of PD is decreased blood flow to certain 
parts of the brain (Kawabata, Tachibana, & Sugita, 1991). Kawabata et al (Kawabata et 
al., 1991) found subjects with PD to have decreased blood flow to frontal and 
temporal cortices, basal ganglia and thalamus when compared with controls. This 
decline in regional blood flow can be caused by disruption of blood vessels as 
described earlier, but no study has systematically examined this relationship. 
 
1.3.1.5 Substantia nigral susceptibility 
 
Susceptibility of the substantia nigra to excessive neuroinflammation and exposure to 
ROS, both leading to neurodegeneration, has been implicated in the pathogenesis of 
PD. One study has shown that the substantia nigra contained four to eight times 
higher the number of microglial cells (i.e., part of the immune system) compared with 
the hippocampus and cerebral cortex (Kim et al., 2000). Activated microglial cells 
secrete defence substances, such as tumour necrosis factor-alpha and superoxide, 
which can be toxic to neurons of the substantia nigra. Hence, the substantia nigra is at 
an added risk of immunologic insults compared with the rest of the brain. This has 
been verified by Liu et al who treated cultures of mesencephalic neuroglia with 
dextrorotatory morphine (i.e., an over-the-counter antitussive drug), and found that it 
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hindered the activation of microglia and thereby protected substantia nigral cells 
(2003). Moreover, exposure to ROS produced during dopamine metabolism in 
dopaminergic cells further increase the vulnerability of the substantia nigra to 




Excitotoxicity refers to a state of neural cell death due to over-excitation of these 
neurons by an excitatory neurotransmitter. Glutamate is the brain’s major excitatory 
neurotransmitter, and its receptors are especially abundant in dopaminergic cells of 
the substantia nigra (Yacoubian & Standaert, 2009). The mechanism by which over-
excitation of neurons results in cell death is not clearly understood. One mechanism 
reported by Rothman suggested that glutamate causes steady depolarisation of 
neurons, which leads to an influx of chloride ions into the neurons (1985). As a result, 
cations and water are attracted by electric and osmotic gradients into the neurons, 
causing cell lysis. Another proposed mechanism connects neural cell death to an 
excessive influx of calcium ions into neurons as a result of glutamate stimulation 
(Choi, 1988). This pathological increase in intracellular calcium concentrations leads 
to many detrimental effects on the cell, including neurofilament proteolysis and 
mitochondrial dysfunction (Gilbert & Newby, 1975). Figure 2-3 illustrates the 




Figure 2-3. The cascade of events leading to neuronal cell death due to glutamate-induced excitotoxicity 
(adapted with permission from Choi, 1988); Ca2+ = calcium; Cl- = chloride; NMDA = N-methyl-D-aspartate; Na+ 
= sodium. 
 
1.3.2  Oxidative stress 
 
1.3.2.1 Background on free radicals 
 
A free radical is any chemical species possessing one or more free electrons. To reach 
a more stable state, free radicals act as electron acceptors from other molecules, and 
are, hence, more reactive compared with the non-radical form of the atom or 

























radicals include superoxide and hydroxyl species. Other related chemical species 
include hydrogen peroxide and peroxynitrite, and—although not free radicals 
themselves—they substantially influence cellular redox state. These molecules are 
collectively known as ROS or as prooxidant species (Simonian & Coyle, 1996). 
 
There are three major sources of ROS generation in neurons: mitochondrial oxidation 
metabolism, enzymatic reactions involving mixed-function oxidation, and 
autoxidation of small molecules. Accumulation of such chemical species can result in 
neural dysfunction or even death (Simonian & Coyle, 1996). However, the body has 
an endogenous mechanism of defence via the antioxidant defence mechanisms. 
Antioxidant defence mechanisms function through removal of oxygen, scavenging of 
ROS or their precursors, inhibition of ROS formation, binding of metal ions needed 
for ROS formation and upregulation of intracellular antioxidant defences (Gilgun-
Sherki et al., 2001). The antioxidant system can be categorised into two groups: 
enzymes, such as superoxide dismutase and glutathione peroxidase, and low 
molecular weight antioxidants, such as glutathione, tocopheroles (i.e., vitamin E) and 
lipoic acid. 
 
1.3.2.2 Oxidative stress 
 
Oxidative stress (OS) is the cytopathological consequence of an imbalance towards 
the prooxidant side in the prooxidant/antioxidant homeostasis (Zhao, 2009). It is the 
result of an increase in ROS production, a decrease in antioxidant defence 
mechanisms or both. The CNS is one of the body systems most exposed to OS (M. A. 
Smith et al., 1998; M. A. Smith et al., 1996). It is particularly vulnerable due to high 
metabolic rate and high rate of oxygen consumption, long exposure to 
neuroinflammation via activated microglia, reduced capacity of neural regeneration 
(i.e., post-mitotic cells), higher contents of polyunsaturated fatty acids, and relatively 
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low levels of endogenous antioxidant defences (Andersen, 2004; Perry, Godin, & 
Hansen, 1982; Tacconi et al., 1991). 
 
Oxidative stress has been implicated as a possible initiating event in the aetiology to 
neurodegenerative diseases. It is not, however, clear whether OS is a cause, an 
epiphenomenon or a consequence of neurodegeneration (Papandreou et al., 2009). 
One hypothesis of a causal relationship—proposed by Jenner and Olanow—takes into 
account a combination of two experimental findings (1996). Firstly, oxidation of the 
compound 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which is known to 
be selectively toxic to dopamine terminals in the striatum, to its metabolites 1-methyl-
4-phenylpyridinuim (MMP+) and 1-methyl-4-phenyl-2,3-dihydropyridinuim (MPDP+) 
has been shown to cause mitochondrial dysfunction, a state of OS and generation of 
ROS in dopaminergic cells (Chiba, Trevor, & Castagnoli, 1984; Johannessen, Adams, 
Schuller, Bacon, & Markey, 1986). Secondly, autoxidation of dopamine has also been 
demonstrated to generate ROS and to oxidatively stress dopaminergic cells of the 
substantia nigra. Although a causal relationship between OS and neurodegenerative 
diseases is thus feasible, the true cascade of events remains uncertain. For example, 
Andersen has recently suggested that OS might only be a part of a ‘cycle’ of insults 
leading to neurodegeneration, rather than a ‘cascade’ of events (2004). Refer to Figure 
2-4 below for an illustration of Andersen’s proposed model of the role of OS in the 
aetiology of neurodegenerative diseases. 
 
1.3.3  Neuroprotection 
 
1.3.3.1 Rationale for using neuroprotective agents in PD 
 
Neuroprotective agents in PD are defined by Yacoubian and Standaert as “therapies 
that slow or prevent further neurodegeneration of neural populations involved in PD, 
both dopaminergic and non-dopaminergic”. Thus, they exclude ‘neurorestorative’ 
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strategies, such as stem-cell transplantation, that aim to replace neuronal cells after 
they have been lost (2009). Because the course of neuronal loss in neurodegenerative 
disorders in general—and in PD specifically—is years-long and slow, it is of clinical 
significance to utilise this time-lag to try to delay or prevent further 
neurodegeneration by the use of neuroprotectants. Slowing the progression of PD has 
always been an unmet medical need for clinicians and patients alike, and is now a 
major focus of research (Kieburtz, 2006). If slowing or halting neurodegeneration 
could be achieved, this would delay the decline in motor symptoms, preserve 
patients’ quality of life, and perhaps avoid the incapacitating complications of 
advanced PD (Suchowersky et al., 2006; Yacoubian & Standaert, 2009). 
 
An ideal neuroprotectant has been described in the medical literature to possess 
certain characteristics. For instance, it should be able to interact with molecules in 
both hydrophilic and lipophilic environments to ensure maximal protection of cells. It 
also has to have minimal cell toxicity, which widens the range of concentration within 
which it can exert neuroprotective effect and improve cell survival. In addition, it 
should preferably be attainable from ‘natural’ sources, such as dietary herbals and 
nutritional supplements (Chao, Yu, Ho, Wang, & Chang, 2008; Sies, 1997). Such 
‘natural’ sources can be better perceived by patients than ‘chemical’ drugs, which can 
increase adherence to taking medications (Jin, Sklar, Min Sen Oh, & Chuen Li, 2008). 
This is pertinent because several studies have shown that PD patients commonly use 
complementary and alternative therapies in addition to their prescribed medications. 
Two studies from the United States (US) reported that 40 to 63% of PD patients use at 
least one nutritional supplement or alternative therapy (Rajendran, Thompson, & 
Reich, 2001; Wolfrath et al., 2006). Another study from the United Kingdom has 
shown that up to 44% of PD patients used complementary therapies (Ferry, Johnson, 
& Wallis, 2002). The most common non-prescribed medications and therapies 
included vitamin supplements, herbs, cod liver oil, massage, acupuncture and 
aromatherapy (Ferry et al., 2002). 
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One of the most important characteristics of a putative neuroprotective agent for PD 
is that it should directly target factors in the pathogenesis of the disease. Since the 
pathogenesis of PD is now thought to be multifactorial (as reviewed in previous 
sections), it would be advantageous to use neuroprotectants that can target multiple 
mechanisms of aetiology at once. Therefore, using Andersen’s model of PD 
pathogenesis (Figure 2-4), it can be deduced that a therapy targeting ROS formation 
can have a multiplicity of benefits. One such class of neuroprotectants is antioxidants. 
 
 
Figure 2-4. Reactive oxygen species appear to be central to the aetiological processes in PD, either by directly 
causing damage (one-way arrow) or inciting a vicious cycle of damage (two-way arrow); ROS = reactive oxygen 
species; SN = substantia nigra (reproduced with permission from Y. Alamri, 2015).  
 
An antioxidant can be defined as any chemical molecule that when present in lower 
concentrations than the substrate to be oxidised, can retard or avert the autoxidation 
or ROS-mediated oxidation of the substrate, resulting in a more stable substrate 
(Halliwell, 1989; Salah et al., 1995). In addition, Salah et al have shown that the more 
hydroxide groups present in a molecule, the greater its antioxidant activity (1995). 
Classification of antioxidant systems has already been alluded to the previous section. 





























Furthermore, they can be synthesised by the cells (e.g., glutathione) or obtained from 
the diet (e.g., polyphenols found in plant-based foods; Sies, 1997). Antioxidants have 
been shown to protect CNS against OS in in vivo and in vitro studies. Although their 
exact mechanism of action is still unclear, a number of mechanisms have been 
proposed including: direct scavenging of ROS and inhibition of neuronal apoptosis 
through inhibition of certain intracellular enzymes (Schroeter, Spencer, Rice-Evans, & 
Williams, 2001). 
 
1.3.3.2 Previous trials of neuroprotective agents in PD patients 
 
Clinical trials using neuroprotective agents in patients with PD have had 
disappointing results. This section aims to highlight some trials of antioxidant agents 
tested as a neuroprotectant and their results. 
 
Coenzyme Q10 
Coenzyme Q10 (CoQ10), also known as ubiquinone, is an electron acceptor for 
mitochondrial complexes I and II/III, and thus acts as an essential cofactor in the 
electron transport chain. CoQ10 has been shown to be a potent antioxidant as it 
slowed the loss of striatal dopaminergic cells in animal studies (Beal, Matthews, 
Tieleman, & Shults, 1998). Trials of its use in human subjects have yielded 
inconsistent data, however. Two large randomised trials have failed to show a 
statistically significant benefit of CoQ10 in patients with PD, and deemed it not 
different to placebo (NINDS Net-PD Investigators, 2007; Storch et al., 2007). 
 
Mitoquinone 
Mitoquinone (MitoQ) is an orally active mimic of CoQ10, but with a substantially 
higher antioxidant capacity. It is the first drug developed of its class. Although it has 
shown encouraging results in in vivo studies, proof of benefit in human subjects with 
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N-Acetylcysteine amide is a novel low molecular weight thiol antioxidant that has 
been developed by Bahat-Stroomza et al (2005). N-Acetylcysteine has been found to 
cross the blood-brain barrier (BBB) in a rat model. Furthermore, N-acetylcysteine 
amide was capable of slowing the rate of dopaminergic cell loss and dopamine level 
decline using three different PD models (Bahat-Stroomza et al., 2005). The efficacy of 
N-acetylcysteine amide has not been demonstrated in humans yet. 
 
Dietary vitamins 
Consumption of foods rich in vitamins, such as vitamin A, C and E, has long been 
associated with a lower incidence of PD, as shown in a number of population-based 
studies (de Rijk et al., 1997; Fahn, 1991; Logroscino et al., 1996). However, in clinical 
trials, dietary vitamin supplementation was shown not to conduct any benefit against 
developing PD. For example, investigators of the Deprenyl and Tocopherol 
Antioxidative Therapy of Parkinsonism (DATATOP) trial came to the conclusion that 
vitamin E was completely ineffective at slowing the decline of PD patients who were 
in the early stages of the disease (Shoulson, 1989). 
 
1.3.3.3 Why have neuroprotective agents failed so far? 
 
As promising as the concept of neuroprotection is, development and clinical use of 
such agents have been slow and of limited success. This stems from many factors 
which can largely be grouped into three categories: limited knowledge, 
methodological challenges in pre-clinical studies and methodological challenges in 





Due to the complexity of PD pathology, and the interplay of several environmental 
and genetic factors associated with its pathogenesis, it is difficult to define PD as a 
single entity with one primary cause. Rather, PD should be viewed as a syndrome 
encompassing multiple disorders with different first presentations and mechanisms 
of aetiology (Leventoglu & Baysal, 2008; Yacoubian & Standaert, 2009). It can be 
difficult to prove definite neuroprotective effects of an agent in a group of patients 
with such a heterogeneous disease. For example, different ‘types’ of PD could be due 
to different combinations of genes, each of which responds differently to a certain 
neuroprotective therapy. Furthermore, it is important to determine at which stage of 
the disease (i.e., early, established or advanced PD) neuroprotective therapies should 
be started. For example, a number of studies have suggested that neuroprotective 
therapies should be used as prophylactics for high-risk groups, such as the elderly. 
This is because neuroprotectants may not, in fact, be able to protect cells that have 
been irreversibly damaged by prolonged exposure to toxic environments (Bahat-
Stroomza et al., 2005; Gilgun-Sherki et al., 2001; Hung & Schwarzschild, 2007). 
Finally, there is insufficient knowledge as to whether antioxidants actually cross the 
human BBB when administered systemically, and this warrants more studies on the 
molecular and cellular transport processes of the brain capillary endothelial system 
(Gilgun-Sherki et al., 2001). 
 
Methodological challenges in pre-clinical studies 
Methodological challenges in the setting of pre-clinical studies can either be due to 
the choice of the neuroprotectant itself, or to the methods used to analyse the 
neuroprotective effects it exerts. Identification of a suitable candidate neuroprotectant 
is very important, as is adequate purity of the sample and the optimal dose to be 
used. Inadequacies in such factors can result in mixed or even negative results 
(Gilgun-Sherki et al., 2001; Hung & Schwarzschild, 2007). Moreover, appropriate 
evaluation of the neuroprotective potential of a candidate agent is essential to 
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produce consistent results. For instance, some studies solely rely on radical 
scavenging tests as a primary indicator of the antioxidant activity of an agent 
(Kähkönen, Heinämäki, Ollilainen, & Heinonen, 2003). While radical scavenging 
potential is an important parameter to consider, there are many other factors, such as 
interaction with metal ions and other antioxidants, that also determine the 
antioxidant activity of an agent, which should also be examined. 
 
Methodological challenges in clinical trials 
One of the most frequent difficulties encountered in clinical studies is how to define 
‘neuroprotection’ in a context where no direct tests are readily available. For example, 
no direct visualisation of neurons in the substantia nigra is possible during the 
patient’s life (Kieburtz, 2006). Therefore, in order to determine the rate of neuronal 
loss as a way of monitoring neuroprotective activity, a surrogate marker needs to be 
employed. Many PD surrogates have been proposed in the medical literature, but 
they are far from optimal. For example, clinical surrogates, such as time delay to the 
requirement for levodopa, have not been fully validated yet (Ravina et al., 2005). 
Similarly, imaging surrogates, such as 18F fluorodopa positron emission tomography, 
were shown to be confounded by the therapeutic effects of the neuroprotective 
intervention (Clarke & Guttman, 2002; Kieburtz, 2006). Finally, since neural 
degeneration of PD occurs slowly and gradually, studies ought to be evaluating the 
patients over a long period of time (Kieburtz, 2006). 
 
1.3.4  Blood-brain barrier 
 
1.3.4.1 Overview of the Brain-barrier system 
 
The brain is one of the most active organs in the body, receiving about 15% of total 
cardiac output and utilising around 20% of the body’s oxygen and glucose (Saladin, 
2010). Despite this large demand of blood, the brain needs to protect itself from 
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potential blood-borne harmful agents, such as antibodies and macrophages. 
Furthermore, it requires a tightly-regulated environment, which is achieved by 
selectively transporting some molecules, but not others, between the blood and the 
brain’s extracellular fluid (ECF). These molecules may either pass in their original 
form, or require some sort of metabolism/modification before transportation (Risau & 
Wolburg, 1990). A barrier system (known as the brain-barrier system ‘BBS’) helps 
achieve these requirements whilst fitting into the microenvironment between the 
brain tissue and blood vessels. 
 
There are potentially two points of entry that need to be protected: the capillaries of 
the choroid plexuses and the capillaries throughout the brain tissue. Still however, 
there remain regions of the brain that are fully exposed to blood. These are close to 
the third and fourth ventricles, and are hence termed circumventricular organs 
(CVOs; Risau & Wolburg, 1990). This access to blood is important for free exchange of 
molecules between brain ECF and blood, and to allow the brain to monitor and 
respond to fluctuations in blood potential of hydrogen (pH), glucose, osmolarity, 
neuroendocrine hormones and other variables. However, CVOs also offer a potential 
route to pathogens, such as human immunodeficiency virus, to enter and invade the 
brain. 
 
The blood-CSF barrier (BCB) protects the brain at the choroid plexuses and is made 
up of ependymal cells joined by complex tight junctions (Saladin, 2010). Ependymal 
cells elsewhere in the brain, however, lack tight junctions, since it is important to 
allow for exchange between CSF and brain ECF (i.e., there is no brain-CSF barrier). 
Tight junctions prevent free passage of molecules between blood and CSF, but a 
number of factors, such as chronic alcohol intake, hypertension and high body 
weight, can cause a disruption of BCB. This leads to a ‘leakage’ of protein into CSF, 
measured as CSF/serum albumin ratio (Kornhuber, Kaiserauer, Kornhuber, & 
Kornhuber, 1987). The disruption of BCB has also been implicated in the pathogenesis 
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of neurodegenerative diseases. This relationship is not fully understood however, as 
Haussermann et al have shown that BCB was actually intact in patients with early PD 
(2001). 
 
The BBB is an endothelial protective layer present in the capillaries coursing the brain 
tissue (Youdim et al., 2003). This endothelial barrier has a number of characteristics 
that make it different from any other endothelial barrier in the body. Firstly, cerebral 
endothelial cells have complex tight junctions that are narrower than other tight 
junctions, and form an ‘unbroken belt’ between the cells, unlike anywhere else in the 
body. This barrier prevents transportation of molecules through the paracellular 
route (Reese & Karnovsky, 1967). Secondly, cerebral endothelial cells have fewer 
pinocytotic vesicles (i.e., a class of vesicles that allows the cell to take up molecules 
from the surrounding milieu) compared with other endothelial cells, and hence limit 
the passage of molecules transcellularly (Reese & Karnovsky, 1967). Finally, BBB cells 
possess certain uptake and efflux transport systems and metabolic enzymes that help 
regulate brain ECF (Youdim et al., 2003). 
 
Two mechanisms have been proposed whereby endothelial cells differentiate to 
become a BBB: predetermined neuroectoderm-derived angioblasts differentiating into 
BBB endothelium, or endothelial cells from outside CNS invading neuroectoderm 
and responding to the neural environment (i.e., astrocyte stimulation) by 
differentiating into BBB (Risau & Wolburg, 1990; Saladin, 2010). The latter proposal 
has garnered more support from published studies including stem-cell 
transplantation experiments (Risau & Wolburg, 1990). Moreover, Qin and Sato have 
found the first appearance of morphologically-distinct endothelial cells in neural 
tissues during BBB development in mouse-embryos to be on embryonic day 10.5 
(1995). However, the timing of BBS formation in humans remains uncertain as it is 
much more difficult to assess BBS function in human embryos (Saunders, 
Dziegielewska, & Mollgard, 1991). 
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1.3.4.2 Mechanisms of crossing the BBB 
 
In order for a therapeutic agent to be able to exert its effects on a targeted tissue or 
organ, it needs to be able to access it. For neuroprotective therapies, for instance, this 
translates into the requirement of crossing from the blood into the brain through the 
BBS. There are a number of mechanisms that various molecules use to cross the BBS, 
the most important of which will be described in this section. Since the blood/brain 
interface is more important in terms of the clinical use of neuroprotectants, only the 
BBB will be considered in this section, although similar principles of molecule 
passage apply equally to the BCB. 
 
Cellular permeability through the BBB 
Normally, only very small quantities of hydrophilic molecules are able to diffuse 
through tight junctions of cerebral endothelial cells (i.e., paracellular pathway). 
Lipophilic molecules, on the other hand, utilise the transcellular pathway—a faster 
and more efficient route for molecular trafficking. Such pathways can be exploited as 
a method of drug delivery across the BBB. For example, addition of a lipophilic group 
or a lipophilic transport vector, such as a nicotinoyl residue, to a drug can enable it 
cross the BBB and get into the brain (Gilgun-Sherki et al., 2001). In addition, since 
essential molecules (e.g., glucose and nucleotides) have specific membrane-bound 
transporters which are present at high concentrations in cerebral endothelial cells, 
drugs whose molecules closely resemble essential molecules may also be transported 
through the same transporters. Finally, macromolecules can occasionally be shuttled 
into the brain via receptor-mediated and adsorptive endocytotic systems; and this can 
be utilised for drug delivery as well (Gilgun-Sherki et al., 2001). 
 
Physiological opening of the BBB 
Since not all drugs can be easily modified to become more permeable to the BBB, 
researchers have been trying to develop other techniques that enable a transient 
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opening of cerebral endothelial cells’ tight junctions. Greenwood has shown that 
inflammatory mediators of the body induced a transient opening of the BBB (1992). 
Not only is this finding clinically important, but it also forms the basis of a potential 
way to open the BBB transiently, but that is well-tolerated by the brain. 
 
Induced opening of the BBB 
Induced opening of the BBB can have some advantages over physiological opening in 
that it can offer a more controlled and selective opening of the BBB. It can also be 
more precisely timed if, for example, an agent can be given to induce opening of the 
BBB and then another to close it. Osmotic opening refers to opening of the BBB 
induced by the use of a hypertonic solution, such as mannitol, which is normally 
administered via an intracarotid injection. Mannitol causes cerebral endothelial cells 
to shrink, opening tight junctions for a window of few hours. This technique has been 
used to deliver chemotherapeutic agents to patients with brain tumours (Gilgun-
Sherki et al., 2001). Chemical opening, on the other hand, employs the use of isotonic 
pharmacological molecules to cause the BBB to open. For example, Black et al have 
shown that leucotriene C4 causes a temporary opening of the BBB (1990). 
 
Pathological opening of the BBB 
Disruption of the BBB can be a complication of major head trauma. However, other 
pathological processes have also been linked to more subtle disruption of BBB and 
capillary permeability. These pathological processes include cerebral ischaemia and 
multiple sclerosis (‘MS’; Friedman et al., 1996; Gilgun-Sherki et al., 2001; Harris, 
Frank, Patronas, McFarlin, & McFarland, 1991). 
 
1.3.4.3 Clinical assessment of whether molecules cross the BBB 
 
If a neuroprotective agent is to be developed and given to patients with PD, it first 
has to pass through the BBS and get into the brain. However, it is not an easy task to 
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directly detect if these molecules do pass into the brain, as there are no simple 
laboratory tests available to do that. If a neuroprotectant does cross the BBS however, 
then it should also be present in the CSF, since there is no brain-CSF barrier. CSF can 
be clinically tested in the laboratory to determine whether certain molecules are 
present in the CSF or not. Samples of CSF can be obtained through a lumbar puncture 
(LP). An LP is a common procedure that is used to gain access to the fluid-filled space 
in the meninges in order to withdraw samples of CSF, measure CSF pressure or 
administer drugs or anaesthesia (N. Cooper, 2002). Although an invasive procedure, 
it carries less risk than, for example, having to biopsy the brain to show that 
molecules of the neuroprotective agent are present. 
 
Due to LP’s invasive nature and its other associated complications (e.g., headache), it 
is not practical to use it as a way of routinely administering the neuroprotectant, 
especially if multiple doses are required. On the other hand, studies have shown that 
when antioxidants were added to animals’ diets, researchers were able to detect 
antioxidant metabolites in these animals’ brains (Kalt et al., 2008). Therefore, dietary 
antioxidants were able to cross the BBS in these animals; and if these results could be 
replicated in human subjects, it would be of potential therapeutic interest to PD and 
other neurodegenerative disease patients. The next section will describe a sub-class of 
dietary antioxidants, anthocyanins, which have shown some promise in pre-clinical 
studies. 
 
1.3.5  Blackcurrant anthocyanins 
 
1.3.5.1 Anthocyanins: Introduction and dietary sources 
 
Anthocyanins are a group of over 500 water-soluble pigments that give a plant its red, 
blue or purple colours. They are often referred to as ‘secondary compounds’; 
compounds that do not usually contribute to the plant’s primary metabolism. Rather, 
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they serve ecological functions that enhance the plant’s survivability—for example, 
anthocyanin pigments have been shown to attract pollinators and seed dispersers 
(Winkel-Shirley, 2001). Anthocyanins are thought to be involved in the health-related 
benefits of consuming fruit and vegetables (Andres-Lacueva et al., 2005). The average 
adult intake of anthocyanins in European and US diets is estimated to be around 180 
to 250 mg per day (Kuhnau, 1976). However, this was reported in individuals 
consuming several servings of fruit and vegetables, and ‘usual’ intake is probably 
much less (Hertog, Hollman, Katan, & Kromhout, 1993; Kuhnau, 1976; Prior, 2003). 
 
Anthocyanins belong to a larger family of compounds called flavonoids. Flavonoids 
are plant polyphenolic compounds (i.e., contain more than one phenol unit); and are 
categorised (see Figure 2-5) into flavonols, flavones, flavanols and anthocyanins 
(Kuhnau, 1976). Anthocyanins are the most consumed flavonoids in European and 
US diets compared with other flavonoids (Hertog et al., 1993).  
 
 
Figure 2-5. Classification of the polyphenolic compounds (adapted with permission from Weinreb, Mandel, 
Amit, & Youdim, 2004). 
 
Almost all dietary anthocyanin intake comes from colourful fruit and vegetables. Kalt 
et al found that the brains of pigs fed on diets restricted to oats, barley and soy 
contained almost undetectable levels of anthocyanins (2008). Among edible plants, 



















sources of anthocyanins. These include berries—such as grapes, blackcurrants and 
blueberries—red cabbage, red onions and eggplants (Wu et al., 2004). In addition to 
fresh fruit and vegetables, extracts from these plants, including juices, wines and jam, 
are also rich in anthocyanins (Kähkönen et al., 2003). 
 
Anthocyanins have unique chemical properties. The colours of anthocyanins are 
affected by their chemical nature, concentration and the pH (Brouillard, 1983). They 
are very active compounds, and have been shown to be most stable in acidic 
environments (i.e., between pH 1.0 and 2.4; Cabrita, Fossen, & Andersen, 2000). 
Moreover, Walton et al have found that anthocyanins become less stable or even 
degrade when they are exposed to decreased acidity (i.e., pH beyond 4.5) or increased 
temperature (i.e., beyond 60 C; 2006). Similarly, the presence of oxygen or light, or 
exposure to infrared radiation, were also found to decrease anthocyanins’ stability in 
in vitro studies (Xiong, Melton, Easteal, & Siew, 2006). Xiong et al documented that 
encapsulating anthocyanins with natural polymers, such as pullulan, preserved the 
stability of some of the anthocyanins; and that degradation products retained the 
antioxidant activity of anthocyanins (2006). 
 
1.3.5.2 Anthocyanins as part of functional foods 
 
Functional foods have been defined as “foods that are part of a normal diet which 
have been fortified or enriched to provide additional health promoting benefits in 
conjunction with normal nutritive properties” (Devcich, Pedersen, & Petrie, 2007). A 
wide range of literature has been published on the health benefits of consuming 
anthocyanin-rich fruit and vegetables. This section will review some of these reported 







Anthocyanins have been the focus of many studies examining different dietary 
sources of antioxidants. In in vitro studies, anthocyanins were shown to protect 
against OS and deoxyribonucleic acid (DNA) damage when human cultured cells, 
such as human neuroblastoma cells and human promyelocytic cells, were incubated 
in anthocyanin-rich solutions (Ghosh, McGhie, Zhang, Adaim, & Skinner, 2006). Bub 
et al have found that DNA oxidative damage (i.e., oxidised DNA bases) was 
significantly reduced in healthy human subjects who were given polyphenol-rich 
juices for two weeks (2003). Similarly, Cho et al reported that consumption of purple 
sweet potato anthocyanin resulted in the inhibition of lipid peroxidation in brain 
extracts of rats (2003). However, results from other human and animal studies have 
been less promising and shown mixed results. For example, when a group of elderly 
patients were given polyphenol-rich desserts for two weeks, investigators found no 
change in participants’ antioxidant status (Carmen Ramirez-Tortosa et al., 2004). 
 
 
Effects on immunity 
Anthocyanins may also exert effects on the immunological status of people who 
consume anthocyanin-rich fruit and vegetables. When human subjects were given 
polyphenol-rich juices to consume, it was found that activated lymphocytes secreted 
more interleukin 2 and that it was easier to mount an immune reaction against 
pathogens in these subjects. In addition, natural killer lymphocytes had an enhanced 
‘killing’ ability due to anthocyanin consumption (Bub et al., 2003). 
 
Memory enhancement 
The use of anthocyanins has also been implicated in the prevention of cognitive and 
behavioural losses seen with aging. Hence, research has focused on trying to improve 
memory by the supplementation of anthocyanin-rich diets. Andres-Lacueva et al 
found that rats fed blueberry anthocyanins and anthocyanin metabolites performed 
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better in cognitive tests, such as the Morris water maze (2005). This indicates 
anthocyanins may have been present in the rats’ brains. Another study also found 
effects of anthocyanins on improving cognitive performance in ethanol-treated rats 
(Al-Habeeb, 2003). 
 
Effects on blood vessels 
Anthocyanins also appear to have a favourable vasodilatory action on the vascular 
system. Nakamura et al have shown that bathing rat aortic ring in an anthocyanin-
rich solution induced a dose-dependent vasorelaxation (2002). Furthermore, in a 
double-blind placebo-controlled human trial, subjects who consumed an 
anthocyanin-rich juice were found to have an increase in forearm blood flow 
(Matsumoto et al., 2005). These favourable effects on blood vessels are hypothesised 
to be due to an anthocyanin-induced increase in nitric oxide synthesis, resulting in an 
endothelium-dependant vasorelaxation via type-1 histamine receptors (Y. Nakamura 
et al., 2002). 
 
Effects on hyperglycaemia and hyperlipidaemia 
The consumption of anthocyanin-rich fruit and vegetables has been linked to a lower 
risk of developing diabetes mellitus and hyperlipidaemia (Tsuda, Horio, Uchida, 
Aoki, & Osawa, 2003). This might be attributed to the fact that consuming ‘healthy’ 
foods can mean less space for ‘bad’ foods. However, Tsuda et al found that dietary 
intake of anthocyanins helped improving insulin resistance precipitated by high fat 
diets in mice. Furthermore, they have found that anthocyanin-rich diets decreased 








1.3.5.3 Why blackcurrants? 
 
Blackcurrants (Ribes nigrum L.) are a species of berries that are commonly consumed 
as part of the diet in many parts of the world, including New Zealand. In fact, New 
Zealand is known for its mass production of high quality blackcurrants. Currently, 
Japan imports 3.6 million US dollars’ worth of New Zealand blackcurrants to use in 
several products including snacks, supplements, jam and cosmetic products (Hansen, 
2009). Although inedible, leaves and buds of blackcurrants are also used in the 
production of some food supplements (Tabart, Kevers, Pincemail, Defraigne, & 
Dommes, 2006). 
 
Blackcurrants are among the most anthocyanin-rich of berries. They contain around 
250 mg of anthocyanins per 100 g of fresh fruit (Koeppen & Herrmann, 1977). 
Amakura et al reported that blackcurrants ranked second in their radical scavenging 
ability among nine other berries, behind blackberries (2000). Furthermore, Tabart et al 
have found that compared with blackcurrant berries, leaves and buds contained three 
times the concentration of phenolic components and six times the antioxidant activity 
(2006). 
 
Another factor that favours the use the blackcurrants in research is their relatively 
simple composition; they contain four major anthocyanins, which account for about 
97.2% of the anthocyanin content in blackcurrants (Slimestad & Solheim, 2002). First 
reported by Chandler and Harper (1962), these four anthocyanins are delphinidin 3-
O-β-glucoside (D3G), delphinidin 3-O-β-rutinoside (D3R), cyanidin 3-O-β-glucoside 
(C3G) and cyanidin 3-O-β-rutinoside (C3R). This simple composition makes 
blackcurrants more convenient to assess for structure-activity relationships and 
bioavailability studies, compared with other berries, such as bilberries—which 
contain around 15 different anthocyanin components (Nakaishi, Matsumoto, 




Therefore, blackcurrant anthocyanins seem a possible candidate neuroprotective 
agent that can be studied for its use in PD patients. The relatively simple composition 
of blackcurrant anthocyanins makes them convenient to be studied in the CSF of PD 
patients. Similarly, based on previous lab-, animal- and human- studies, the potent 
antioxidant effects of anthocyanins should—in theory—help alleviate OS that 
dopaminergic cells in substantia nigra undergo, as well as enhance endogenous 
antioxidant defences resulting in less ROS formation (Bub et al., 2003; Cho et al., 
2003). Achieving these effects means slowing down the neural degeneration in the 
substantia nigra and—by extension—neuroprotection. 
 
1.3.5.4 Human metabolism and transport of blackcurrant anthocyanins 
 
Metabolic properties of anthocyanins have been the subject of recent research. This 
section will concentrate on human metabolism and transport of blackcurrant 
anthocyanins. However, since some areas in this field have not yet been researched in 
humans, animal studies will also be occasionally cited. 
 
Gastric and intestinal absorption 
Blackcurrant anthocyanins have been shown to be absorbed from the stomach and 
small intestines in humans (Miyazawa, Nakagawa, Kudo, Muraishi, & Someya, 1999; 
Nielsen, Dragsted, Ravn-Haren, Freese, & Rasmussen, 2003). Several mechanisms of 
absorption have been proposed, including permeation through organic anion 
transporters, such as bilitranslocase—a membrane protein involved in the uptake of 
bilirubin and other molecules—which is found in the gastric mucosa; however, the 
exact mechanism is not yet clear (Passamonti, Vrhovsek, Vanzo, & Mattivi, 2003). 
Although blackcurrant anthocyanins are absorbed fairly rapidly (peak plasma 
concentration reached around 45 minutes post-ingestion), presence of food in the 
stomach seems to slow this down (plasma concentration peaks around 90 minutes 
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post-ingestion). Moreover, the absorption rate of blackcurrant anthocyanins has been 
estimated to be low, varying from 0.007 to approximately 1.4% of ingested dose 
(Rechner et al., 2002). The authors of the study have attributed this low rate to the 
inability to estimate or measure the extent of tissue distribution or biliary excretion of 
these anthocyanins. Blackcurrant anthocyanins appeared in the plasma in their intact 
forms or as sulfoconjugated forms (Vitaglione et al., 2007). Non-blackcurrant 
anthocyanins have also been recently detected in human plasma. Healthy participants 
were fed grape/blueberry juice and smoothies; blood samples were obtained almost 
every 10 minutes from the time of ingestion. Concentrations peaked at about 60 
minutes post-ingestion for C3G and D3G (Kuntz et al., 2015). Of note, participants 
were only allowed to drink water for three hours after ingestion of the juice or 
smoothie. 
 
Crossing the BBB 
Fewer studies have specifically looked into whether or not anthocyanins cross the 
BBB. Youdim et al have shown that C3R, among other anthocyanins, crossed cell 
surfaces of ECV304 cells (an in vitro model of the BBB). They suggest that some of 
these anthocyanins diffuse via the paracellular pathway (2003). However, some 
scientists have criticised the use of ECV304 as a model, since it does not fully mimic 
the physiological environment of the BBB, particularly in the arena of efflux 
transporters (Begley, 2004). In animal studies, Talavéra et al were able to detect 
blackberry anthocyanins in the brains of rats (2005). They suggest that anthocyanins 
could be carried into the CNS by a similar means to that in the gut, namely a 
bilitranslocase-like transporter. 
 
Urinary and faecal excretion 
Absorbed blackcurrant anthocyanins are excreted through the kidneys. Matsumoto et 
al have found that the urine concentrations of the four blackcurrant anthocyanins 
were 0.11% (± 0.05) of the oral dose in the first 8 hours after ingestion (2001). In 
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contrast to plasma, all forms of blackcurrant anthocyanins (i.e., intact, 
glucuronidated, methylated and sulfoconjugated) were detected in the urine. This is 
perhaps because glucuronidated and methylated compounds are formed in the 
kidney, and hence are directly excreted in the urine (Vitaglione et al., 2007). On the 
other hand, blackcurrant anthocyanins that are not absorbed from the stomach and 
small intestines pass into the lower segments of the digestive tract. In the colon, these 
anthocyanins are broken down, mainly due to the neutral pH in the colon as well as 
metabolism by colonic microflora (Passamonti et al., 2003). Figure 2-6 shows a scheme 
of proposed metabolic pathways of cyanidin-glucoside (a family of anthocyanins of 





Figure 2-6. Proposed pathways of cyanidin-glucoside metabolism; CyG = cyanidin-glucoside; Cy = cyanidin 
aglycon; PCA = protocatechuic acid; Ald2 = aldehyde; Cy-gluc = cyanidin-glucuronide; Cy-met-gluc = cyanidin-























































1.4   Insulin-like growth factor-1 trial 
 




Insulin-like growth factor-1 (IGF-1), also known as somatomedin C, is a hormone 
polypeptide produced by the liver (Rinderknecht & Humbel, 1978). Whilst it mainly 
exerts an endocrine function, it also has autocrine and paracrine targets. As the name 
suggests, IGF-1 plays pivotal physiological roles in growth and anabolism (see 
below). A similar hormone, insulin-like growth factor-2 (IGF-2), plays a major role in 
fetal growth (He et al., 2013); however, further discussion of IGF-2 is beyond the 
scope of this thesis. The two insulin-like growth factors, their two receptors and seven 
binding proteins are collectively referred to as the “IGF axis” (Lodhia, 




Structurally homologous to insulin, IGF-1 is made up of 70 amino acids connected by 
three disulphide bonds (Rinderknecht & Humbel, 1978). The aminoterminal of IGF-1, 
made up of three amino acids, plays a major role in binding IGF-1 to its binding 
proteins. If the IGF-1 aminoterminal is treated with an acid protease, it is cleaved to 
form cyclic glycine-proline (cGP; discussed below; Nilsson-Håkansson et al., 1993; 
Sara et al., 1993; Yamamoto & Murphy, 1994). 
 
1.4.1.3 Transport around the body 
 
The majority of circulating IGF-1 is bound to one of the insulin-like growth factor-
binding proteins (IGFBP). Binding to IFGBPs allows the body to regulate IGF-1, as 
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only the unbound form of IGF-1 (i.e., “free” IGF-1) is biologically active (reviewed by 
Binoux, 1995). Therefore, serum concentration of IGF-1 does not necessarily reflect 
biological activity. 
 




Upwards of 75% of circulating IGF-1 is bound to IGFBP-3 (Binoux, 1995). Binding to 
IGFBP-3 prevents it from activating IGF receptors and thus protects IGF-1 from being 
metabolised (Binoux, 1995). Free IGF-1, on the other hand, is rapidly metabolised or 
internalised after interacting with IGF receptors. Given the short window of 
opportunity during which free IGF-1 can be measured, other indices have been 
suggested (Guan et al., 2015; Sifakis, Akolekar, Kappou, Mantas, & Nicolaides, 2012). 
The IGF-1/IGFBP-3 ratio is currently being employed as a surrogate for free IGF-1 
(i.e., higher IGF-1/IGFBP-3 ratio indicates lower free IGF-1). The reliability of this 





Once cleaved, the tri-peptide (i.e., glycine-proline-glutamate) aminoterminal of IGF-1 
exists in a trans:cis isomeric mixture (80:20); the cis-isoform is then further 
metabolised to form cGP (Nilsson-Håkansson et al., 1993; Sara et al., 1993; Yamamoto 
& Murphy, 1994). Glycine-proline-glutamate has been demonstrated to elicit the 
release of acetylcholine and dopamine from murine brain slice cultures, independent 




The biological activity of cGP itself, however, was not established until later (see 
review by Samonina, Ashmarin, & Lyapina, 2002). Recently Guan and her colleagues 
(2014) demonstrated that cGP regulates IGF-1 bioavailability by competitively 
interfering with IGF-1 binding to IGFBP-3 (see Figure 2-7); they postulate that the 
cGP/IGF-1 ratio (i.e., higher cGP/IGF-1 indicates higher free IGF-1) may in fact be a 




Figure 2-7. The interplay between IGF-1, cGP, IGFBP-3 and the associated ratios; cGP = cyclic guanine-proline; 
IGF-1 = insulin-like growth factor-1; IGFBP-3 = insulin-like growth factor binding protein-3 (adapted with 
permission from Guan et al., 2015). 
 
1.4.3  IGF-1 in health and disease 
 
1.4.3.1 General remarks 
 
Whereas IGF-2 is a major growth factor during the fetal period, IGF-1 assumes a 
bigger growth-promoting role in children and adults. In fact, IGF-1 mediates most of 
the anabolic effects of growth hormone— these extend to a multitude of cell types 

















visceral cells (Bikle et al., 2015; Christopoulos, Msaouel, & Koutsilieris, 2015; Nieto-
Estevez, Defterali, & Vicario-Abejon, 2016). 
 
IGF-1, however, does not act in isolation and is part of an intricate system of several 
signalling pathways and downstream mediators (Yakar et al., 2002). The cascade of 
events (with subsequent trophic effects of IGF-1) is mainly triggered by the high-
affinity binding of IGF-1 to its receptor, IGF-1-receptor. IGF-1, however, can also bind 
to other related receptors—including insulin receptors—albeit with lower affinity 
(Cheng et al., 2000); this may account for the observed hypoglycaemic effect of IGF-1 
when given in pharmacological doses (Bang, Polak, Woelfle, & Houchard, 2015). 
 
1.4.3.2 IGF-1 and neuronal health 
 
Perhaps one of IGF-1’s best characterised roles is in neuronal growth physiology. It 
has been demonstrated as a pivotal substance throughout the lifecycle of neurons; 
this includes trophic effects on developing neurons and inducing differentiation (i.e., 
neuropoliferation; Russo, Gluckman, Feldman, & Werther, 2005), aiding neuronal 
repair and survival—even when neurons are damaged—(i.e., neuroprotection; 
Rabinovsky, 2004) and supporting neuronal development and neuroplasticity (i.e., 
neuromodulation; Benarroch, 2012; Fernandez & Torres-Aleman, 2012). 
 
1.4.3.3 IGF-1 and neurological dysfunction 
 
The premise of a neuroprotective/neurorestorative effect of IGF-1 holds a certain 
appeal for its clinical implications. As a result, intense research has been undertaken 
to explore the underpinnings of IGF-1 and its metabolites for possible bedside 
applications (Guan & Gluckman, 2009). The two main neurological applications for 
IGF-1 and its derivatives have been therapeutic uses in acute hypoxic/ischaemic 
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insults (Guan & Gluckman, 2009) and diagnostic applications (more so in 
neurodegeneration due to the protracted clinical course; discussed below). 
 
The therapeutic applications of IGF-1 and its active metabolites for neurological 
disorders remain hampered by pharmacodynamic trepidations and pharmacokinetic 
impracticalities. For example, not only is central administration of IGF-1 invasive and 
cumbersome, but it also results in poor neuronal uptake (Pardridge, 1997). Peripheral 
administration, on the other hand, results in objective neuroprotection in rat brains 
damaged by hypoxia/ischaemia (Liu, Fawcett, Thorne, & Frey, 2001; Saatman et al., 
1997). However, peripheral administration exposes other non-neuronal tissue to IGF-
1; given the potent anti-apoptosis effect of IGF-1, there is a theoretical risk of 
promoting mitogenesis and/or carcinogenesis (especially in pharmacological doses). 
 




Several associations, although preliminary at times, between IGF-1 and PD have been 
drawn in the literature. Not only is the survival of substantia nigra neurons 
(including dopaminergic cells) dependent on IGF levels during embryogenesis 
(Zawada, Kirschman, Cohen, Heidenreich, & Freed, 1996), but they also express a 
high number of IGF-1-receptors later in life (Mashayekhi, Mirzajani, Naji, & Azari, 
2010). Furthermore, metabolites of IGF-1 (including cGP) have been shown to protect 
dopaminergic cells from 6-hydroxydopamine-induced oxidative injury in murine 
models of PD (Guan et al., 2000; Krishnamurthi, Mathai, Kim, Zhang, & Guan, 2009; 
Quesada, Lee, & Micevych, 2008). This effect may be related to IGF-1’s known role as 
a potent inhibitor of programmed cell death (i.e., apoptosis), such that abundance of 




Deficiency of IGF-1 (whether quantitative or qualitative), on the other hand, may 
accelerate the rate of cellular demise. Whilst a short lifespan for abnormal cells is 
advantageous (e.g., to curb the promulgation of neoplastic cells; Gallagher & LeRoith, 
2011), normal permanent cells (i.e., cells incapable of reproduction such as 
dopaminergic neurons) may suffer from a short lifespan since they cannot regenerate. 
This latter observation was the basis of a recent hypothesis linking maternal exposure 
to bisphenol A (which down-regulates IGF-1 in fetuses) to an increased risk of PD 
later in life (Huang et al., 2014). Qualitative IGF-1 deficiency or “IGF-1 resistance” 
(characterised by a blunted end-organ response to IGF-1 and/or impairment of IGF-1 
function) has also been implicated in PD progression, namely motor and cognitive 
decline (Ma et al., 2015; Picillo et al., 2013), although similar results were not 
reproduced in other studies (see below). 
 
1.4.4.2 IGF-1 as a biomarker for PD 
 
Because of the seemingly intertwined relationship between IGF-1 and PD, the former 
has been suggested as a biologically plausible biomarker for PD. This has arisen after 
observing higher plasma IGF-1 concentrations in PD patients than in controls (Chung 
et al., 2005; Godau et al., 2011; Ma et al., 2015; Numao, Suzuki, Miyamoto, Miyamoto, 
& Hirata, 2014; Picillo et al., 2013). However, a number of other studies failed to show 
a significant difference in plasma IGF-1 concentrations in PD patients compared with 
controls (Numao et al., 2014; Schaefer, Vogt, Nowak, & Kann, 2008; Tuncel, Inanc 
Tolun, & Toru, 2009). 
 
Added to the inconsistent findings above, several confounders that affect IGF-1 levels 
preclude its usefulness as a biomarker in PD. These include the known wide inter-
individual variability (Verheus et al., 2008), and the effect of age (Godau, Herfurth, 
Kattner, Gasser, & Berg, 2010; Juul et al., 1994), weight (Faupel-Badger, Berrigan, 
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Ballard-Barbash, & Potischman, 2009), comorbidities (e.g., diabetes mellitus; Teppala 
& Shankar, 2010) and medication use (e.g., anti-depressants; Kopczak et al., 2015). 
 
Finally, there is a paucity in the literature on the explicit use of IGF-1 as a biomarker 
for PD in longitudinal studies (i.e., as a progress and monitoring biomarker; Bernhard 
et al., 2016; Numao et al., 2014; Picillo et al., 2013). In a recent study by Bernhard and 
colleagues, patients with moderate PD (disease duration 4-8 years) but not early PD 
(disease duration ≤ 3.5 years) had significantly higher baseline plasma concentrations 
of IGF-1 compared with healthy controls (2016). IGF-1 levels were not found to 
correlate with annual cognitive changes as assessed by the Mini-Mental State 
Examination (MMSE). The generalisability of these results maybe rather limited, 
however, due to the arbitrary delineation of disease severity, the small number of 
participants (n = 36) and the use of MMSE rather than other more suitable 
instruments for cognitive assessment. 
 
 
1.5   C-type natriuretic peptide trial 
 
1.5.1  Introduction 
 
1.5.1.1 Natriuretic peptides 
 
Natriuretic peptides refer to a family of structurally homologous peptides 
synthesised by various cells in the body. They act to promote urinary excretion of 
sodium (i.e., natriuresis) which is physiologically coupled with water excretion (i.e., 
diuresis) from the ECF compartment. This serves in the body’s regulation of its fluid 
status and mean arterial pressure. Natriuretic peptides exert their effects mainly by 
binding to one of several natriuretic peptide receptors (NPR). Members of this 
natriuretic peptide family include atrial natriuretic peptide (ANP), B-type natriuretic 
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peptide (BNP), C-type natriuretic peptide (CNP, discussed in detail below), and more 
recently, dendroaspis natriuretic peptide (‘DNP’, Schirger et al., 1999) and urodilatin 
(Schulz-Knappe et al., 1988).  
 
To understand the function of these natriuretic peptides, it is useful to consider the 
nomenclature used in the endocrinology literature. The suffix –“crine” (εκκρίνει Gr.) 
denotes the process of secretion. Secreted substances (e.g., peptides) function to alter 
the recipient cell’s behaviour and physiology. Depending upon the location of 
recipient cells, different prefixes are used. From proximal to distal, these include: 
intracrine signals (i.e., substances that act inside the cell in which they were produced 
without physically leaving the cell), autocrine signals (i.e., substances that act on the 
cell in which they were synthesised by binding to receptors on its outer membrane), 
juxtacrine signals (i.e., these affect cells/structures physically contacting the cell which 
produced the juxtacrine molecules), paracrine signals (i.e., substances that affect 
nearby local cells) and finally endocrine signals (i.e., molecules that travel in the 
circulation to a distant target). 
 
1.5.1.2 ANP and BNP 
 
ANP is perhaps the most extensively studied natriuretic peptide. It is mainly 
produced by and stored in cardiac myocytes in the atria (Nemeh & Gilmore, 1983; 
Sonnenberg, Chong, & Veress, 1981). Atrial myocytes release ANP in response to 
excessive atrial stretch (e.g., by hypervolaemia) in order to lower the circulatory 
volume and restore fluid homeostasis (Lopez et al., 1995; Nemeh & Gilmore, 1983). 
ANP achieves this by binding to type-A NPR (NPRA) found in the vascular smooth 
muscle and kidney tubules (i.e., endocrine action), which leads to vasodilation and 




BNP was previously named the brain natriuretic peptide as it was first identified in 
porcine brain extracts (Sudoh, Kangawa, Minamino, & Matsuo, 1988). In humans, 
however, BNP is largely synthesised by ventricular cardiac myocytes (Takahashi, 
Allen, & Izumo, 1992). Much like ANP, BNP is also released in response to cardiac 
stretch in which case it promotes natriuresis by binding to NPRA (Kambayashi et al., 
1990). 
 
1.5.2  CNP structure and synthesis 
 
CNP is synthesised as a large prohormone form (i.e., proCNP) by a variety of tissue 
cells around the body (Tawaragi et al., 1991). It then undergoes modification by the 
endoprotease enzyme, furin, the process of which yields two products: CNP-53 (also 
referred to as the aminoterminally extended form) and an aminoterminal fragment, 
NTproCNP (Wu, Wu, Pan, Morser, & Wu, 2003). NTproCNP was first isolated and 
studied in Christchurch, New Zealand by Prickett and his colleagues (2001). CNP-53 
is further processed by an unknown mechanism, perhaps an exopeptidase, to 
produce CNP-22 and another aminoterminal fragment, which is yet to be identified. 
Although limited literature pertaining to the identity of this aminoterminal fragment 
being NT-CNP-53 exists (Komatsu et al., 1991; Sudoh, Minamino, Kangawa, & 
Matsuo, 1990), the radioimmunoassay method utilised has not been validated and is 
deemed too insensitive, both reasons of which abrogate confidence in the generated 
data (Prickett et al., 2001). 
 
CNP -53 and -22 are the biologically active forms, whilst the functions of NTproCNP 
(and NT-CNP-53) are yet to be elucidated (Minamino, Kangawa, & Matsuo, 1990; 
Pemberton, Siriwardena, Kleffmann, & Richards, 2014). Vlachopoulos et al have 
recently demonstrated a relationship between NTproCNP and indices of arterial 
function (2010); however, NTproCNP was used as a proxy for CNP, rather than being 
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the regulator of arterial function per se. See Figure 2-8 for a visual representation of 
the CNP molecule and its synthesis pathway. 
 
 
Figure 2-8. The pathway of proCNP processing—initially by the intracellular enzyme, furin, to produce 
NTproCNP and CNP. Downstream processing, by an unknown mechanism, results in the bioactive CNP-22 
(reproduced with permission from Zakeri et al., 2013). 
 
1.5.3  CNP metabolism and degradation 
 
Part of the reason why CNP only exerts its effects locally is the rapidity with which it 
is cleared from the circulation after secretion. Once intracellular proCNP is processed 
by furin, the two products, CNP-53 and NTproCNP are secreted across the cell 
membrane in equimolar amounts (Schouten et al., 2011). Whereas the catabolic fate of 
NTproCNP is largely still unknown (Schouten et al., 2011), the biologically active 
forms of CNP (i.e., CNP-53 and its derivative, CNP-22) are swiftly cleared by three 




Neprilysin-1 is a membrane-bound zinc-binding metalloprotease (i.e., an enzyme 
whose catalytic activity involves a metal; Kenny, Bourne, & Ingram, 1993). 
Neprilysin-1 is known by many other names including neutral endopeptidase-1 
(NEP-1), cluster of differentiation 10 and enkephalinase (Thong et al., 2014). NEP-1 
appears to not only hydrolyse CNP, but also ANP, BNP, urodilatin and other 
peptides and receptors (Kenny et al., 1993). NEP-1 is highly expressed in both the 
CNS and elsewhere. In rats, NEP-1 has been found in the basal ganglia, choroid 
plexus, dentate gyrus, ependyma, hippocampus, hypothalamus, olfactory bulb and 
tubercle and the spinal cord’s superficial laminae of the dorsal horn (Facchinetti, 
Rose, Schwartz, & Ouimet, 2003). With ageing, murine brains expressed less NEP-1 
production and activity (Higuchi, Iwata, & Saido, 2005). In humans, NEP-1 has been 
found to be expressed in many tissues, including adipose (Katsuda et al., 2013), brain 
(Mazur-Kolecka & Frackowiak, 2006), liver (Dragovic, Deddish, Tan, Weber, & Erdos, 
1994) and testicular tissues (Thong et al., 2014). Similar to aged murine brains, CSF of 
patients with early AD has been reported to contain reduced levels of NEP-1 
(Maruyama et al., 2005). 
 
NPRs are a family of receptors that bind the various natriuretic peptides. One 
classification system of NPRs is whether the receptor activates guanylyl cyclase (GC) 
or not (Anand-Srivastava, 2005). GC-activating receptors include NPRA and B-type 
NPR (NPRB); NPRA primarily binds to ANP and, with about 10 times less affinity, to 
BNP (Moya et al., 1998)—meanwhile NPRB is the primary receptor for CNP 
(discussed in the following section). Activation of the GC pathway leads to a cascade 
of events the end-result of which is often a stimulatory response. NPRC, on the other 
hand, is considered a non-GC activating receptor (Matsukawa et al., 1999). Its affinity 
to the three most studies natriuretic peptides, in descending order, is: ANP, CNP and 
then BNP (Suga et al., 1992). NPRC is the most widely expressed in the body 
(including neural tissue) of all NPRs (Matsukawa et al., 1999). Its principal role is the 
uptake and internalisation of natriuretic peptides (Nussenzveig, Lewicki, & Maack, 
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1990). In fact, NPRC was thought of being a “clearance receptor” for a period of time 
(Anand-Srivastava, 2005). However, it is now known NPRC is also implicated in 
several other physiological functions, including the generation of inhibitory signals 
through second messengers (Anand-Srivastava, Sairam, & Cantin, 1990; and see 
review by E. R. Levin, 1993). 
 
Insulin-degrading enzyme is also known as insulysin, and akin to NEP-1, is a large 
zinc-dependent metalloprotease (Shen, Joachimiak, Rosner, & Tang, 2006). Whilst the 
function of insulin-degrading enzyme has most extensively been described in ANP 
metabolism (Müller, Schulze, Baumeister, Buck, & Richter, 1992), a role in CNP 
degradation has also been described. In vitro studies have demonstrated reduced 
expression of insulin-degrading enzyme led to increased CNP-induced activation of 
NPRB (i.e., consistent with CNP inactivation) and vice versa (Müller et al., 1992; Ralat 
et al., 2011). The presence of insulin-degrading enzyme within the natriuretic peptide 
milieu also resulted in paradoxical effects on receptor activation, especially by BNP 
(Potter, 2011). It appears, therefore, that insulin-degrading enzyme modulates 
potency and receptor preference, in descending order, of: ANP, CNP and BNP 
(Potter, 2011). 
 
Finally, a few other mechanisms of clearing CNP have been recently proposed. For 
example, Whyteside and colleagues recently identified neprilysin-2 in human brain 
tissue (2008). Whether neprilysin-2, or other suggested mechanisms, preferentially 













While ANP and BNP seem to affect the body in similar ways, evidence shows that 
CNP is different. Unlike ANP and  BNP’s endocrine functions, CNP appears to act 
locally (i.e., autocrine and paracrine functions). Furthermore, CNP binds to NPRB 
(Koller et al., 1991) as opposed to ANP and BNP binding to NPRA (see Figure 2-9). 
This, in part, accounts for the weak natriuretic effect of CNP compared with ANP or 
BNP (Canaan-Kuhl, Jamison, Myers, & Pratt, 1992). 
 
 
Figure 2-9. Anatomy of NPRB; the function of the receptor is discussed below 
(reproduced with permission from Pejchalova, Krejci, & Wilcox, 2007). 
 
The full range of functional roles of CNP in healthy individuals is yet to be 
determined. However, CNP has been implicated in several developmental and 
physiological pathways. Below is a discussion on CNP’s functions according to site 







1.5.4.2 Cardiovascular system 
 
As mentioned earlier, contrary to the endocrine functions of ANP and BNP, CNP 
operates on autocrine and paracrine levels. Therefore, it is logical to assume that CNP 
does not play a significant role in controlling the body’s systemic blood pressure (i.e., 
mean arterial pressure); this deduction has been corroborated by findings by Lopez et 
al (1997). Rather, CNP appears to act upon microcirculations (e.g., coronary blood 
vessels, Wiley & Davenport, 2001), causing local vasodilation. CNP achieves this by 
hyperpolarising (and therefore relaxing) vascular smooth muscle cells—hence, 
referring to CNP as an endothelial-derived hyperpolarising factor (Chauhan et al., 
2003). Perhaps more clinically-promising is CNP’s ability to inhibit cardiac and 
vascular remodelling post-injury (e.g., post-myocardial infarction, Soeki et al., 2005). 
CNP is believed to curtail cardiac myocyte hypertrophy, smooth muscle proliferation 
and tissue fibrosis (Bouchie, Hansen, & Feener, 1998). Such function has also been 
implicated in CNP’s role as an anti-atherogenic agent (Casco et al., 2002). 
 
1.5.4.3 Endochondral bone 
 
Perhaps one of the most studied arenas of CNP physiology is its involvement in long 
bone growth (Peake et al., 2014). CNP regulates cell growth and differentiation, 
ultimately leading to endochondral ossification (i.e., the essential process underlying 
long bones formation and growth; Olney, 2006). In mice, mutations knocking out 
genes encoding CNP (Chusho et al., 2001; Fujii et al., 2010) or NPRB (Tsuji & Kunieda, 
2005) result in a dwarf phenotype and skeletal dysplasia. In humans, CNP has been 
suggested to play an integral role in contributing to a person’s height. To that effect, a 
genetic mutation of NPRB results in extreme short stature (a condition called 
acromesomelic dysplasia, type Maroteaux; Bartels et al., 2004), while high CNP 
production/signalling is believed to contribute to the tall phenotype of some Northern 
European populations (Estrada et al., 2009). 
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1.5.4.4 Reproductive organs 
 
CNP also appears to be critical for normal reproductive organ function. What is 
interesting is that CNP is pivotal for both reproductive organogenesis (i.e., organ 
development) in an embryo as well as maintaining normal sexual function in an adult 
in both sexes. 
 
In female mice, the non-pregnant uterus and ovaries contain more CNP messenger 
RNA than any other organ (Stepan, Leitner, Bader, & Walther, 2000). In fact, CNP was 
found to be essential for ovarian development and function (including the 
maintenance of oocyte meiotic arrest; Yang, Wei, Ge, Zhao, & Ma, 2016), and NPRB-
deficient mice were found to develop ovarian hypoplasia (Tamura et al., 2004). 
Moreover, uteri of non-pregnant rats contain a hundred times more NPRB (i.e., CNP 
receptor) than NPRA (Dos Reis et al., 1995). During pregnancy, CNP messenger RNA 
expression increases several-fold in the murine uterus, but decreases significantly in 
the ovaries (Stepan et al., 2001). It is hypothesised that the increase in CNP has a 
muscle-relaxing effect which protects the gestation by sidestepping premature uterine 
contractions (Drewett, Fendly, Garbers, & Lowe, 1995). The dramatic decrease in 
ovarian CNP, on the other hand, is thought to reflect the gestational decline in 
luteinising hormone levels (which controls ovarian CNP production), (Jankowski et 
al., 1997). In healthy pregnant female humans, CNP and NRPB were detected in 
reproductive organs, more in the placenta than in the uterus (Stepan, Faber, 
Stegemann, Schultheiss, & Walther, 2002). Intriguingly however, the pattern was 
reversed (i.e., more CNP in the uterus and less in the placenta) in gestations 
complicated by pre-eclampsia and intra-uterine growth restriction (Stepan, Faber, 
Stegemann, et al., 2002; Stepan, Faber, & Walther, 2002). 
 
In males, CNP has been implicated in normal testicular function; it appears to 
modulate murine blood-testis barrier function (Xia, Mruk, & Cheng, 2007) as well as 
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contribute to molecular signalling in porcine seminal plasma (Chrisman, Schulz, 
Potter, & Garbers, 1993). In humans, Middendorff et al have shown that CNP and 
NPRB are present in the human testis (1997). In another study, the same group 
reviewed the several functional roles of testicular CNP, including regulating germ cell 
development, spermatozoon motility and testosterone synthesis (see Middendorff et 
al., 2000). In the penis, CNP is thought to contribute to erectile function, after NPRB 
was found to be expressed in human corpus cavernosal tissues (Küthe et al., 2003). To 
that effect, patients with vascular erectile dysfunction were found to have lower 
NTproCNP levels compared with controls (Vlachopoulos et al., 2009). 
 
1.5.5  CNP and the nervous system 
 
1.5.5.1 Presence of CNP in the CNS 
 
CNP is the most abundant of all natriuretic peptides in the CNS, at least in the case of 
rats and humans (Komatsu et al., 1991). Plasma levels of CNP-22 and NTproCNP 
increased when arterial versus venous samples across the head and neck (i.e., an 
arteriovenous gradient) were examined in sheep (Charles et al., 2006) and humans 
(Palmer, Prickett, Espiner, Yandle, & Richards, 2009). Whether this represents CNS 
contribution to the systemic pool of CNP is controversial, however. This is because 
the same research group has found an inverse relationship between plasma and CSF 
levels of CNP-22 in human subjects before undergoing non-acute orthopaedic surgery 
(Schouten et al., 2011). These apparently contradicting results may be explained using 
the following argument—the physiological condition of the subjects in the two 
human studies is likely to have been different. Patients in the study by Palmer et al. 
would have likely been sedated, but perhaps not anaesthetised, for the procedure 
before samples were obtained (2009); CSF turnover is known to increase during sleep 
(see review by Johanson et al., 2008), which could theoretically account for a ‘cerebral’ 
source explaining the step-up in the arteriovenous gradient. Samples from patients in 
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the study by Schouten et al., on the other hand, were obtained from awake patients 
before they were anaesthetised (2011). The other possibility is that ‘non-cerebral’ 
sources contributed to the CNP pool in the sampled returning venous plasma; these 
could include the eyes (Fernandez-Durango, Nunez, & Brown, 1995) or the cervical 
dorsal root ganglia (Kishimoto et al., 2008). 
 
1.5.5.2 CNP in health 
 
The exact role of CNP within the CNS is not completely understood. To date, 
however, CNP appears to be implicated in different physiological pathways rather 
than exerting a single overarching effect. 
 
In mice, natriuretic peptides, including CNP, have been shown to modulate axonal 
branching and growth in several areas of the embryonic brain and spinal cord (Zhao 
& Ma, 2009). In rats, CNP has been shown to be critical in the development of neural 
progenitor cells, which ultimately lead to perinatal neurogenesis (Müller et al., 2009). 
Moreover, Decker et al have demonstrated a role for CNP in regulating hippocampal 
synaptic plasticity and influencing hippocampal interneurons in such a manner that it 
may potentially aid in memory formation (2010). Finally, in a model of bovine BBB 
cells, CNP has recently been found to significantly influence the expression of 
zolouna occludens-1 (i.e., a type of tight junctions expressed in the BBB), which 
thence led to increased BBB permeability (Bohara et al., 2014). It is still too early to 
extrapolate such putative effects of CNP on human BBB, however (see review by 
Guo, Barringer, Zois, Goetze, & Ashina, 2014). 
 
Studies on CNP and the human CNS have been less forthcoming. Togashi and 
colleagues confirmed the presence of CNP in human brain and CSF (1992). 
Furthermore, they found CNP-53 to be the predominant form in the brain, while 
CNP-22 was the predominant form in CSF (Togashi et al., 1992). Whether this 
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indicates differential processing of CNP in the human CNS remains a conjecture. 
Moreover, Kaneko et al. measured CNP levels in the CSF of 15 neurologically intact 
subjects. They found a mean CNP concentration of 2.13 (± 0.27) pmol/l (1993). 
Modestly higher concentrations were found in another cohort of 51 healthy 
orthopaedic patients 7.9 (± 3.2) pmol/l, although one subject had PD and another had 
diabetic neuropathy (Schouten et al., 2011). 
 
1.5.5.3 CNP in patients with non-PD neurological disorders 
 
A few studies have examined the role of CNP in the pathogenesis of, as well as being 
a biomarker for, AD. The biologically active forms of CNP (i.e., CNP-53 and CNP-22) 
have exposed hydrophobic regions (Kourie & Henry, 2002). This structural 
configuration makes these peptides particularly “sticky” and facilitates their binding 
to amyloid (Kourie & Henry, 2002). Moreover, NEP-1—shown to decrease with age 
(Higuchi et al., 2005)—is one of the best characterised enzymes that degrade amyloid-
β (‘Aβ’, Hersh & Rodgers, 2008). In fact, NEP-1-overexpressing murine brains 
exhibited less Aβ and the mice performed better on behavioural tasks (Marr et al., 
2003). Taken together, these findings suggest a possible clinical utility for CNP and/or 
NEP-1 in the diagnosis (i.e., distinction from other causes of dementia) and 
prognostication of AD. In fact, Maruyama and colleagues have demonstrated reduced 
NEP-1 activity in CSF of patients with early AD (2005). Further studies are required to 
delineate the potential of CNP or NEP-1 as biomarkers for AD. 
 
Several other human studies have tried to ascertain a role of CNP in various 
neurological disorders. In the sample studied by Kaneko et al, 15 patients had a 
variety of neurological disorders (e.g., subarachnoid haemorrhage and traumatic 
brain injury ‘TBI’); CSF levels of CNP did not differ in this group compared with 
normal controls (1993). On the other hand, another Japanese group has shown that 
CNP levels in the CSF have indeed risen in the acute setting (i.e., within 24 hours) of 
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subarachnoid haemorrhage; plasma CNP levels remained steady, however (Ikeda, 
Ikeda, Onizuka, Terashi, & Fukuda, 2001). In patients with TBI, lower plasma CNP 
levels were predictive of ensuing sepsis (Bahrami et al., 2010). 
 
Finally, there has also been an interest in CSF levels of cyclic guanosine 
monophosphate (cGMP, a downstream secondary messenger of CNP-induced 
activation of NPRA, NPRB and nitric oxide pathways). The value of CSF cGMP in 
neurodegenerative disorders remains controversial, however. For instance, whereas 
one study found lower CSF concentrations of cGMP in amyotrophic lateral sclerosis 
(ALS) patients (Iłecka, 2004), another study failed to replicate this finding (Oeckl et 
al., 2012). 
 
1.5.5.4 CNP and PD 
 
In the murine brain, CNP (Langub, Watson, & Herman, 1995) and its receptor, NPRB 
(Herman, Dolgas, Rucker, & Langub, 1996), are highly expressed in the 
mesencephalon where dopaminergic neurons originate. Moreover, CNP has been 
shown to blunt dopamine release in response to cocaine given to rats (Thiriet et al., 




1.6   Exosome trial 
 
1.6.1  Introduction 
 
Extracellular vesicles have garnered recent interest as promising biomarkers for a 
plethora of disease processes. Excreted by normal and pathological cells, these 20- 
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1 000 nm vesicles serve, among other functions, as a way of cell-to-cell 
communication (van der Pol et al., 2014). This communication may be external (i.e., 
interaction between vesicular membrane protein and recipient cell membrane 
protein) or internal (i.e., internalisation of the vesicular content by the recipient cell); 
the content of these vesicles reflect specific traits of the cell of origin. 
 
Based upon size and function, these extracellular vesicles have been classified in the 
literature into two to six groups – depending on the reporting study. As will become 
apparent below, a consensus on naming or classifying these vesicles remains lacking 
to date. There is, however, reasonably sufficient evidence to support classifying 
extracellular vesicles into four categories: apoptotic vesicles, exosomes, membrane 
particles and microvesicles. Table 2-2 summarises key details of each class of vesicles. 
 
Table 2-2. The four major classes of extracellular vesicles. 
 Apoptotic vesicles Exosomes Membrane particles Microvesicles 
Size 
(nm) 
1 000-5 000 
(Hristov, Erl, 




Geuze, & Sixma, 
1999) 
50-600 (Marzesco et 
al., 2005) 
20-1 000 
(Heijnen et al., 
1999) 
Shape Multiple (Hristov 
et al., 2004) 
Cup-shaped 
(Heijnen et al., 
1999) 
Cup-shaped 






Most cell types Most cell types Epithelial cells only 
(Marzesco et al., 
2005) 
Most cell types 
Content DNA and histones 








Goilav, Max, & 
Tuschl, 2016) 
CD133 = cluster of differentiation 133; DNA = deoxyribonucleic acid; RNA = 
ribonucleic acid. 
 
Of relevance to the biological markers trial are the exosomes, small membrane-
enclosed vesicles with a size distribution of 30-100 nm (Heijnen et al., 1999). 
Exosomes were first discovered in the 1980s by Dr Rose Johnstone, of McGill 
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University, and colleagues during their work on erythrocyte maturation (Johnstone, 
Adam, Hammond, Orr, & Turbide, 1987).  
 
1.6.2  Nomenclature 
 
The suffix -some (from sôma or body, σῶμα Gr.) is often attached to various terms 
referring to cellular organelles. Endosomes, for example, are membrane-bound 
vesicles located intracellularly and that substantially vary in size. The term “exosome” 
itself reflects the similarity between the vesicular extrusion of exosomes and reverse 
endocytosis (see Biogenesis below)—this was coined by Johnstone. Descriptive 
terminology attached to exosomes, however, has been confusing. One system names 
the vesicles based upon the source from which they are obtained. For example, 
epididimosomes are obtained from semen, whereas oncosomes are derived from 
cancerous cells. The other system employs methods of isolation and mechanisms of 
biogenesis to make the distinction between the different extracellular vesicles.  
 
1.6.3  Biogenesis 
 
The synthesis pathway of exosomes is intricate and complicated—the details of which 
are beyond the scope of the biological markers study. In brief, contents of the intra-
cellular endosomes destined to be exported out of the cell are packaged into 30-100 
nm vesicles. During this multi-step process, the membrane of these packaging 
vesicles acquires several proteins, including cluster of differentiation antigen 63 
(CD63)—which has been utilised as a marker for exosomes.  
 
The formation of the package bodies results in the presence of multiple vesicles 
within the endosome itself, which is why it is also referred to as a multi-vesicular 
body (see Figure 2-10). If the membrane of the endosome fuses with the plasma 
membrane of the cell, the vesicular contents are excreted out of the cell, and are called 
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exosomes. Once released, such vesicles may be taken up by the same secreting cell, a 
neighbouring cell or a distant cell; akin to previously described autocrine, paracrine 
and endocrine signals, respectively.  
 
 
Figure 2-10. Pathway of exosome biogenesis according 
to Akers et al (reproduced with permission 2013); 
MVB = multi-vesicular body. 
 
1.6.4  Isolation of exosomes 
 
The classic method of isolating extracellular vesicles has been differential 
centrifugation and ultracentrifugation. They are then classified into different 
categories according to size, density and expression of protein markers. This 
approach, however, has recently proven problematic for several reasons (Colombo, 
Raposo, & Thery, 2014). 
 
First, the utility of traditional centrifugation and ultracentrifugation methods is 
limited since neither technique lends itself as amenable for high-throughput 
screening, often required in clinical applications. Furthermore, it is now known that a 
single cell may produce different extracellular vesicles, some of which share 
characteristics and functions. Finally, using protein markers to classify exosomes may 
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be challenging as such proteins are often found in cells of multiple lineages. In the 
case of CD63, for example, its presence has been documented in vascular 
endothelium, leucocytes and platelets. Whether CD63 can, thus, serve as a reliable 
marker for exosomes remains debatable, and further studies are essential to 
determine the specificity and sensitivity of CD63 for exosomes.  
 
The International Society for Extracellular Vesicles, as a result, has expressed concern 
over the quality of published literature utilising these methods and has, therefore, 
published guidelines to standardise extracellular vesicle isolation methods. Colombo 
and colleagues have recently reviewed the various methods employed and the 
evidence behind each (2014). 
 
1.6.5  Exosomes in the CNS 
 
1.6.5.1 Physiological processes 
 
Exosomes have been described in a number of processes—both physiological and 
pathological—within the CNS. Exosomes have been implicated in normal neuronal 
development, as demonstrated by in vitro secretion of exosomes by cortical and 
hippocampal neurons (Akers et al., 2013). In response to nerve injury, Schwann cell-
derived exosomes have been shown to stimulate axonal healing and neuronal 
regeneration (Lopez-Leal & Court, 2016). Moreover, exosomes serve as a 
communication vehicle between different neurons (Schiera, Di Liegro, & Di Liegro, 
2015). For instance, Frühbeis et al have documented exosome-mediated 
oligodendrocyte-to-neuron, and vice versa, communication (2013). Not only that, but 
exosomes released from oligodendrocytes were also found to contain neuroprotective 
substances (glycolytic enzymes, proteins and RNA) when signals were generated 




Even beyond the confines of the CNS, exosomes were found to have transferred 
genetic material from haematopoietic cells and Purkinje neurons, implying a neuro-
immune signalling response in inflammatory states (Ridder et al., 2014), and 
providing indirect evidence that peripheral exosomes are able to cross the BBB. More 
direct evidence comes from peripherally injected exosomes which were found to 
cross murine BBB and to be present in neurons (Alvarez-Erviti et al., 2011).  
 
1.6.5.2 Pathological processes 
 
In contrast to the described neuroprotective function of exosomes, they have also 
been suggested to perpetuate neurodegeneration in certain pathological processes. 
Exosome-mediated transfer of misfolded proteins (e.g., mutated α-synuclein protein 
in PD) has been shown to occur from diseased cells to the extracellular milieu and to 
normal cells (Stuendl et al., 2016). Indeed this propagation pattern is an aetiological 
characteristic of several of the neurodegenerative disorders which progress along 
distinct neuroanatomical pathways. 
 
1.6.5.3 Exosomes in PD 
 
In serum samples obtained from PD patients (idiopathic and genetic), the most 
common type of microsomes were found to be exosomes; these exosomes did not 
differ in their size or concentration compared with samples obtained from healthy 
subjects (Tomlinson et al., 2015). However, analysis of the content of the exosomes 
from PD sera revealed characteristic protein changes. Twenty-three “exosomal” 
proteins were found much more abundantly in serum samples from PD patients 
compared with normal subjects and ALS patients (see Tomlinson et al., 2015 for 
detailed protein analysis). Furthermore, some of these proteins are known to possess 
antioxidant and/or chaperone properties (Tomlinson et al., 2015) which implies 
function-specific adaptation of exosome packaging in response to the disease state 
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(i.e., PD). Such peripheral (i.e., non-CNS) changes to exosomes have been described in 
PD (Besong-Agbo et al., 2013; Scherzer et al., 2007), although their significance is still 
debatable.  
 
Alpha-synuclein-containing exosomes were found to be in significantly higher 
concentrations in plasma of PD patients compared with controls (Shi et al., 2014); the 
investigators also found a significant correlation between exosomal α-synuclein 
concentration in plasma and PD severity (Shi et al., 2014). The same study by Shi and 
colleagues (2014), as well as other recent in vivo studies (Kunadt et al., 2015), have 
demonstrated the presence of α-synuclein in CSF exosomes in PD patients. However, 
unlike plasma, measurement of exosomal α-synuclein in CSF did not reveal any 
clinically meaningful correlations with PD status (Kunadt et al., 2015; Shi et al., 2014). 
 
 
1.7   Human eye movements 
 
1.7.1  The purpose of human eye movements 
 
Human saccadic eye movements serve a basic function: to rotate the eyes towards an 
object of interest so as to allow the brain to perceive it and its surrounding 
environment. The goal is to ensure that the image of the object of interest falls on the 
fovea centralis, where visual acuity is at its sharpest and colour sensitivity is maximal. 
Because the body and the object can be stationary or in motion, an intricate system of 
other eye movement types exists also (Swenson, 2006). 
 
1.7.2  Types of human eye movements 
 
Five types of eye movements fall within one of two functional classes (Anderson & 
MacAskill, 2013). The first class of eye movements serves to swiftly bring the fovea 
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centralis to bear on the object of interest. This primarily requires a fast ‘jump’ of the 
eyes from a previous target to the newly acquired target. Such eye movements are 
referred to as saccades (Vilis, Hepp, Schwarz, & Henn, 1989; discussed in more detail 
in the following section). Once the object of interest is fixated, the second class of eye 
movements tries to stabilise the fovea on the object of interest regardless of body or 
object motion. To achieve this, four other types of eye movements are utilised, which 
are: optokinetic nystagmus (OKN), smooth pursuit, vergence (convergence and 
divergence) and vestibulo-ocular reflexes (VOR; rotational and translational). 
 
To illustrate the different types of eye movements, consider the following example: 
the buzzing sound of a nearby bee reflexively catches the attention of a man reading a 
book and he rapidly shifts his sight towards it (i.e., saccades). As the bee flies from 
side to side, he follows its movements (i.e., smooth pursuit). If the bee is joined by a 
swarm of bees flying from side to side, OKN allows his eyes to follow the swarm (via 
a combination of saccadic and pursuit eye movements). Alternatively, if the bee flies 
away from him into the distance, his eyes will diverge as it moves further and further. 
If the bee flies towards him, however, his eyes will converge as it moves closer and 
closer. If the bee flies very close to him, he may try to avoid it by moving his head to 
one side while still looking at it. The VOR compensates for head movements by 
generating eye movements of equal magnitude but in the opposite direction 
(Swenson, 2006). 
 




As briefly noted in the previous section, saccades are rapid eye movements that are 
often described as jump- or jerk- like movements of the eyeball (Yarbus, 1967; pp. 129-
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147). Saccades are so rapid that, combined with other central processes, we cannot see 




Types of saccadic eye movements can be grouped into one of two categories, based 
upon the setting in which each type is more likely to occur. The first category—which 
encompasses eye movements that are more likely to occur naturally (i.e., in real 
life)—includes memory-guided saccades, microsaccades and reflexive saccades 
(Anderson & MacAskill, 2013). Memory-guided saccades refer to saccadic eye 
movements made towards a location where, from memory, the required information 
is most likely to be. For example, a Windows© PC user automatically looks at the top 
right corner of the screen to locate the X button when trying to close an active Word 
document. Microsaccades are smaller jumps of the eye that occur spontaneously upon 
ocular fixation (Swenson, 2006). They are thought to be essential to save visual 
perception from fading (Martinez-Conde, Macknik, & Hubel, 2004), to correct 
fixations (Otero-Millan et al., 2011), as well as being involved in other attention and 
perception functions (see review by Martinez-Conde, Macknik, Troncoso, & Hubel, 
2009). Lastly, reflexive saccades, perhaps the most intuitive to understand, refer to 
eye movements made when a new target appears at a random location eccentric to a 
previous point of fixation (Anderson & MacAskill, 2013). The man in our previous 
example made a reflexive saccade shifting his eyes from the book to the bee. A fourth 
type of saccadic eye movements, spontaneous saccades, is sometimes grouped with 
this category. It refers to ‘aimless’ saccades made during another activity (e.g., 
speech) or while resting in the dark before falling asleep (Pierrot-Deseilligny, Rivaud, 
Gaymard, Muri, & Vermersch, 1995). 
 
The other category involves saccadic eye movements that are much less likely to be 
experienced outside laboratory settings. This category includes antisaccades and 
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delayed and predictive saccades. Antisaccades denote the action of suppressing 
looking at a target and instead making a saccade in the opposite direction. Predictive 
saccades, on the other hand, refer to saccades between two targets alternating 
between fixed positions at a fixed rate (Anderson & MacAskill, 2013). Such eye 
movements, albeit artificial, can be particularly helpful in behavioural psychology 




In the following sections and chapters, a few saccade-related parameters will be 
mentioned repeatedly. It is helpful, therefore, to establish a definition of each of these 
parameters (Wilson, Glue, Ball, & Nutt, 1993). Saccade amplitude refers to the size of 
the saccade, which in turn determines the accuracy of the saccade. Amplitude is 
frequently measured in degrees or, less frequently, in arcminutes (i.e., 1o = 60 
arcminutes). Non-angular measures of amplitude may also be used (e.g., eye 
movements during reading), but these are often used in specific fields of study 
unrelated to work presented here. A related parameter to amplitude is gain. The gain 
is the ratio of the participant’s saccade amplitude divided by the desired saccade 
amplitude (i.e., target eccentricity). Under ideal conditions, this ratio is approximately 
one or slightly less; deviation from this norm is referred to as saccade dysmetria. 
Thus, gains greater than one denote a hypermetric saccade (i.e., one that is too large), 
whereas gains less than one signify a hypometric saccade (i.e., saccade that is too 
small). 
 
Saccade duration is the total time it takes to complete the saccade. Most saccades are 
completed within tens of milliseconds (ms). Saccade latency refers to the time it takes 
from the appearance of a target to the onset of a saccade in response to that target. 
Unlike other saccade parameters, latency is tremendously variable (typically 70-350 
ms). Finally, saccade peak velocity is the highest speed reached during a saccade. 
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Slowed saccades have reduced velocities, but can still be fairly accurate (Beydagi, 
Yilmaz, & Suer, 1999). 
 
1.7.3.4 Neural pathway 
 
The neural network underlying human saccadic eye movements is complex and 
involves multiple cortical and subcortical structures. To complicate matters further, 
each specific saccade type has a partially differing neural circuit within the network. 
To help understand the overall organisation of such a complex system, it is useful to 
start with ‘the big picture’; that is, an area triggers a signal which may be modulated 
by various other areas within the brain before an oculomotor response (i.e., a saccade) 
is generated. 
 
There are three major cortical areas that directly trigger saccades when stimulated, 
and at least two other major areas involved in the preparation of saccades. Each area 
appears to specialise, albeit partially, in triggering a specific type of saccade or a 
specific amplitude of saccadic eye movement (Pierrot-Deseilligny et al., 1995). Areas 
that directly trigger saccades are the frontal eye field (‘FEF’; Petit et al., 1993), the 
parietal eye field (Muri, Iba-Zizen, Derosier, Cabanis, & Pierrot-Deseilligny, 1996) and 
the supplementary eye field (‘SEF’; Paus, Petrides, Evans, & Meyer, 1993). Areas 
preparing saccades are involved in the cognitive aspect of saccade generation, and 
include the anterior cingulate gyrus (motivational modulation of saccades) and the 
dorsolateral prefrontal cortex (‘dlPFC’; modulation of saccades based upon the 
environmental context; (Paus, Petrides, Evans, & Meyer, 1993; Petit et al., 1993). 
 
The generated output signals are relayed, via the corticostriatal pathway, to the basal 
ganglia (discussed in further detail in the following section). From there, signals 
travel to the superior colliculus (SC) and brainstem, where motor impulses are 
generated and a saccade is initiated (see review by Sparks, 2002). 
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1.7.3.5 The role of the basal ganglia 
 
The basal ganglia are aggregated subcortical grey-matter nuclei situated deep within 
the white matter. The basal ganglia influence human saccadic eye movements via two 
pathways: direct and indirect (elaborately reviewed by Hikosaka, Takikawa, & 
Kawagoe, 2000). Among the basal ganglia involved in saccadic regulation are the 
caudate nucleus (CN), external globus pallidus (GPe), substantia nigra pars reticulata 
(SNr) and subthalamic nuclei (STN). The SNr, located in the midbrain, plays a 
particularly integral role as it receives signals from the CN (in the direct pathway), 
and the GPe and STN (in the indirect pathway) as explained below. 
 
As alluded to in the previous section, saccadic neural signals are relayed to the SC 
and brainstem before a motor impulse can be generated. The SNr tonically inhibits 
the SC, which leads to the suppression or termination of the saccadic neural signal 
(Hikosaka, Sakamoto, & Usui, 1989). For a saccade to be generated, the CN exerts a 
‘direct’ inhibitory effect on the SNr, effectively dis-inhibiting the SC. This ‘double 
negative’ approach is thought to be more precise compared with a pure excitatory 
circuit (Hikosaka et al., 1989). 
 
In the indirect pathway, the GPe and STN (activated by GPe and higher centres) 
stimulate the SNr—the function of which is to inhibit the SC—(Parent, Bouchard, & 
Smith, 1984). Therefore, this leads to the suppression of saccades, which may not 
always be undesirable. For example, fixating on a stationary object of interest requires 
the suppression of saccadic eye movements. 
 
The two pathways, although appearing antagonistic, are not mutually exclusive, and 
often function in concert (K. Nakamura & Hikosaka, 2006). The net result is 
suppression of unwanted saccades whilst facilitating appropriate ones. It is when 
such physiological balance is disturbed that eye movement abnormalities arise. One 
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such ‘disturbance’ is the degeneration of the basal ganglia seen in PD (Yugeta et al., 
2010). 
 
1.7.4  History of eye movement recording 
 
1.7.4.1 History of laboratory-based eye movement recording methods 
 
It has been around 115 years since eye movements were first recorded; in 1901, Dodge 
and Cline produced the first photographic evidence of eye movement recordings (in 
Wade & Tatler, 2005). Since then, studies on human eye movement behaviour started 
appearing in the literature. Tasks during which eye movements were recorded were 
largely restricted to the confines of the laboratory. This was because the rudimentary 
eye-tracker systems utilised then had to be mounted on a bench, and for which 
recordings necessitated a stationary-held head. Eye movements were recorded from 
participants who were reading (Buswell, 1920), typing (Butsch, 1932) and viewing 
pictures (Buswell, 1935). 
 
These early studies showed that ocular fixations precede motor actions. However, it 
was not until the seminal work of Russian psychologist Alfred Yarbus from the 1950s 
that an understanding of the role of human eye movements (especially saccades) in 
visual exploration was cemented (Yarbus, 1967). Instead of being mere reflexive 
responses, he showed that the behaviour of eye movements changes drastically based 
upon the task asked of the subject (i.e., a “top-down” control of eye movements).  
 
1.7.4.2 History of dynamic eye movement recording methods 
 
Bench-mounted eye trackers, although robust, restrained eye movement research to 
stationary tasks with a laboratory setting. To study the behaviour of eye movements 
during real-life dynamic activities, another eye tracking system was needed. In the 
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1950s, a British psychologist, Norman Mackworth, successfully devised a portable eye 
tracker which employed a helmet-mounted camera (Thomas, 1968). Although bulky 
and cumbersome to use, Mackworth and his colleagues were able to widen the circle 
of tasks for which eye movements could be recorded. In 1962, he was able to study 
the eye movements of drivers (Mackworth & Thomas, 1962). 
 
Through the years, portable eye trackers decreased in size and increased in capability 
(Duchowski, 2003). Technology shifted from being based upon scleral shift coils to 
modern infrared video recording technology (van der Geest & Frens, 2002). By the 
1990s, eye movement scientists finally managed to escape the laboratory and study 
eye movement behaviour in a range of real-life tasks, including: driving (Land & Lee, 
1994), playing table tennis (Land & Furneaux, 1997), reading music (Furneaux & 
Land, 1999), making tea (Land, Mennie, & Rusted, 1999) and playing cricket (Land & 
McLeod, 2000). 
 
Current portable eye trackers are much more sophisticated than Mackworth’s (e.g., 
modern trackers utilise two cameras instead of one). Applications of remote eye 
tracking have expanded and the current technology has enabled a transition of the 
study of oculomotor behaviour from bench to bedside. Such clinical applications 
include the examination of eye movement patterns of radiologists (Kundel, Nodine, 
Conant, & Weinstein, 2007) and the study of gaze responses in visually-impaired 
children (Kooiker et al., 2016). 
 




Given the crucial role of the basal ganglia in the generation of appropriate saccades, it 
is expected that abnormalities of saccades occur in basal ganglial disease (e.g., PD). In 
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fact, studies on saccadic parameters in PD have been reported since as early as the 
1960s (Anderson & MacAskill, 2013). Until recently, however, results have been 
inconsistent and, if not contradictory (see examples in Crawford, Goodrich, 
Henderson, & Kennard, 1989; O'Sullivan et al., 2008; and Ventre, Zee, Papageorgiou, 
& Reich, 1992). Such disappointing results can be potentially explained by several 
factors as explained below. 
 
Human development and ageing 
Munoz and colleagues (1998) found saccade latency in humans decreases 
dramatically until around 12 years of age, and only starts to slowly increase past age 
30. In another study, subjects over 50 years tended to perform memory-guided 
saccadic tasks less reliably and to be distracted more easily by visual stimuli (Fukuda 
& Hikosaka, 1994). Basal ganglial function was hypothesised to underlie such 
differences as the basal ganglia undergo development until the age of 12, and then 
start to undergo slow age-related degeneration after 50 years of age (Fukuda & 
Hikosaka, 1994). Because idiopathic PD is considered a “disease of the old”, age is 
less likely to have significantly contributed to such inconclusive results. However, it 
should still be taken into account in saccade studies involving young patients with 
familial PD and early-onset idiopathic PD. 
 
Disease heterogeneity 
Parkinsonism encompasses several heterogeneous, and often pathologically distinct, 
clinical syndromes. When “idiopathic” PD patients are selected for a saccade study, 
the diagnosis is usually made upon clinical criteria alone, without autopsy 
confirmation (see review in Brooks, 2012). Different parkinsonsian syndromes may 
have different saccadic profiles, leading to discrepancies if grouped together as a 





Effect of dopamine-replacement therapy 
Another factor to consider when examining the eye movement literature in PD is the 
effect of dopamine-replacement therapy on saccades. Previous studies have revealed 
conflicting findings, including both improvement and deterioration of eye movement 
performance. Two mechanisms could explain such a discrepancy: task-specific effects 
of dopaminergic medications (e.g., reactive vs. memory-guided; Cubizolle, Damon-
Perriere, Dupouy, Foubert-Samier, & Tison, 2014; Terao, Fukuda, Ugawa, & 
Hikosaka, 2013), and a form of dopamine-dysregulation dysfunction to the 
oculomotor system (Terao, 2014). 
 
Methodological inconsistency  
Most saccade studies in PD patients until around 2011 involved a small number of 
participants (Anderson & MacAskill, 2013). The resultant low statistical power can be 
another contributing factor to the reported conflicting results. 
 
Cognition status 
Cognitive status has been repeatedly shown to influence performance of saccadic 
tasks (Mosimann et al., 2005). PD patients displaying even mild impairment of 
cognition performed less well compared with PD patients with normal cognition 
(MacAskill et al., 2012). Failure to account for cognitive status may underscore the 
inconclusive findings of early saccades studies in PD. 
 
1.7.5.2 Cognitive deficits in PD and eye movements 
 
More recent saccades studies in PD, which have addressed some of the 
abovementioned factors, have started to shed light on particular patterns of saccade 
abnormalities in PD patients. Perhaps the most useful method of exploring the 
literature is by stratifying the studied PD populations according to cognitive status 
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for abnormalities of real-life (i.e., via clinical examination) and ‘artificial’ (i.e., in a 
laboratory setting) saccades. 
 
Eye movement abnormalities in PD patients with normal cognition 
It is thought that the manifestations of eye movement dysfunction in PD patients with 
normal cognition (PD-N) are directly due to the loss of dopaminergic terminals 
within the basal ganglia. Eye movement abnormalities that occur later in the course of 
the disease may instead be related a more widespread dopamine-independent 
neuronal loss (Terao et al., 2011). Clinical examination of eye movements may only 
reveal subtle abnormalities in patients with early PD, the most common of which are 
hypometric saccades (White, Saint-Cyr, Tomlinson, & Sharpe, 1983). In the laboratory, 
these patient exhibit hypometric memory-guided saccades and increased errors in 
antisaccades. Moreover, when asked to visually explore line drawings, PD patients 
were found to scan smaller regions (compared with controls), a result of smaller 
saccade amplitudes and longer fixation intervals (Matsumoto et al., 2011). 
 
Eye movement abnormalities in PD patients with mild cognitive impairment 
Clinical examination findings in PD patients with mild cognitive impairment (PD-
MCI) are largely similar to those in PD-N patients. However, in the laboratory, there 
appears to be a direct correlation between cognitive dysfunction and saccade latency. 
Increased latency is particularly prominent in reflexive and memory-guided saccades 
(Terao et al., 2011). As cognitive status deteriorates, eye movement abnormalities 
similar to those observed in PD-D, though milder, start to manifest (MacAskill et al., 
2012).  
 
Eye movement abnormalities in PD patients with dementia 
There is a paucity of published literature on eye movement dysfunction in demented 
PD patients (PD-D). In one study, PD-D patients were less likely to make predictive 
saccades and more likely to make errors when performing antisaccade tasks 
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(Mosimann et al., 2005). MacAskill and his colleagues (2012) found reflexive saccade 
latency, but not amplitude, to vary significantly with cognitive status, being more 
prolonged in PD-D patients than in PD-MCI patients (but not in PD-N patients 
compared with normal controls). Archibald et al, on the other hand, found PD-D 
patients to exhibit reduced saccadic amplitudes and longer fixation durations (2013). 
Their study, however, involved cognitively demanding visual exploration tasks, 
rather than random targets. 
 
 
1.8   Neuropsychological testing 
 
1.8.1  Introduction 
 
Neuropsychological assessment began in the early 1900s, when educational 
psychologists Spearman, and later Binet and Simon, began trying to quantify the 
elusive notion of ‘intelligence’ (Boake, 2002). Since then, a plethora of tests have been 
developed, getting more refined and reliable by the day. The scope encompassed by 
such tests is vast, and what began as techniques to measure intelligence or screen 
army recruits have now been expanded to include innumerable educational tests. 
Such tests are helping scientists today in understanding the nature and varieties of 
mental abilities, both from normal and pathological perspectives. 
 
This section provides an introduction to the neuropsychological tests used in my 
behavioural markers study. A brief history and description of the test is followed by a 
review of the test performance in different patient groups (especially PD). I then 
relate the test to the eye movements required to support it. I believe this will provide 
a unique insight into cognition and oculomotor control, especially in PD participants; 
such information is not ordinarily gathered when the tests are carried out in the 








As examining eye movements would allow “careful observation” of how PD patients 
proceeded on neuropsychological tasks, this justified my motivation to study them. I 
decided to address the associations between eye movement and the performance on 
seven tasks (detailed below) in PD patients. 
 
In the behavioural markers study, a battery of neuropsychological assessments was 
used to test key cognitive domains (discussed below), including executive function, 
language, learning and memory, processing speed, visuospatial function, and 
working memory and attention. Owing to the exploratory nature of the behavioural 
markers study, the main focus was to obtain an “overall impression” of eye 
movement behaviour during the performance of several neuro-psychological tests. 
 
Standardised tasks were chosen for a number of reasons. First, the use of overly 
complicated tasks does not generally offer any additional advantage over simpler 
tasks. In fact, the opposite may be true; Lezak et al (2012) comment that complex tasks 
are generally less likely to yield meaningful information pertaining to a specific 
cognitive deficit. Furthermore, simpler tasks were easier to project visually, and the 
resultant eye-tracking data were not prohibitively laborious to analyse. Lastly, 
performing such neuropsychological tests while wearing an eye-tracker or being fixed 
to a machine is, at the very least, rather uncomfortable; relatively simpler tasks, with 
frequent breaks in between, provided the participants with sufficient comfort and 
ease to get through the whole study. 
 
 
… numerical scores convey only a limited amount of information about an 
individual’s performance. Careful observation of how patients proceed on 
constructional tasks and the types of errors they make is necessary to distinguish the 
possible contributions of perceptual deficits, spatial confusion, attentional 
impairments, organizational limitations, motor planning and/or execution 
difficulties, even motivational problems. 
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Cognitive domains refer to the various mental processes that encompass a human’s 
ability to acquire and understand knowledge. Naturally, such processes work in 
unison to allow for a smooth navigation of the world. Whilst a few 
neuropsychological tests have been designed as global assessments of cognition (e.g., 
the Mini-Mental State Examination), other tests attempt to examine the specific 
contribution of certain domains in a given task. This latter category of 
neuropsychological tests may be especially useful in trying to delineate the nature of 
“cognitive impairment” with which the patient presents. For PD patients, specific 
assessment of five cognitive domains has been recommended by the Movement 
Disorders Society Task Force (Litvan et al., 2011); these are: attention and working 
memory; executive function; language; memory; and visuospatial function. 
 
1.8.2.2 Attention and working memory 
 
This domain pertains to the ability to store, maintain and retrieve items on a short-
term time-scale (Just & Carpenter, 1992). Neuropsychological tests used to assess 
attention and working memory including the digits forwards, backwards and 
sequencing tests, and the Symbol Digits Modalities Test (SDMT; discussed below). 
 
1.8.2.3 Executive function 
 
Executive function refers to the capability of simultaneously controlling and 
coordinating higher-order processes, such as working memory, task switching, 
planning and goal-oriented activities (Elliott, 2003). Executive function is assessed by 
81 
 
a number of neuropsychological tests, including the Category Switching Test, Stroop-




Language involves a range of complex and intertwined skills (Saur et al., 2010). These 
include processes to express as well as to comprehend oral (i.e., speech) and written 
language. Such processes are the sine qua non of effective communication with others, 
and patients in whom language processes are defective (e.g., post-stroke aphasia) are 
particularly prone to mental health disorders especially depression (De Ryck et al., 
2014). Two neuropsychological tests commonly used to examine language are the 




Memory refers to the ability to encode, store, consolidate and recall information 
pertinent to the long-term acquisition of knowledge about skills and experiences. 
Long-term memory has been categorised into implicit and explicit memories. Implicit 
memory is that which is subconsciously acquired and utilised; procedural memory, a 
form of implicit memory, refers to the ability to perform particular tasks without 
conscious awareness or attention to previous experiences (Schacter, 1987). Explicit 
memory (also referred to as declarative memory), on the other hand, involves the 
conscious recollection of concepts and personal experiences (episodic memory) as 
well as factual information (semantic memory; Ullman, 2004). 
 
Of relevance to the behavioural markers study was the assessment of episodic 
memory of participants. This is because such memory is particularly affected by age-
related as well as neuropathology-related cognitive impairment. In addition, episodic 
memory is relatively easier to assess than other types of long-term memory (e.g., 
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procedural memory; Tromp, Dufour, Lithfous, Pebayle, & Despres, 2015). Relevant to 
the current thesis, recent research has examined the effect of anthocyanin powder, 
extracted from blueberries, on episodic-like memory in mice (Beracochea et al., 2016). 
In humans, episodic memory can be assessed both verbally (e.g., the California Verbal 
Learning Test-II) and non-verbally (e.g., the Brief Visuospatial Memory Test-Revised).  
 
1.8.2.6 Visuospatial function 
 
This domain comprises processes that not only enable a person to perceive the visual 
world (e.g., shapes, angles and details), but also perceive spatial relationship between 
objects and their environments and reproduce what they see if needed (Mervis, 
Robinson, & Pani, 1999). This intricate system allows for successful and meaningful 
navigation in the environment. Neuropsychological tests to assess visuospatial 
function include the Judgement of Line Orientation (JLO) and the Rey-Osterrieth 
Complex Figure copy test. 
 
1.8.3  Neuropsychological tests used in the behavioural markers study 
 
1.8.3.1 Judgement of line orientation 
 
Judgement of line orientation (JLO) examines the visual perception of angular 
relationships. The participant is presented with two angle ‘test’ lines, in full or in part, 
and is asked to match them to 11 numbered ‘reference’ lines (which form a semi-circle 
below the test line pair; see examples in Figure 4-11). JLO exists in two forms, H and 
V, both of which possess the same items but arranged in a different order. A learning 
effect from re-testing subjects was inconsequential in normal controls and minimal in 







The original JLO consists of 30 items, generally arranged in an ascending order of 
difficulty. Subjects are shown five practice items prior to commencing the actual test. 
Each test item is scored 1 for correct responses and 0 for incorrect responses; thus 
giving a score range of 0-30. Scores ≥ 23 are considered normal, while scores < 18 are 
considered a fail and often indicate severe cognitive deficit (Benton, Varney, & 
Hamsher, 1978). Scores of women and subjects older than 75 years tend to be 
consistently lower than scores of men and younger subjects. Therefore, score 
correction factors for age and sex are applied depending upon the participant’s 
demographics. 
 
PD patients have been reported to score significantly lower on the JLO test than 
matched normal controls. Performance does not appear to be influenced by disease 
severity or duration (B. E. Levin et al., 1991), although a single study did show a 
correlation with both parameters (Montse et al., 2001). PD patients were also found to 




Figure 4-11. Two examples of JLO's test lines (a) 
to be matched to the corresponding reference 




Visuospatial dysfunction has been proposed to underlie the inferior performance by 
PD patients (Hovestadt, de Jong, & Meerwaldt, 1987). Making such a claim can be 
problematic, however. This is because assessment of specifically visuospatial function 
in PD patients is often confounded by problems with attention, frontal lobe function, 
information processing speed and manual dexterity. 
 
The nature of the JLO test means that it is unlikely to be confounded by frontal lobar 
dysfunction (Benton, Hannay, & Varney, 1975), or speed of processing or 
psychomotor abilities (Finton, Lucas, Graff-Radford, & Uitti, 1998). Nonetheless, the 
‘traditional’ use of the JLO remains slightly challenging for PD populations. The 
reasons behind this are twofold; first, JLO does not differentiate an attentional deficit 
from a visuospatial dysfunction as an explanation for the inferior performance by PD 
subjects. Moreover, the ‘traditional’ method of scoring JLO (i.e., counting the number 
of correct and incorrect responses and assigning a single overall score) ignores 
potentially interesting information on the mechanism of errors made. To illustrate, 
the score of a subject who makes six systematic errors (solely right-sided items, for 
example) becomes indistinguishable from a subject whose six errors were spatially 
random. 
 
A more detailed analysis by Ska et al (1990) classified JLO errors into different types 
(see Table 4-3). Using the Ska classification, analysis of errors made by PD subjects in 
one study revealed significantly higher rates of intraquadrant-type (QO2 and QO3; 
refer to Table 4-3) errors compared with normal controls and AD patients (Finton et 
al., 1998). Another larger study corroborated these findings, as well as detecting 








Table 4-3. Ska classification of JLO error types (1990; adapted with permission). 
Abbreviation Description 
QO1 An oblique line is incorrectly identified as another oblique line and 
is different by only one spacing. 
QO2 An oblique line is incorrectly identified as another oblique line and 
is different by two or three spacings. 
QO3 Both oblique lines are displaced one or two spacings in the same 
direction, and maintain the initial spacing. 
QO4 Both oblique lines are displaced without maintaining the initial 
spacing. 
V The vertical line is incorrectly identified as an oblique or 
horizontal line. 
H A horizontal line is incorrectly identified as an oblique or vertical 
line. 
VH The vertical line and one of the horizontal lines are incorrectly 
identified. 
IQO An oblique line is displaced from the original quadrant to the 
other quadrant. 
IQOV An oblique line is displaced from the original quadrant to the 
other quadrant, and the vertical line is incorrectly identified. 
IQOH An oblique line is displaced from the original quadrant to the 
other quadrant, and a horizontal line is incorrectly identified. 
 
1.8.3.2 Montreal Cognitive Assessment 
 
Introduction 
The Montreal cognitive assessment (MoCA) was developed in order to overcome the 
limitations of the MMSE in detecting patients with MCI or early dementia 
(Nasreddine et al., 2005). Several reports indicated that the MMSE was inadequate in 
differentiating patients with MCI or mild dementia from healthy elderly individuals, 
primarily due to a ceiling effect (Ihl, Frolich, Dierks, Martin, & Maurer, 1992; Wind et 
al., 1997). 
 
The MoCA is freely accessible online (www.mocatest.org), which contributes to its 
increasing popularity. It is available in three English versions to minimise any 
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learning effects, and is also available in many other languages and in a modified 
version for the blind. 
 
The MoCA is an easy and quick tool to aid in assessing global cognitive status within 
the clinical setting. It takes 10 to 15 minutes to administer, and was designed to test 
eight different cognitive areas. These include: attention and concentration, 
calculations, conceptual thinking, executive function, language, memory, orientation 
and visuoconstructional skills. A 30-point scale assesses abstract thinking (i.e., 
commonality between two words), confrontational naming (i.e., three animal 
illustrations), digit repetition forwards and backwards, five-minute delayed recall of 
five words, orientation for place and time, sentence repetition, serial subtraction, 
sustained attention using target detection, verbal fluency for a single letter, and 
visuospatial and executive functioning (i.e., abbreviated trail making test, cube 
copying and clock drawing; Lezak et al., 2012; pp. 770-771). 
 
MoCA in PD 
In the original validation study (Nasreddine et al., 2005), a cutoff score of ≥ 26 was 
defined as normal. To account for the “education effect”, the developers proposed an 
addition of one point for subjects with 10-12 years of education, and two points for 4-
9 years of education. Currently, the MoCA Normative Data for Age, Culture and 
Education trial is underway (Nasreddine, 2013); it aims to provide normative data 
across ages and education levels for 10 different languages and cultures. 
 
To date, the MoCA has been successfully used in patients with various disorders 
including PD. The superiority of the MoCA over the MMSE in PD has been 
corroborated by multiple studies. The MMSE remains an unvalidated tool in PD, with 
no optimal screening cut-off score (Hoops et al., 2009), and inadequate sampling of 
executive functions (Zadikoff et al., 2008). Compared with the MMSE, the MoCA is 
less prone to a ceiling effect (Mamikonyan et al., 2009; Nazem et al., 2009), better 
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assesses cognitive domains particularly affected by PD (namely, executive and 
visuospatial functions; Gill, Freshman, Blender, & Ravina, 2008; Kasten, Bruggemann, 
Schmidt, & Klein, 2010), and holds adequate psychometric properties that support its 
use as a stand-alone cognitive screening tool (Chou et al., 2010; Watson et al., 2013). 
Furthermore, the MoCA demonstrated better diagnostic ability to delineate PD-N, 
PD-MCI and PD-D as compared with the MMSE. Suggested MoCA screening scores 
were PD-N ≥ 26, PD-MCI 21-25 and PD-D ≤ 20 (Dalrymple-Alford et al., 2010). 
 
Animal identification task 
Confrontational naming refers to the ability to name objects when prompted by, in 
the case of the MoCA for example, line drawings. The process of naming is complex 
and commonly requires effective visual-perceptual, semantic as well as phonological 
processing (Tsang & Lee, 2003). Goodglass and Wingfield hypothesised a two-stage 
process to naming (1998). The first stage entails a direct link between an object and its 
name, leading to a quick response by the person. If this link is interrupted, however, a 
second stage is activated in which a slower associative process is involved. This way, 
the person might use associated words, concepts or sounds (e.g., rhinoceros for a 
hippopotamus) to self-prompt (Tartter, 1998). 
 
Compared with their young counterparts, older subjects were found to make more 
errors and take longer when naming objects from pictures. These could be attributed 
to a multitude of reasons including age-related neuronal loss, as well as a reduction in 
the speed of sensory and motor processing (Tsang & Lee, 2003). Moreover, older 
subjects tend to be cautious and more rigid when performing cognitive tasks, 







1.8.3.3 Matrix reasoning 
 
The matrix reasoning (MR) task is made up of a series of visual pattern completion 
and analogy problems. The subject is required to choose the item that best completes 
the pattern from a multiple choice array. The test is presented in a 2x2 matrix (hence 







When MR was first introduced, it was designed as a measure of the subject’s fluid 
intelligence (Gf1). Gf is the ability to solve problems in novel situations, irrespective of 
prior acquired knowledge. Gf has been linked to the dorsolateral prefrontal cortex 
and anterior cingulate cortex (Duncan et al., 2000). 
 
The MR task is thought to contrast with other WAIS-III tests, such as Vocabulary, 
which measure crystallised intelligence (Gc); this refers to the ability to solve 
problems based upon previous experiences and knowledge, and thus tends to 
                                                 
1 The notion of a general intelligence (also known as the g factor) was first conceptualised by 
Charles Spearman, and later by his student, Raymond Cattell (Cattell, 1971). 
Figure 4-12. An example task of the MR (Harcourt 
Assessment Inc., 2005); reproduced with permission. 
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improve with age. Gc has been linked to brain regions associated with long-term 
memory, including the hippocampus (Mangina & Sokolov, 2006). 
 
The notion of MR measuring Gf has been recently disputed, however (Glascher et al., 
2009). In a recent study by Travel et al, patient subgroups with prefrontal cortical 
damage (dorsolateral and/or ventromedial) did not score any differently on the MR 
task than patients with brain damage outside the prefrontal cortex (2009). In fact, 
scaled score means of the MR and Vocabulary tasks were identical for patients with 
prefrontal cortical damage. The authors explained that MR may actually be more of a 
“hold” test that reflects the subject’s premorbid intelligence (i.e., shows little change 
with brain damage). 
 
To date, specific data on MR in PD patients are lacking. Almost all studies that have 
used the various versions of Wechsler’s scales in PD have failed to report the subscale 
data (i.e., individual test results, such as MR or Vocabulary results).  
 
1.8.3.4 Visual search tasks (Where’s Wally?™ and Jeddah map) 
 
To be able to get by in daily life, humans are dependent upon intact “mechanisms of 
attention” (Lezak et al., 2012; pp. 426); that is, they ought to be able to direct their 
attention to a particular task, divide attention if distracted, and sustain attention until 
the task-at-hand is completed. Research on normal human behaviour when searching, 
maps for example, has been an area of active research. Colour-coding items on a map 
has been shown to reduce search times (Philips, 1979). Shive and Francis modelled 
map search times based upon target eccentricity and target-distractor colour 
distinctiveness (2013).  Providing distractions (e.g., interactive maps), on the other 
hand, was disadvantageous to performance (Yeh & Wickens, 2001). Whilst research 
on eye movements on map search tasks per se is lacking, useful insights into human 




Humans have been found to perform at a near optimal level during visual 
exploration (Chukoskie, Snider, Mozer, Krauzlis, & Sejnowski, 2013; Najemnik & 
Geisler, 2005). Despite exhibiting poor inter-fixation processing of information (Irwin, 
1991) and not having perfect memory (Hayhoe, Bensinger, & Ballard, 1998), we are 
able to efficiently process information from each fixation. We achieve this by 
employing efficient eye movement strategies whilst utilising minimal neural 
resources (Najemnik & Geisler, 2005). 
 
Visual search tasks vary in their complexity according to the required cognitive and 
attentional demands; they can range from simple free-viewing scenes to more 
demanding scenes (e.g., searching a map) or even specifically designed ‘puzzle’ 
scenes with busy backgrounds and one or more distractors (e.g., Where’s Wally?™). 
Otero-Millan and his colleagues showed that saccade dynamics varied noticeably 
according to the scene shown and tasks(s) performed by participants (2008). 
Compared with a blank scene, participants made more saccades which were of 
shorter durations and smaller magnitudes when shown a Where’s Wally?™ scene 
(Otero-Millan et al., 2008). 
 
1.8.3.5 Symbol digit modalities test 
 
The Symbol digit modalities test (SDMT) is a symbol substitution test that 
predominantly examines speed of processing for material that demands complex and 
sustained attention. However, such skills as motor persistence, oculomotor scanning 
and visuomotor coordination are also required for good performance on the test (A. 
Smith, 1982). 
 
In the reference key, each of the novel symbols is accompanied by a number from one 
to nine. Below the key are rows of boxes filled with any one of the symbols, below 
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each of which is an empty box where the corresponding number is to be filled in by 
the subject (see Figure 4-13). There is a total of 120 boxes (the first 10 are used for 
practice), and the subject is awarded one point for each correctly coded item. Age-






Unlike other symbol substitution tests, the format of the SDMT offers three 
advantages. First, participants solve the test by writing numbers, a more familiar 
action when compared with drawing the symbols as done in WAIS-IV’s Coding task. 
Moreover, the SDMT may be administered orally as well as in written format, as the 
responses require numbers rather than symbols. Third, because the symbols used 
contain three pairs of mirrored figures, the SDMT is potentially able to uncover more 
subtle difficulties with attention and orientation (A. Smith, 1982). 
 
While the SDMT has been used in many neurological disorders, including AD 
(Fleisher et al., 2007), HD (Lemiere, Decruyenaere, Evers-Kiebooms, Vandenbussche, 
& Dom, 2002; Starkstein et al., 1988), MS (Huijbregts et al., 2004) and TBI (Draper & 
Ponsford, 2008), its use in PD has been less common. This is perhaps due to the fact 
that SDMT performance, especially for the written version, is speed-dependent; 
therefore, motor slowing in PD would be an evident disadvantage. 
 
Figure 4-13. The key and first row of empty boxes to be 
filled by participants completing the task (adapted SDMT 
version from Benedict et al., 2012). 
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PD patients have been shown to perform worse on the SDMT compared with normal 
controls. In the studies published in PD groups, only the oral version of the SDMT 
was used. Hansch and his colleagues (1982) found a significant relationship between 
SDMT scores and P300 latency. The P300 is a class of long-latency positive components 
of event-related potentials that provide means of evaluating cognitive function 
independent of specific motor responses. Furthermore, Worringham et al have shown 




1.9   Overall aims and hypotheses 
 
1.9.1  Overall aims 
 
The overarching aim of the work presented (i.e., biological markers and behavioural 
markers studies) is to examine the role of different biomarkers at various stages of the 
disease process: early in the disease course when neuroprotectants are needed (i.e., 
blackcurrant anthocyanin and insulin-like growth factor-1 trials), in established PD 
(i.e., C-type natriuretic peptide trial) and as the disease progresses to involve 
cognition (i.e., exosomes trials and eye movement studies). 
 
Specific aims are discussed in the introductory section of each chapter to follow. The 
hypotheses, based on the above review of the pertinent literature, are outlined in the 
concluding section below. 
 
1.9.2  Project hypotheses 
 
In the previous sections, I contended that a single biomarker is unlikely to 
encapsulate the multitude of clinicopathological aspects of PD. Therefore, I 
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hypothesised that several biomarkers of different categories and types ought to be 
employed at the various stages of the disease. This way, clinically meaningful 
changes in disease status—both motor and non-motor—may be captured. 
 
I further hypothesised that analyses of metabolites present in biofluids— plasma and 
CSF—may potentially identify biological markers for assessing PD status and 
progression—these, in turn, could be employed in future clinical research, therapeutic 
trials, and overall patient care.  Finally, I hypothesised that a detailed assessment of 
saccadic function during cognitively-demanding tasks in PD patients may assist in 



































































2.1   Participants 
 
The protocol of this study was approved by the Upper South A Regional Ethics 
Committee, New Zealand (reference URA/10/03/022). The initial proposed sample 
size (n = 20) was opposed by the Ethics Committee who recommended “no more than 
10 to 12” participants ought to undergo two LP for research purposes.  All 
participants gave written informed consent before any study-related procedures were 
done. The study stretched over six months. The start date was 05/09/2010 and the stop 
date was 05/03/2011. 
 
Participants were eligible to enrol in the study irrespective of the stage of disease or 
time since diagnosis. All participants were aged 40 years or older and met the Queen 
Square Brain Bank criteria for idiopathic PD as confirmed by a movement disorders 
neurologist (TA). All participants were recruited form the Van der Veer Movement 
Disorders Clinics and the New Zealand Brain Research Institute volunteer database, 
and were initially approached by the Primary Researcher (YA). 
 
Exclusion criteria included any other explanation for parkinsonism (e.g., drug-
induced parkinsonism) or a history of CNS disorders (apart from mild TBI). A history 
of a major medical illness which might impede on the absorption or excretion of 
blackcurrant antioxidant species, such as significant gastrointestinal or renal 
disorders, was also considered as an exclusion criterion. Likewise, participants with 
hypertension or metabolic disturbances (including protein synthesis disorders), or 
those who were smoking, excessively consuming alcohol (i.e., more than 15 standard 
units per week), pregnant, breast-feeding or obese (body mass index ≥ 30 kg/m2) were 
also excluded, since these factors have been reported to disturb normal functioning of 
the BBS (Haussermann et al., 2001; Robert, Godeau, Moati, & Miskulin, 1977). Finally, 
participants were excluded if they did not speak and read English, had major 
depression within the past six months, had a major cognitive or psychiatric disorder 
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or any other contraindications to study-related procedures, such as anticoagulation 
therapy or hypersensitivity to blackcurrants or gelatine. 
 
 
2.2   Study setting 
 
2.2.1  Study design 
 
The study was designed as an open-label study of biofluids aiming at determining the 
concentrations of various biological metabolites in the plasma and CSF of PD 
participants. It was planned as a repeated measure, within-subjects design, 
comparing plasma and CSF metabolite concentrations four weeks apart. The study 
was divided into three visits, and all participants had to present to the NZBRI for 
these visits. 
 
2.2.2  Visit one 
 
This visit was to ensure that all participants had understood what the study involved 
and that they agreed to participate. An informed consent form was provided for all 
participants to sign; a photocopy of the form was supplied to the participant upon 
request. Next, the participants underwent several assessments of their PD course, as 
well as other general health and cognitive assessments. These included the Hospital 
Anxiety and Depression Scale (HADS), the MMSE, the Montreal Cognitive 
Assessment (MoCA) and the Movement Disorders Society (MDS) Unified Parkinson’s 
Disease Rating Scale (UPDRS). The visit lasted about 75 minutes. At the end, 
participants were instructed to consume an anthocyanin-low diet starting 12 hours 
prior to each of their subsequent visits. Major constituents of this diet included white 




2.2.3  Visit two 
 
This visit took about 5 hours. It involved taking samples to measure metabolite 
baseline levels in the CSF (through an LP done by a clinician) and in the blood 
(through venepuncture of a vein in the antecubital fossa by the primary researcher). 
All patients were observed for a period of four hours in case post-LP headache 
developed. After that, participants were given the blackcurrant capsules and were 
instructed to take 6 capsules daily. This visit was designated day = 0 of treatment. 
 
2.2.4  Visit three 
 
This visit was four weeks after visit two (day = 28) of treatment and lasted about 6 
hours. All assessments of PD, general health and cognition were repeated (i.e., LP, 
venepuncture, HADS, MMSE, MoCA and UPDRS). Participants were also 
encouraged to provide feedback on any improvements or adverse effects they had 
noted since starting the intervention. During this visit, participants took their last 
dose of blackcurrant capsules; and samples of CSF and blood were drawn again after 
30-45 minutes of the last capsules consumed. All patients were observed for a period 
of four hours in case post-LP headache developed.  This marked the termination of 
the blackcurrant anthocyanin treatment. 
 
 
2.3   Cerebrospinal fluid sample collection and analysis 
 
2.3.1  Setting 
 
All participants were supplied with an information sheet on LP (Neurosciences Ward, 
2005) to read while equipment was being prepared. Participants were encouraged to 
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ask questions. Risks were explained again verbally prior to the procedure. All LP 
were performed by a senior registrar-level clinician (neurology or anaesthesia). 
 
2.3.2  Equipment 
 
Cardinal Health® (Ohio, USA) lumbar puncture trays (see Figure 2-1) were used. We 
utilised 22G pencil-point (atraumatic) spinal needles with stylets. CSF samples were 
collected in coded plain Falcon tubes™ (BD Biosciences®, Massachusetts, USA). 











2.3.3  Technique 
 
All LP were performed with the participants in the lateral decubitus position. Most 
participants chose to lie on the left side, since it was easier given the setup of clinical 
rooms. Some participants, however, preferred to lie on the right side for one or both 
LP because of associated musculoskeletal symptoms (e.g., arthritis or back pain). 
Anatomical landmarks (i.e., anterior superior iliac crests for an L3/L4 level) were 
assessed by clinical examination. 
 
An aseptic method was employed. The skin was cleaned with chlorhexidine 
gluconate 0.5% in 70% alcohol (Riotane, Perrigo®, Australia). Anaesthesia of the skin 
and soft tissues was achieved by injecting 5 ml of lidocaine 1% (Claris, Multichem NZ 
Limited, NZ). Once in the subarachnoid space, CSF pressure was measured and 
recorded. 
 
Around 7 ml of clear CSF was collected by each LP. One LP resulted in blood-
contaminated CSF, which did not clear with continued dripping of CSF. The sample 
was discarded and another LP at a higher level (L2/L3) was attempted and resulted in 
obtaining clear CSF. The amount of CSF collected (around 7 ml) was substantially 
larger than the amount collected for clinical purposes (around 1-2 ml). Although 
seemingly high, greater volumes of CSF (as much as 30 ml) have been safely collected 
for research purposes in the past (Peskind et al., 2005). 
 
2.3.4  Interim processing of samples 
 
CSF samples were transported on wet ice to Endolab® (Christchurch, NZ) within 15 
minutes of collection. Upon arrival, samples were taken to the cold room, where they 
were centrifuged at 3 000 revolutions per minute (RPM) for 15 minutes. The 
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supernatant was aliquoted equally between two plain tubes and stored under -80 C in 
alarmed freezers within 30 minutes of sample receipt. 
 
Various analyses were conducted in several laboratories locally (i.e., CNP trial in 2011 
and exosome trial in 2014), nationally (i.e., IGF-1 trial in 2015) and internationally (i.e., 
blackcurrant anthocyanin trial in 2011). Due to the different assay requirements of the 
various biological markers studied, the collected samples were used fresh, frozen and 
thawed as per the collaborators’ recommendations. The CNP trial utilised fresh 
samples (i.e., pre-freezing). Frozen samples (one of the plain tubes from each 
participant) were sent internationally for the blackcurrant trial. Thawed samples were 
divided equally to allow sufficient volumes for the IGF-1 and exosome trials. The 
details of post-processing volumes of CSF samples sent to each laboratory are shown 
in Table 2-1. 
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BCA study CNP study Exosome study Growth factor study 
BCA CNP/NTproCNP cGMP NEP Exosomes IGF-1 cGP 














 CAA9200 1.6 ml 2.1 ml 1.1 ml 0.6 ml 0.6 ml None None 
CAA9202 1.6 ml 2.1 ml 1.1 ml 0.6 ml 0.6 ml None None 
CAA9203 1.6 ml 2.1 ml 1.1 ml 0.6 ml 0.6 ml None None 
CAA9204 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9205 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9206 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9208 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9210 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9218 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9219 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 














 CAA9201 1.6 ml 2.1 ml 1.1 ml 0.6 ml 0.6 ml None None 
CAA9211 1.6 ml 2.1 ml 1.1 ml 0.6 ml 0.6 ml None None 
CAA9212 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9213 1.6 ml 2.1 ml 1.1 ml 0.6 ml 0.6 ml None None 
CAA9214 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9215 Excluded as participant developed pneumonia around the time of the second visit 
CAA9216 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9217 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9221 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9222 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
CAA9223 1.4 ml 2.1 ml 1.1 ml 0.6 ml 0.5 ml 0.25 ml 0.05 ml 
BCA = blackcurrant anthocyanins; cGMP = cyclic guanosine monophosphate; cGP = cyclic glycine-proline; CNP = C-type 
natriuretic peptide; IGF-1 = insulin-like growth factor-1; NEP = neprilysin; NTproCNP = aminoterminal fragment of proCNP. 
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BD Vacutainer® Push Button Collection Sets (BD Biosciences®, Massachusetts, USA) 
were used. We utilised 21-guage needles. Blood samples were collected in coded 
EDTA- and heparin- coated BD Vacutainer® Push Button Collection Tubes (BD 
Biosciences®, Massachusetts, USA). Powder-free latex non-sterile examination gloves 




All blood samples were obtained by venepunctures of the antecubital fossa on the 
asymptomatic side. All venepunctures were performed by the primary researcher 
(YA). For one participant, however, two attempts of obtaining blood samples failed, 
and he was taken to the Blood Service at Canterbury Health Laboratories 
(Christchurch, NZ) where blood samples were obtained after two further attempts. 
 
An aseptic method was employed. The skin was cleaned with 70% isopropyl alcohol 
swab (Medi-Swab™, Smith & Nephew, London, UK) and allowed to dry. Around 15 
ml (divided equally between EDTA and heparin tubes) were collected by each 
venepuncture. The amount of plasma extracted from the collected blood was 
approximately 4.5 ml. 
 
2.4.3 Interim processing of samples 
 
Blood samples were transported on wet ice to Endolab® (Christchurch, NZ) within 45 
minutes of collection. Upon arrival, samples were taken to the cold room, where they 
were centrifuged at 3 000 RPM for 15 minutes. Plasma was aspirated into a plain tube 
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and stored under -80 C in alarmed freezers within 30 minutes of sample receipt. As 
with CSF samples, various analyses were conducted on the plasma samples in several 
laboratories locally (i.e., CNP trial in 2011 and exosome trial in 2014), nationally (i.e., 
IGF-1 trial in 2015) and internationally (i.e., blackcurrant anthocyanin trial in 2011). 
 
 
2.5   Study endpoints 
 
The primary efficacy endpoints were blood and CSF biological metabolite-
concentrations four weeks apart. Secondary end points were changes seen in PD 
standard questionnaires (i.e., UPDRS, HADS, MMSE and MoCA) over the same time 
period. 
 
The primary safety endpoints were reports of adverse events or incidental findings in 
CSF or blood analyses that would have negatively affected the results of the study. 
The participants were contacted by the primary researcher a day and again 10 days 
after their LP in case any adverse events had developed. Incidental findings of clinical 
significance by the CSF or blood analyses were directly discussed with the patient, by 
their physician (Prof. Tim Anderson). 
 
 
2.6   Statistical analysis 
 
Calculating the study power was a requirement of the application for ethical 
approval. With the initially proposed 20 participants, and a Type I error rate set at 
0.05, a one-tailed repeated measures t-test would have had a power of 0.79 to detect 
an effect size of 0.5 or greater. Complying with the Ethics Committee 
recommendations for the sample size (n = 11) led to a decrease in power to 0.46. For 
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data that departed substantially from a normal distribution, nonparametric statistics 




































3.1   Study sample characteristics 
 
3.1.1  Demographics 
 
Eleven participants were enrolled in the biological markers study. The mean age was 
66.5 years (± 11.0). All participants were male, and—except one participant who 
identified as Māori—all identified as Pākehā.  
 
The mean duration since symptom onset was 6.1 years (± 2.5), while the mean 
duration since diagnosis was 4.2 years (± 2.6). At the time of the trial, all participants 
except one were on anti-PD medications (levodopa in nine, and monoamine oxidase 
inhibitor in one). 
 
3.1.2  Anthropometric measurements 
 
One participant developed aspiration pneumonia during the blackcurrant therapy 
period, and was unable to undergo the second LP. Data on his vital signs were, 
therefore, excluded from Table 3-1. Prior to the LP, participants’ blood pressure and 
heart rate were recorded. Once the spinal needle was in the subarachnoid space, and 
before collecting the samples, CSF pressure was measured. 
 
Table 3-1. Pre-LP vital signs for all participants except one. 
 Visit 1 Visit 2 T-test p 
Systolic BP 
(mm Hg) 
Mean 136 141 t9 = -0.53 0.61 
SD 8 10 
Diastolic BP 
(mm Hg) 
Mean 77 82 t9 = -1.22 0.25 
SD 3 4 
HR (beats per 
minute) 
Mean 75 68 t9 = 1.15 0.28 
SD 5 3 
CSF pressure 
(cm H2O) 
Mean 15.3 13.8 t9 = 1.13 0.29 
SD 1.9 1.4 
BP = blood pressure; HR = heart rate. 
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Scores of the HADS were available for 10 participants, who completed the 
questionnaire both prior to commencing, and after finishing, the blackcurrant 
treatment. Participants scored significantly lower after receiving the blackcurrant 
therapy (see Table 3-2 for details). Significant reductions were present on the anxiety-
subscale but not the depression-subscale scores when examined separately. 
 
Table 3-2. Differences in HADS scores before and after blackcurrant therapy. 
  Before After T-test p 
Total HADS Mean score 9.5 5.4 t9 = 3.45 0.007 
SD 6.8 3.9 
Anxiety 
sub-scale 
Mean score 5.4 2.5 t9 = 2.69 0.025 
SD 3.6 1.8 
Depression 
sub-scale 
Mean score 4.1 2.9 t9 = 2.03 0.074 
SD 3.5 2.7 
 
3.1.3  Clinical staging 
 
Clinical staging of participants was performed using parts III and IV of the modified 
UPDRS (Goetz et al., 2007). Part IV of the assessment incorporates the modified 
Hoehn and Yahr scale (Goetz et al., 2004). Ten paired scores were available for both 
the UPDRS parts III and IV. No statistically significant differences were observed in 
motor function resulting from blackcurrant therapy (see Table 3-3). 
 
Table 3-3. Mean scores of parts III and IV of the UPDRS before and after blackcurrant therapy. 
 Before After T-test p 
UPRDS III Mean score 34.5 31.6 t9 = 0.32 0.32 
SD 12.5 11.7 
mH&Y* Mean stage 2.2 1.9 t9 = 0.21 0.21 
SD 0.2 0.7 
* = modified Hoehn and Yahr stage 
 
The more-affected side was also assessed in participants. Data were available for nine 
participants only; almost half of whom had right-sided symptoms (n = 4), whilst the 
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other half had left-sided symptoms (n = 5). All participants reported they were right-
handed. 
 
3.1.4  Neuropsychological tests 
 
There was virtually no change in the MMSE scores pre- and post- blackcurrant 
therapy. Moreover, even though the mean MoCA score after blackcurrant treatment 
was higher, this did not reach statistical significance. See Table 3-4 for details. 
 
Table 3-4. Participant scores of neuropsychological tests and UPDRS pre- and post- blackcurrant treatment. 
 Before After T-test p 
MMSE Mean score 28.5 28.6 t9 = -0.21 0.84 
SD 1.1 1.6 
Range 27-30 26-30 
MoCA Mean score 25.9 26.4 t9 = -0.89 0.40 
SD 2.6 3.6 
Range 22-29 21-30 
 
3.1.5  Discussion 
 
3.1.5.1 HADS scores 
 
Participants’ HADS scores on the anxiety but not depression sub-scale significantly 
decreased (i.e., improved) after a month of receiving blackcurrant therapy. Several 
explanations can account for this finding (Alamri, MacAskill, & Anderson, 2016). 
 
It could be suggested that the anxiety related to having an LP, especially for the first 
time, could have augmented HADS scores during the participants’ first visit. 
Understandably, anxiety about such an invasive procedure is often experienced by 
both patients (Peskind et al., 2005) and their caregivers (Haimi-Cohen, Amir, Harel, 




Studies to date on pre-LP anxiety have either utilised unvalidated anxiety measures 
(Peskind et al., 2005) or have investigated anxiety after the procedure has been 
completed (Haimi-Cohen et al., 1996; Peskind et al., 2005). In a study that evaluated 
anxiety before as well as after LP, scores were generally higher before the procedure 
(Nguyen, Nilsson, Hellstrom, & Bengtson, 2010). 
 
What may argue against this explanation, however, is the lack of difference exhibited 
by participants on more objective measures. Physiological parameters (i.e., blood 
pressure and heart rate) were not different between the two visits. This makes ‘pre-LP 
anxiety’ less likely to have been a significant confounder. 
 
It is difficult to attribute such positive effects to the blackcurrant treatment per se due 
to a number of reasons. First, a putative effect of blackcurrants may be biologically 
implausible in light of our findings of anthocyanins not reaching the CNS (see next 
section). Furthermore, participants of this open-label trial were pre-emptively aware 
of the intervention being administered, raising the possibility of a Hawthorne effect 
(e.g., altering their lifestyles or daily habits due to the knowledge of being observed). 
Finally, the attention our participants received during the study period could have 
positively affected their mood. 
 
With such potential confounding difficulties, it may not be possible to assess whether 
the observed association could be true. High dietary berry-fruit intake has been 
associated with multiple health benefits (Devcich, Pedersen, & Petrie, 2007), which 
could potentially include psychological wellbeing. Notwithstanding, the nature of the 
study cannot establish a true association between high blackcurrant anthocyanin 





3.1.5.2 Clinical staging 
 
Significant improvements on the UPDRS were not expected to be observed. PD is a 
chronic disease whose pathological processes are thought to start many years prior to 
diagnosis (Fearnley & Lees, 1991). The impetus for using neuroprotective agents in 
symptomatic PD patients is to slow or halt the neurodegenerative process, rather than 
restore lost dopaminergic cells (Yacoubian & Standaert, 2009). Still however, the 
biological markers study was not designed to examine this, as it was beyond the 
scope of the study. 
 
3.1.5.3 Neuropsychological tests 
 
There were no significant changes in the participants’ scores of the MMSE or MoCA 
between visits. For the MMSE, scores did not improve despite administration of the 
same test, which indicates no significant learning effect. In anticipation of this 
potential problem when designing the study, it was decided that two different 
versions of the MoCA would be administered on the two visits. Therefore, any 
observed changes should be more likely to reflect true changes rather than 
improvement due to a learning effect. 
 
One caveat is that the recruitment for this study did not control for the participant’s 
baseline cognitive function. Most participants were thought to have normal cognitive 
function, although three participants demonstrated an element of mild cognitive 
impairment (i.e., low scores on the MMSE and MoCA). This was not formally 
evaluated at the time, however. Whether the observed ‘no effect’ of blackcurrant 
anthocyanins on cognitive status was due to a ceiling effect—a commonly cited 
problem for the MMSE—remains a speculation. A dedicated study of potential effects 
of blackcurrant consumption on cognitive status in PD patients with cognitive 
impairment may perhaps shed light on this. 
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3.2   Blackcurrant anthocyanin trial 
 
3.2.1  Background and aim 
 
Before human clinical trials on a new therapy could be started, areas of potential 
methodological pitfalls should be studied in detail to try to minimise them and to 
yield more definitive results. In the realm of dietary antioxidants as neuroprotective 
agents, these, according to Kieburtz, include: a sound scientific rationale, efficacy and 
relevance in animal studies, safety and tolerability and BBB penetration (2006). The 
first three of topics have already been covered quite extensively in the previous 
chapters. 
 
There is no human study, to date, that has examined whether anthocyanins cross the 
BBB and be present in the CSF/brain in patients with neurodegenerative diseases. 
Therefore, the principle aim of this project is to examine whether any of the 
blackcurrant anthocyanin species cross the BBB and be present in the CSF of patients 
with PD. My hypothesis is that blackcurrant anthocyanin species would be detected 
in plasma, and also in CSF. A secondary aim of the study is to examine if any non-
anthocyanin phytometabolites are present in human CSF and plasma after 
blackcurrant ingestion. 
 
3.2.2  Methods 
 
3.2.2.1 Study intervention 
 
Blackcurrant anthocyanin concentrate capsules—Super Currantex® 20 (Just The 
Berries Ltd., New Zealand) were used in this study. Each capsule contained 100 mg of 
blackcurrant anthocyanins. Table 3-5 shows the nutritional facts of the trial capsules. 
Participants were instructed to take three capsules twice daily for a period of four 
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weeks, with the last dose taken at the beginning of Visit 3 (i.e., 45 minutes prior to 
biofluid sample collection). 
 
Table 3-5. Nutritional facts of the blackcurrant capsules used in the trial (as supplied by Just The Berries, 
Ltd.); GMO = genetically modified organisms. 
Main nutrients Per 2 capsules (1.39g) 
Energy 5.24 Kcal 
Protein 204 mg 
Fat 81 mg 
Carbohydrate 874 mg 
Vitamin C 200 mg 
Main ingredients Per 1 capsule 




Anthocyanins 100 mg 
Other ingredient(s) Gelatine capsule 
Does not contain Artificial flavours, preservatives, added sugar, 
salt, colours, gluten, wheat, yeast, dairy, soya, 
corn and GMO. 
 
3.2.2.2 Pre-analysis treatment 
 
Frozen CSF and plasma samples were sent to the James Hutton Institute, Dundee, 
Scotland. Samples were kept under -80 C at all times. Analysis of blueberries has not 
demonstrated significant effect on anthocyanin levels from sample freezing 
(Lohachoompol, Srzednicki, & Craske, 2004). 
 
To ensure removal of proteins and possible contamination in order to increase 
sensitivity prior to analysis, samples were subjected to a clean-up process. Each 
sample was divided into five 200 µl aliquots. Duplicate samples were subjected to a 
universal extraction procedure developed at the James Hutton Institute into which 10 
µg morin was added as an internal standard. This method (Dobson et al., 2004; 
Shepherd et al., 2007) uses a mixed chloroform, methanol, and water extraction stem 
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that yields two fractions, which contain polar (aqueous/methanol) and nonpolar 
(chloroform) metabolites (i.e., small molecular weight [< 2 kDa]). Briefly, samples 
were analysed on a LCQ-DECA system (Thermo, Hemel Hempstead, United 
Kingdom), comprised of a Surveyor autosampler, mass spectrometer-pump and 
photodiode array detector, and an iontrap mass spectrometer. Chromatography was 
performed on a C18 Synergi Hydro RP column (4 μm, 2 mm × 150 mm; Phenomenex, 
Macclesfield, United Kingdom), and the mobile phase used for the separation of 
crude samples was a linear gradient spanning 35 min of 0.2% formic acid in deionised 
water to 0.2% formic acid in 90% acetonitrile at a flow rate of 200 μl/min. The sample 
injection volume was 10 μl, and the re-equilibration time was 10 min. 
 
3.2.2.3 Chemical analysis 
 
The method details have been described elsewhere (Fortalezas et al., 2010). The 
method employed has been shown to detect anthocyanin species in both in vitro 
(Fortalezas et al., 2010) and in vivo (Dobson et al., 2004; Shepherd et al., 2007) studies 
with high sensitivity. 
 
In brief, metabolite analyses employed electrospray ionisation− mass spectrometer in 
positive- (proton charge) and negative- (electron charge) modes, using the following 
mass spectrometer conditions: sheath gas (N2), 70 psi; auxiliary gas, 15 psi; spray 
voltage, 4 500 V; and capillary temp, 250 C. Only the polar fractions were analysed 
and three technical replicates were used. All measured metabolites (including non-








3.2.2.4 Statistical analysis 
 
Significance was defined as measurable difference in metabolite levels pre- and post- 
treatment observable in ≥ 50% of patient population. A paired-samples t-test was 
conducted to compare anthocyanin levels before and after blackcurrant therapy. 
 
3.2.3  Results 
 
3.2.3.1 Subjective feedback 
 
Most participants did not notice any symptomatic improvement, motor or otherwise. 
One participant, however, experienced substantial subjective improvement in his 
tremor, and continues to take blackcurrant supplements to date. The only adverse 
effect of the blackcurrant capsules, reported by several participants, was dark black 
stools. 
 
3.2.3.2 CSF analyses 
 
Number of samples 
One participant developed pneumonia near the time of his second visit, and it was 
decided not proceed with the second LP. Therefore, a total of 20 samples (i.e., 10 
paired samples) were sent for analysis. 
 
Positive-mode analysis 
A total of 23 metabolites were detected. None of the four main blackcurrant 
anthocyanins (C3G, C3R, D3G or D3R) were identified in any of the CSF samples. 
Moreover, none of the identified compounds (i.e., other polyphenols, endocrine 
molecules and drug metabolites) were significantly different between the pre- and 





Forty-six metabolites were detected in total. Similar to positive mode analysis, no 
blackcurrant anthocyanins were identified, and the difference in concentrations of 
identified compounds did not reach statistical significance. 
 
3.2.3.3 Plasma analyses 
 
Number of samples 
Blood samples were successfully collected from all participants. Extracted plasma 
samples were 22 in total (i.e., 11 paired samples). 
 
Positive-mode analysis 
Compounds identified in plasma were substantially more numerous, 75, compared 
with CSF. However, none of the blackcurrant anthocyanins were identified. Several of 
the identified compounds were significantly higher in the post-treatment samples 
compared with pre-treatment samples. See Table 3-6 for a list. 
 
Table 3-6. List of compounds whose concentrations were significantly higher in plasma samples after 








Cortolone-3-glucuronide 0.77 1.22 
Decanoylcarnitine 1.27 1.57 
Epigallocatechin sulphate 0.85 2.48 
Kaempferol 0.45 2.14 
N-acetyl-L-glutamyl 5-phosphate 1.30 2.04 
P-glycoprotein 0.84 3.27 
UDP-L-rhamnose 0.59 2.19 






A total of 46 metabolites were detected. Similar to negative mode analysis of CSF, no 
blackcurrant anthocyanins were identified, and the difference in concentrations of 
identified compounds did not reach statistical significance. 
 
3.2.4  Discussion 
 
3.2.4.1 Subjective feedback 
 
Objective extrapolation of findings from subjective reports of improvements or harm 
may be problematic at the best of times. This is perhaps because claims cannot be 
easily measured or validated, especially when reported post hoc. 
 
It is interesting to note, however, that the participant who reported symptomatic 
relief of his tremor was the youngest (age 48 years). Whether this observation mounts 
to anything meaningful is doubtful given the small number of participants in the trial, 
and the known therapeutic benefit of the ‘placebo effect’ on PD tremor (Pogarell et al., 
2002).  
 
Stool colour may significantly be affected by the person’s diet. The dark pigment of 
anthocyanins is a well-established cause of dark/black stools in persons who consume 
large amounts of anthocyanin-rich diets (Escribano, Pedreño, García-Carmona, & 
Muñoz, 1998; Goehde, Ajaj, Lauenstein, Debatin, & Ladd, 2004). It is, therefore, not 
surprising that several participants reported this finding. The discoloured stool ought 
not to alarm the consumer; however, consumers of such supplements should be 
advised to seek prompt medical attention if faecal odour and consistency change—a 





3.2.4.2 CSF and plasma analyses 
 
The blackcurrant anthocyanin trial did not demonstrate the presence of blackcurrant 
anthocyanins in CSF and plasma samples of PD patients after a month of oral 
blackcurrant concentrate supplementation. To the authors’ knowledge, this is the first 
study to examine whether supplemental anthocyanins obtained through oral intake 
crossed the BBB in humans. 
 
Our findings, while intriguing, were unexpected. The oral bioavailability of 
blackcurrant anthocyanins—as obtained from plasma of healthy subjects consuming 
blackcurrant smoothies—is known to be high, ranging between 91.7 and 96.5% 
(Kuntz et al., 2015). The mean time to maximal plasma concentrations varies between 
58 to 68 minutes after ingestion of blackcurrant juice or smoothie (Kuntz et al., 2015). 
Whilst data on the anthocyanin bioavailability and time-to-maximal-concentration 
from blackcurrant capsule have not been formally studied, one would expect a 
reasonable rise in the plasma concentration after capsule ingestion—even to a just 
detectable level. 
 
Given the results of previous research showing the presence of anthocyanins in 
blackberry-fed animals’ brains, one would expect a similar presence in human brains. 
This apparent discrepancy, however, can be explained by several factors. 
 
First, we analysed CSF samples as a proxy of the presence of anthocyanins within the 
CNS. While it is unlikely that dietary anthocyanins would be present in the brain 
without being in the CSF, we cannot rule out this possibility with certainty. Previous 
animal studies have used brain-tissue extracts instead of CSF samples; this approach 




Second, animals used in previous studies were healthy animals, whereas our subjects 
had PD. Whether the compromised integrity of the BBB in PD patients affected the 
transport of anthocyanins to the CNS remains speculative. Current literature, 
however, argues against this possibility. For example, Kortekaas and colleagues have 
found an increased brain uptake of molecules that do not usually cross the BBB in PD 
rat models (2005). Moreover, BBB efflux transporters, such as P-glycoprotein, have 
demonstrated reduced activity in PD animal models (Schinkel et al., 1994) and 
patients on positron emission tomography scanning (Bartels et al., 2008). Therefore, it 
appears as if the BBB in PD can act like a safe that keeps molecules in and does not 
easily let them out. 
 
Finally, the significance of the time-lag between last dose ingestion and sample 
analysis is unclear. Previous research has confirmed the presence of intact 
anthocyanins in healthy human urine, but not plasma, after consumption of 
blackcurrant juice (Hollands et al., 2008; Netzel, Strass, Janssen, Bitsch, & Bitsch, 
2001). Jin et al were able to detect breakdown metabolites of blackcurrant anthocyanins 
in human plasma (2011). However, intervals at which blood samples were collected 
were not stated explicitly (“periodically up to 480 minutes after ingestion of 
[blackcurrant] juice”, Jin et al., 2011). In another study, anthocyanins were detected in 
plasma 1 (peak), 2 and 4 hours post-ingestion of purified anthocyanin supplements 
(Zhu et al., 2011). 
 
3.2.4.3 Compounds that increased significantly in plasma post-treatment 
 
Background 
The significant increase in plasma levels of the following non-anthocyanin 
compounds after blackcurrant treatment was not necessarily expected. Of note, none 
of all identified compounds significantly decreased post-blackcurrant 
supplementation. The pertinent literature was examined in a post hoc attempt to 
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rationalise our findings. However, because the literature is relatively scarce, most of 
the assertions below are merely speculative. 
 
Cortolone-3-glucuronide 
Cortolone-3-glucuronide is an endocrine by-product that results from the hepatic 
glucuronidation of cortolone in the human steroid synthesis pathway (Hosoda, 
Yokohama, & Nambara, 1984). Levels of cortolone-3-glucuronide in biofluids have 
been assessed as potential biomarkers in the metabolic syndrome (Yu, Ning, Yu, & 
Tang, 2014) and in studies of traditional Chinese medicine (Li et al., 2015; Wang et al., 
2015). 
 
There are no studies that examine the relationship between cortolone-3-glucuronide 
and blackcurrant anthocyanins. However, in a study of eight individuals, urinary 
levels of cortolone-3-glucuronide significantly increased after consuming 400 ml of 
citrus juice (orange and lemon juice mixture) daily for four days (Medina et al., 2013). 
The authors concluded that the detected rise might have been due to upregulation of 
the pathway by one or more compounds found in citrus juice (Medina et al., 2013). 
Whether a similar mechanism accounts for the observed increase in our study 
remains a conjecture. Studies on cortolone-3-glucuronide in relation to blackcurrant 
consumption are lacking. 
 
Decanoylcarnitine 
Also known as acylcarnitine, this compound is involved in the regulation of fatty acid 
metabolism, ketone body synthesis and blood glucose homeostasis (McGarry & 
Foster, 1973; Williamson, Browning, Scholz, Kreisberg, & Fritz, 1968). Clinically, 
measuring blood levels of decanoylcarnitine has been found to be useful in 
differentiating the several biochemical phenotypes of the umbrella disorder, medium-
chain acyl-CoA dehydrogenase deficiency (Gramer et al., 2015). To date, no studies 
have examined the relationship between decanoylcarnitine and blackcurrant 
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anthocyanins. Similar to the case of cartolone-3-glucuronide, blackcurrant treatment 
could have upregulated one or more pathways in which decanoylcarnitine is 
involved, leading to a demonstrable rise in plasma post-treatment. 
 
Epigallocatechin sulphate 
Epigallocatechin sulphate is the sulphated form epigallocatechin (EGC), a 
polyphenolic compound that belongs to the flavanol category of flavonoids (Kuhnau, 
1976). EGC is most abundant in tea (especially green and, to a lesser extent, black 
varieties; Singh, Shankar, & Srivastava, 2011). Even when taken in mega-doses, EGC 
has poor oral bioavailability. However, it has been detected in both human plasma 
(Chow et al., 2003) and urine (Lee et al., 2002) after oral intake. No study to date has 
reported the detection of EGC after blackcurrant ingestion or its presence in human 
CSF. 
 
Many health benefits have been attributed to EGC consumed in tea; perhaps more so 
than anthocyanins. Such benefits include anti-angiogenic effects (Domingo et al., 
2010), anti-cancer properties (reviewed in Yang et al., 2011), anti-infective effects 
(Steinmann, Buer, Pietschmann, & Steinmann, 2013) and anti-inflammatory and anti-
oxidant attributes in rheumatoid arthritis (Riegsecker, Wiczynski, Kaplan, & Ahmed, 
2013). Additionally, a topical green tea-extract (containing EGC) has recently been 
approved for use in condylomata accuminata (Furst & Zundorf, 2014). There are 
several open trials under way investigating the use of EGC in many disorders, 
including AD (Friedemann, 2015) and Huntington’s disease (‘HD’; Priller, 2015). 
 
Utilising the same rationale for using anthocyanins in PD (i.e., targeting OS), EGC has 
also been investigated in multiple in vitro and in vivo models of PD. EGC has been 
found to reduce the aggregation of α-synuclein monomers, thereby attenuating their 
toxicity (Lorenzen et al., 2014). Furthermore, EGC partially counteracted the effect of 
L-DOPA on cholinergic cell apoptosis (i.e., diminished dopamine autoxidation; Lee, 
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Choi, Lee, & Lee, 2013). In rat models, EGC reduced the neuroinflammatory response 
observed in lipopolysaccharide-induced PD (Al-Amri, Hagras, & Mohamed, 2013). 
 
Human studies exploring EGC and PD have been less numerous. Epidemiological 
studies have demonstrated an association between tea (especially green) consumption 
and a lower risk of PD in Finland (Hu, Bidel, Jousilahti, Antikainen, & Tuomilehto, 
2007), Singapore (Tan et al., 2008) and the US (Checkoway et al., 2002). In a phase II 
clinical trial, green tea polyphenol supplements resulted in significantly lower 
UPDRS scores at 6 but not 12 months (Chan, Qin, & Zheng, 2009). An ongoing clinical 
trial is investigating EGC in patients with multiple system atrophy (Levin, 2015). 
 
It is apparent that it may be challenging, if not impossible, to disentangle which 
compound(s) directly lower PD risk. For example, the observed inverse association 
between PD risk and tea consumption (see review by Caruana & Vassallo, 2015) may 
have been due to caffeine and not EGC. On the other hand, EGC has also been found 
in in vitro studies of blackcurrant fruit (Butnariu, 2014)  and leaves (Vagiri et al., 2015), 
although its level was the lowest compared with other polyphenols detected (Vagiri 
et al., 2015). Perhaps the observed lower risk of PD in populations who have high 
berry-fruit consumption (Gao, Cassidy, Schwarzschild, Rimm, & Ascherio, 2012) may 
have been due to a combination (or neither) of EGC and anthocyanins. 
 
Kaempferol 
Kaempferol is another phytochemical that is similar to EGC, but belongs to another 
flavonoid family, the flavonols (Kuhnau, 1976). Of the daily human intake of 
flavonols, kaempferol makes up around 20% (Liu, 2013), and is found in a variety of 
fruit and vegetables, including blackcurrants, blackberries, raspberries, peaches, 
broccoli, Brussels sprouts, cucumber, lettuce and squash (see review in Calderon-
Montano, Burgos-Moron, Perez-Guerrero, & Lopez-Lazaro, 2011). In in vitro studies, 
kaempferol levels were found to be comparatively higher in the leaves (Vagiri et al., 
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2015) than in the fruit (Mikkonen et al., 2001); no in vivo studies exist to date. Not only 
is kaempferol poorly absorbed (Barve et al., 2009), but it is also readily metabolised 
into its glucuronide, methyl and sulphate forms (Chen et al., 2010). 
 
Kaempferol appears to possess a number of beneficial health properties; these have 
been enumerated in multiple pre-clinical studies: potent anti-inflammatory activities 
(Crespo et al., 2008; De Melo et al., 2009), antioxidant effects (Erben-Russ, Bors, & 
Saran, 1987) and cancer-deterrent properties (Lin, Juan, Shen, Hsu, & Chen, 2003). 
Clinical studies, on the other hand, have been much less common. In fact, there 
appears to be only one study that is currently under way that is examining the role of 
kaempferol (in ginkgo biloba) on intra-uterine growth-restricted infants (Abdellah, 




Several molecules were detected in significantly higher quantities in plasma post-
blackcurrant treatment. These include: N-acetyl-L-glutamyl 5-phosphate, P-
glycoprotein and UDP-L-rhamnose. The significance of these seemingly ubiquitous 
molecules is uncertain. No literature exists in relation to linking these compounds 
with blackcurrant intake or in PD patients. 
 
3.2.4.4 Study limitations 
 
The trial had several limitations that deserve to be mentioned. The sample size was 
small (n = 11), mainly as a result of complying with Ethics Committee 
recommendations. Regardless of the sample size, the study was mainly geared as a 
proof-of-concept trial; in fact, conducting a full clinical trial may not be feasible at this 
stage (i.e., a sample of at least 21 participants would be required to detect a large 




Given the biological markers study only involved male participants, this limits the 
generalisability of the study results. Most studies on sex-based differences in the 
permeability of the BBB have been on animal models. In general, the BBB of female 
members of a species appears to be more permeable compared with males (see 
review by Oztaş, 1998), although this pattern was reversed in drosophila males when 
courtship factors were studied (Hoxha et al., 2013). The only indication of sex-specific 
differences in BBB permeability in humans comes from a single study in which 
females were found to have significantly higher CSF concentrations of endocrine 
amines compared with males (Odink, Korthals, & Vette, 1987). 
 
This sex-based difference in BBB permeability, however, is unlikely to fully account 
for the negative findings of the blackcurrant anthocyanin trial. Gao and colleagues 
found berry-fruit intake was associated with a lower risk of developing PD, more so in 
men than in women (Gao et al., 2012). 
 
The duration and dose of the blackcurrant therapy were chosen arbitrarily. However, 
the per-day intake of anthocyanins our patients received (600 mg per day) was well in 
excess of the reported average daily intake of 250 mg on a typical Western diet 
(Kuhnau, 1976). 
 
Finally, analysis of CSF and plasma samples was conducted in another country. 
Every step in specimen collection and transport was meticulously planned and 
carried out in accordance with scientific protocols (see an example by Tworoger & 
Hankinson, 2006). However, while compromises to sample quality arising due to 






3.2.4.5 Future research 
 
The findings, if corroborated, could have implications in future study of the dynamics 
of human BBB in patients with PD, especially in regards to drug and molecular 
delivery. Whether the putative benefits of high berry-fruit intake in protecting again 
PD are due to the usually-associated healthy lifestyle (Prendergast, Mackay, & 
Schofield, 2016) or the berry-fruit flavonoid compounds themselves ought to be 
studied further. To conclude, blackcurrant anthocyanins are not detected in plasma or 




3.3  Insulin-like growth factor-1 trial 
 
3.3.1  Background 
 
Endocrinology researchers took interest in IGF-1 and its metabolites probably well 
before any role of IGF-1 in neurological research was appreciated. With the recent 
surge in the incidence of acquired insulin resistance—most commonly in the form of 
type 2 diabetes mellitus—research into dietary habits has gained momentum (Goff & 
Duncan, 2010). 
 
Among these studies have been assessments of the role of dietary fruit and vegetable 
intake on the levels of IGF-1 and its metabolites. For instance, higher intake of fruit 
and vegetables early in life was found to be associated with higher levels of IGFBP-2 
(and perhaps IGFBP-3) in adulthood (Krupp et al., 2016). In a nematode model, an 
anthocyanin-rich feeding mixture was found to prolong the nematode’s life-span. The 
authors proposed that the anthocyanins led to the activation of transcription factors 
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that, in turn, interfere with insulin/IGF-1 signalling pathways (Chen, Muller, Richling, 
& Wink, 2013). 
 
The main aim of this study was to examine the effect of blackcurrant anthocyanin 
intake on CSF and plasma levels of IGF-1 and its metabolites in humans. This was 
done in an attempt to elicit a potential mechanism for the putative benefits on 
consuming berry-fruits in reducing PD risk; we hypothesise that this occurs through 
normalisation of the known IGF-1-resistance in PD. 
 
3.3.2  Methods 
 
3.3.2.1 Pre-analysis sample processing 
 
CSF and plasma sample acquisition and pre-analysis treatment have been described 
in the previous chapter. Frozen samples were allowed to thaw in room temperature. 
Once thawed, half the volume from each tube was kept in Christchurch for the 
exosome trial (see following section), whilst the other half was shipped on wet ice via 
World Courier® (AmerisourceBergen, Pennsylvania, USA) to The Liggins Institute, 
University of Auckland (Auckland, New Zealand). 
 
3.3.2.2 IGF-1 analysis 
 
Plasma and CSF IGF-1 level were measured using a commercially available Human 
IGF-1 ELISA Kit (Crystal Chem Inc., Chicago, Illinois, USA). Eighty μl of antibody 
conjugate were added to each well of the 96-well microplate pre-coated with anti-
IGF-1 antibody, then 20 µl of sample diluted 1: 21 in dilution buffer or 20 µl of 
standards were added to each well. The plate was placed on a shaker and incubated 
for an hour, then the well contents were washed five times using 300 µl of wash 
buffer per well. Subsequently, 100 µl of enzyme-conjugated anti-IGF-1 antibody were 
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added to each well and placed on a shaker to incubate for 30 minutes at room 
temperature, followed by another five times washing step using 300 µl of wash buffer 
per well. Then, 100 µl of substrate solution were added to each well and incubated for 
15 minutes in the dark at room temperature, and the reaction was stopped by the 
addition of 100 µl of stop solution. The absorbance was measured using a plate reader 
at 530 nm excitation wavelength and 590 nm emission wavelength. The assays were 
repeated twice for CSF samples (due to the limited amounts of samples available) and 
four times for plasma samples. 
 
3.3.2.3 cGP analysis 
 
Sample extraction of cGP  
cGP-d2 was used as an internal standard for cGP assay as described by (Singh-Mallah 
et al., 2016). cGP-d2 (50 μl of 500 ng/ml) was added to 100 μl of plasma, vortex mixed. 
The solution was transferred to a 1-ml Phree phospholipid removal cartridge 
(Phenomenex, Auckland, New Zealand) contained in a 4.5-ml tube. Five-hundred μl 
of 1% formic acid in Acetonitrile (MeCN) were added to the cartridge and centrifuged 
at 1 000 g for five minutes at 4 C to enable the collection of the filtrate. The filtrate was 
dried using a vacuum concentrator (1.5 millitorr ‘mTorr’ for an hour, then 0.7 mTorr 
for 45 minutes, at room temperature). The dried samples were reconstituted in 100 µl 
10% methanol/water and transferred to a UPLC vial for quantitation then centrifuged 
at 500 rpm for five minutes at 4 C to sediment any remaining particulates. Standards 
were prepared by spiking cGP into charcoal stripped human plasma, quality control 
samples, with cGP at two different concentrations, were utilised and then subjected to 
the same extraction procedure as the samples.  
 
HPLCms assay 
The chromatography conditions consisted of a Synergy Hydro 2.5 µm column 
(Phenomenex) 100 x 2 mm with an initial mobile phase composition of 10% 
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methanol/90% water flowing at 200 μl per minute with a column temperature of 35 C. 
The mass spectrometry conditions consisted of electrospray ionisation in positive 
mode with a voltage of 4 000 V, a sheath gas flow of 30 ψ, an auxiliary gas flow of 2 ψ, 
and a capillary temperature of 250 C. Fragmentation was achieved with argon at 1.2 
mTorr as the collision gas and a dissociation voltage of 35 V. The mass spectrometer 
was run in selective reaction monitoring mode with the following two transitions 
155.1 to 70.2 m/z and 157.1 to 70.2 m/z utilised for cGP and cGP-d2 respectively. The 
retention time for both peaks was 3.6 minutes. Unknown samples were quantitated 
using the peak area ratio of cGP/cGP-d2 compared with the standard curve of known 
concentrations.  
 
3.3.2.4 IGFBP-3 analysis 
 
Plasma and CSF IGFBP-3 levels were measured using a commercially available 
Human IGFBP-3 ELISA Kit (Crystal Chem Inc., Chicago, Illinois, USA). Fifty μl of 
dilution buffer were added to each well of the 96-well microplate pre-coated with 
anti-IGFBP-3 antibody, then 50 μl of sample diluted 1: 505 in dilution buffer or 50 μl 
of standards were added to each well. The plate was placed on a shaker and 
incubated for an hour, then the well contents were washed five times using 300 μl of 
wash buffer per well. Subsequently, 100 μl of enzyme-conjugated anti-IGF-1 antibody 
were added to each well and placed on a shaker to incubate for an hour at room 
temperature, followed by another five times washing step using 300 μl of wash buffer 
per well. Then, 100 μl of substrate solution were added to each well and incubated for 
30 minutes in the dark at room temperature, and the reaction was stopped by the 
addition of 100 μl of stop solution. The absorbance was measured using a plate reader 










Seven paired samples of CSF and 11 paired samples of plasma were available for 




Neither CSF concentrations nor plasma concentrations of IGF-1 changed significantly 
after commencement of blackcurrant therapy. In addition, there was no correlation 
between IGF-1 concentrations in the CSF and plasma (r = 0.09, p = 0.75), with a CSF: 




Concentrations of cGP in CSF increased significantly after blackcurrant therapy (t1,6 = 
4.58, p = 0.001). Plasma concentrations, on the other hand, remained largely 
unchanged. The correlation between cGP concentrations in CSF and plasma was 
significant (r = 0.69, p = 0.014); however, there was no correlation between cGP 
concentrations before and after blackcurrant treatment in CSF (r = 0.04, p = 0.87) or 
plasma (r = -0.12, p = 0.69). 
 
Blackcurrant supplementation had no effect on the cGP/IGF-1 ratio in either CSF or 
plasma. However, there was a significant correlation between plasma cGP/IGF-1 ratio 








Levels of IGFBP-1 were generally low in plasma and undetectable in CSF; this was 
unchanged from before or after blackcurrant therapy. IGFBP-2 was the predominant 
IGFBP in plasma; blackcurrant anthocyanin intake did not alter its CSF or plasma 
concentrations, however. IGFBP-3, on the other hand, was the principle IGFBP in 
CSF, but its CSF and plasma concentrations were unaffected by blackcurrant therapy.
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Table 3-7. CSF and plasma concentrations of IGF-1 and related metabolites before and after blackcurrant anthocyanin treatment. 
 CSF (ng/ml) Plasma (ng/ml) CSF: plasma ratio (%) 
N Before After N Before After Before After 
IGF-1 7 1.59 ± 0.6 2.29 ± 1.6 11 179 ± 47.1 175 ± 42.5 0.9% 1.3% 
cGP 7 7.8 ± 2.1 12.1 ± 2.3 11 14.5 ± 4.1 16.2 ± 8.2 53.8% 74.7% 
IGFBP-1 Undetectable 10 1.91 ± 0.8 3.1 ± 1.5 N/A N/A 
IGFBP-2 7 83.7 ± 12.2 85.5 ± 13.1 10 433.1 ± 120.6 408 ± 86.4 19.3% 21% 
IGFBP-3 7 24.8 ± 7.2 27.7 ± 8.7 11 3 038.9 ± 345 3 022.2 ± 179.5 0.8% 0.9% 
cGP = cyclic glycine-proline; CSF = cerebrospinal fluid; IGF-1 = insulin-like growth factor-1; IGFBP 
= insulin-like growth factor-binding protein; N/A = not available. 
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3.3.3.5 Correlation of biomarkers with patient characteristics 
 
Plasma concentrations of IGF-1 were examined for any correlation with the 
patients’ age, degree of motor impairment (as assessed by UPDRS-III) and 
degree of cognitive impairment (as assessed by the MoCA). No significant 
correlation was found between plasma IGF-1 concentration and age (r = 0.1, p = 
0.2), UPDRS-III score (r = -0.12, p = 0.96) or MoCA score (r = 0.22, p = 0.01). Owing 
to the limited number of available CSF samples and the low concentration of 
IGF-1 detected, similar correlational analyses with patient characteristics could 
not be conducted. 
 




This preliminary study of IGF-1 and related molecules in PD patients revealed 
two significant findings. Concentrations of cGP in CSF are correlated with the 
cGP/IGF-1 ratio in plasma; this, therefore, suggests that changes in CSF 
concentrations of cGP may serve as an indirect biomarker for monitoring IGF-1 
function in PD. Additionally, we found that blackcurrant supplementation is 




IGF-1-resistance has been reported in PD, as evident by reports of, albeit 
inconsistent, raised IGF-1 concentrations in plasmas of PD patients (Numao, 
Suzuki, Miyamoto, Miyamoto, & Hirata, 2014; Picillo et al., 2013). Akin to 
hyperinsulinaemia observed in insulin-resistant diabetic patients (Weyer, 
Hanson, Tataranni, Bogardus, & Pratley, 2000), increased hepatic production of 
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IGF-1 may be a physiological response to IGF-1 resistance in PD patients; unlike 
the established relationship between hyperinsulinaemia and diabetes, however, 
the cause/role of IGF-1-resistance and PD is unclear. 
 
The concentration of IGF-1 in CSF is approximately 1% of that in plasma, 
although no statistically significant correlation could be drawn between the two 
parameters. IGF-1 has been demonstrated to have a limited ability to cross the 
BBB (Thorne, Pronk, Padmanabhan, & Frey, 2004). This would support de novo 
synthesis within the CNS, although the less-likely speculation of slow uptake 




Unlike IGF-1, cGP is a smaller and more lipophilic molecule (Guan et al., 2007); 
these properties allow easier crossing of the BBB. This likely explains the 
observed high concentration of cGP in CSF (around 52% of that in plasma pre-
blackcurrant treatment and around 71% of that in plasma post-blackcurrant 
treatment). Another source of CSF cGP might be de novo metabolism of CSF IGF-
1; this only appears to play a minor role, however (Yamamoto & Murphy, 1995). 
 
3.3.4.4 cGP/IGF-1 ratio 
 
We observed a statistically significant correlation between plasma cGP/IGF-1 
ratio and cGP concentration in CSF. Because the majority of circulating IGF-1 is 
biologically inactive (Binoux, 1995), merely increasing total IGF-1 concentrations 
in plasma may not necessarily overcome the proposed state of resistance (within 
the limits of homeostasis). Instead, increasing cGP concentrations (a metabolite 
and also a regulator of IGF-1 bioavailability) may be another compensatory 
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mechanism for the proposed IGF-1-resistance in PD. This, in turn, may explain 
the observed high cGP/IGF-1 ratio. 
 
Impairment of IGF-1 function has recently been reported in a small case series of 
obese women (Guan et al., 2015). The investigators demonstrated the utility of 
the plasma cGP/IGF-1 ratio as a biomarker for weight change. Whether this can 
be extrapolated to PD remains very theoretical. This is mainly because of the 
differences in pathophysiological parameters between the two conditions (see 
Table 3-8), although a recent review (Spielman, Little, & Klegeris, 2014) 
highlighted more links than previously considered in the literature. 
 
Table 3-8. Major differences between IGF-1-related biomarkers in obesity and PD. 
 Obesity Parkinson’s disease 
Site of IGF-1 resistance Peripheral Central > peripheral 
cGP/IGF-1 ratio High in plasma High in CSF > plasma 
Main IGFBP IGFBP-3 (in plasma) IGFBP-2 (in CSF) 
cGP = cyclic glycine-proline; CSF = cerebrospinal fluid; IGF-1 = insulin-like 




The profiles of the different IGFBP in PD are not well-documented. In a study of 
biofluid concentration of IGF-1-related biomarkers, PD patients had higher 
concentrations of all IGFBP compared with controls (Mashayekhi, Mirzajani, 
Naji, & Azari, 2010); the reported concentrations, however, were uniformly low. 
Moreover, Reijnders and colleague found IGFBP-2 to be the predominant IGFBP 







3.3.4.6 Role of blackcurrant anthocyanins 
 
The findings of the IGF-1 trial analyses lend some support to our conclusions 
derived from the present trial. We hypothesised a potential neuroprotective 
effect of blackcurrant anthocyanins on dopaminergic neurons, since no 
anthocyanin species per se could be detected in plasma or CSF. In this trial, we 
found cGP concentrations in CSF increased significantly after blackcurrant 
therapy. Dietary anthocyanins (from consumed berry-fruits) may exert their 
neuroprotective effect, if any, by influencing the BBB’s endothelial/ependymal 
cellular milieu (leading to a subsequent change of molecular trafficking or 
vascular resistance, for example). Indeed, the effects of anthocyanins on 
improving endothelial function (Zhu et al., 2011) and vascular resistance (Liu, Li, 
Zhang, Sun, & Xia, 2014) have been demonstrated in in vitro and in vivo studies. 
Our conclusions, however, remain highly speculative given the small sample and 
the lack of larger more robust corroborative studies. 
 
 
3.4   C-type natriuretic peptide trial 
 
3.4.1  Background 
 
In serum, levels of NTproCNP have been utilised as a marker for inflammation 
(a pathological process suggested to be a harbinger to PD development). Two 
studies by the same group have found elevated NTproCNP levels in sera of PD 
patients (Koziorowski, Tomasiuk, Szlufik, & Friedman, 2012), especially in 
patients receiving dopamine agonist therapy (Tomasiuk, Szlufik, Friedman, & 
Koziorowski, 2014). The authors concluded that drugs such as ropirinole had a 





To date, there appears to be no study that has examined CNP levels in the CSF of 
PD patients. Given the paucity of CNP research in the CSF of PD patients, the 
main aim of this trial was to measure CNP (and related biomarkers) levels in 
collected biofluid samples. Our hypothesis is PD patients would have higher 
concentrations of CNP and/or NTproCNP in the CSF. A secondary aim was to 
attempt to draw any correlations between measured biomarker levels and 
disease characteristics of PD participants. 
 
3.4.2  Methods 
 
3.4.2.1 Pre-analysis sample processing 
 
CSF and plasma sample acquisition and pre-analysis treatment have been 
described in the previous chapter. Sample analysis was undertaken in Endolab® 
(Christchurch, New Zealand). 
 
3.4.2.2 Sample analysis 
 
CNP assays utilised a commercial CNP-22 antiserum (Phoenix Pharmaceuticals, 
Belmont, CA). This antiserum also cross-reacts equally with CNP-53, which is the 
main bioactive form in the human CSF (Espiner, Dalrymple-Alford, Prickett, 
Alamri, & Anderson, 2014). Within and between assay coefficients of variation 
were 3.8% and 5.5% respectively at 9 pmol/l (Espiner et al., 2014). NTproCNP in 
CSF was measured by radio-immunoassay (as described by Schouten et al., 2011) 
after extraction using Sep-Pak® cartridges (Waters Corporation, Massachusetts, 
USA). Within and between coefficients of variation were 6.8% and 8.4% 




3.4.2.3 Statistical analysis 
 
Initial inspection of the data revealed multiple outliers which would have 
skewed relationships tested by the parametric Pearson’s correlation. Therefore, 
nonparametric statistics were employed instead. In addition, results from the 
present study were compared with data from a population reference group 
(Schouten et al., 2011). 
 
3.4.3  Results 
 
3.4.3.1 CSF samples 
 
A total of 21 CSF samples (11 pre- and 10 post- blackcurrant therapy) were 
available for CNP analysis. The median CSF concentration of CNP was 8.6 
pmol/l (range 4.9-19.0), whereas the median NTproCNP concentration in CSF 
was 677 pmol/l (range 487-1340); see Figure 3-1. No correlations between CSF 
concentrations of CNP and NTproCNP were evident in samples collected from 
visit 1 (r = 0.17, p = 0.61) or visit 2 (r = 0.26, p = 0.47). The median NTproCNP/CNP 
ratio in CSF was 79.9 (range 53.7-144.4). Blackcurrant anthocyanin intake did not 
alter CSF concentration of CNP or NTproCNP. 
 






































There was no significant association between CNP-related parameters in CSF 
and disease duration or severity. However, the NTproCNP/CNP ratio was 
positively associated with the participant’s age (r = 0.63, p < 0.001). CSF opening 
pressure was negatively associated with age (r = -0.61, p = 0.048), but unrelated to 
NTproCNP/CNP ratios. No consistent effect of systolic, diastolic or pulse 
pressures was noted on the concentration of CNP or NTproCNP. 
 
3.4.3.2 Plasma samples 
 
A total of 22 plasma samples (11 pre- and 11 post- blackcurrant therapy) were 
available for CNP analysis. Whilst the median plasma concentration of CNP was 
0.68 pmol/l (range 0.38-2.47), the median NTproCNP concentration in plasma 
was 17.7 pmol/l (range 11.8-33.2). The median NTproCNP/CNP ratio in plasma 
was 21.6 (range 11.8-46.6). Blackcurrant anthocyanin intake did not alter plasma 
concentration of CNP or NTproCNP. 
 
Plasma NTproCNP and CSF NTproCNP concentrations were significantly 
positively correlated in visit 1 (r = 0.86, p = 0.001) but not visit 2 (r = 0.59, p = 0.07). 
Concentrations of CNP, on the other hand, showed no consistent correlation. 
There was no significant association between CNP-related parameters in plasma 
and disease duration or severity. 
 
3.4.3.3 Outlier samples 
 
All samples from one participant exhibited markedly high concentrations of CNP 
and NTproCNP on both visits, compared with the other PD participants. This 
particular participant was the oldest (age 80 years), and was on 14 different 
medications (i.e., polypharmacy due to other comorbidities). The CSF and 
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plasma ratios of NTproCNP/CNP were within the range of other PD 
participants, however. 
 
3.4.3.4 Comparison with a reference group 
 
Reference sample characteristics 
The reference range of CNP-related values with which results from this study are 
compared came from a pool of 51 elective orthopaedic patients (18 male) who 
had undergone spinal anaesthesia prior to their procedures (Schouten et al., 
2011). Only one patient in that sample had neurological disease (PD). The time of 
day for LP was similar in both samples. Likewise, most patient parameters, 
including co-morbidities, medications and vital signs, were similar—the only 
notable differences were the higher mean systolic blood pressure (mean 152 mm 




CSF analyses from both samples are presented in Table 3-9. CNP-peptide 
concentrations in CSF do not appear to be affected by systemic haemodynamics 
or CSF pressure. However, samples from both groups exhibit a significant 
positive association between NTproCNP/CNP ratio in the CSF and age (r = 0.77, 
p = 0.005 in PD; and r = 0.28, p = 0.045 in the reference sample).  
 
Table 3-9. CNP-related metabolites in CSF samples from the present study and a reference sample 
(Schouten et al., 2011). 
 CNP trial Reference group* p 









ratio (median, range) 
Visit 1: 80 (66-95) 
Visit 2: 71 (61-89) 
130 (112-159) < 0.001 




In PD participants, a significant association between plasma CNP and 
NTproCNP levels was noted (r = 0.61, p = 0.046 for visit 1; and r = 0.25, p = 0.47 for 
visit 2). This close coupling of the two CNP forms was also found in the reference 
group (Schouten et al., 2011). Unlike the reference group, however, two 
contrasting patterns were observed in the PD participants: NTproCNP 
concentrations in plasma were strongly positively correlated with those in CSF in 
visit 1 (r = 0.86; p < 0.001) but not visit 2 (r = 0.59; p = 0.07)—whereas no 
relationship was found in the reference group (Schouten et al., 2011). Moreover, 
the significant inverse relationship between plasma and CSF levels of CNP found 
in the reference group (Schouten et al., 2011) was not observed in PD 
participants. 
 
Plasma CNP concentration exhibited significant and positive association with the 
participant’s age (r = 0.83, p = 0.002). However, plasma CNP was not found to 
correlate with systemic pulse pressure in either visit 1 (r = 0.54; p = 0.09) or visit 2 
(r = 0.15, p = 0.7). 
 
3.4.4  Discussion 
 
3.4.4.1 General remarks 
 
The present study is the first to report of CSF analyses of CNP metabolites in 
patients with PD. Our findings were largely in keeping with findings from a 
large concurrent study in which stored samples were obtained from the original 
DATATOP cohort (Espiner et al., 2014). In addition, samples from the present 
study were compared with values drawn from a reference age-matched 
population without neurological disorder (apart from subject with PD; Schouten 
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et al., 2011). Blackcurrant anthocyanins do not appear to affect the concentration 
of CNP or CNP in CSF or plasma. 
 
3.4.4.2 CSF and plasma samples 
 
In our participants, the concentration of NTproCNP in CSF was significantly 
lower than that of the reference group. Components of the CNP signalling 
pathway are found throughout the CNS (Herman, Dolgas, Rucker, & Langub, 
1996), and hence, concentrations of CNP and NTproCNP are normally much 
higher in CSF than in plasma (Schouten et al., 2011). Because CNP undergoes 
rapid degradation and/or clearance by neural tissues, measurement of 
NTproCNP may be a more valid biomarker given its stability (Prickett, Yandle, 
Nicholls, Espiner, & Richards, 2001). 
 
In PD, the activity of NEP-1—an enzyme that rapidly degrades CNP—has been 
shown to be reduced (Llorens-Cortes, Javoy-Agid, Agid, Taquet, & Schwartz, 
1984). This may explain our findings of reduced NTproCNP/CNP ratio in the 
presence of unchanging CNP. In other words, there appears to be a concomitant 
reduction in both CNP production and clearance in PD (Espiner et al., 2014). 
 
Plasma concentrations of NTproCNP in PD patients in the present study were 
thought to be lower than those of the reference group, although this was not 
statistically tested (E. Espiner, personal communication, May 27, 2014).  
Koziorowski et al (2012) reported raised plasma concentrations in patients with 
long-standing PD compared with controls. Reconciliation of this apparent 
contradiction in future studies is important—especially because a plasma-based 





3.4.4.3 Other results 
 
The differences in blood pressure parameters between our participants and those 
of the reference group cannot be explained, but are likely to be inconsequential to 
the CNP trial findings (Espiner et al., 2014). Whether pre-operative anxiety poses 
a significant contributor to the raised blood pressure observed is speculative, as 
the literature has not been consistent (Conceicao, Schonhorst, Conceicao, & 
Oliveira Filho, 2004; Lira et al., 2010). Due to the timing of sample analysis for 
CNP from the present study coinciding with the 2011 Christchurch Earthquake, 
CNP-related values were not tested or corrected for BNP cross-reactivity as was 
done for the reference range sample (Schouten et al., 2011). However, values of 
CNP peptides, in both CSF and plasma, replicated closely when re-measured at 
an interval of four weeks.  
 
3.4.4.4 Future research 
 
The comparability of the two study populations (i.e., PD participants and 
historical non-controlled healthy subjects) remains limited despite similar sample 
collection and analysis methods. However, several questions—both pertaining to 
CNP in general and specifically in PD—have arisen from our observations. The 
link between CSF NTproCNP and plasma NTproCNP observed in PD 
participants but not the reference group is intriguing; future efforts ought to 
corroborate such finding with concurrent control subjects, and aim to uncover 
any underlying pathophysiological mechanism(s). 
 
The effects of medications on CNP are difficult to disentangle; all participants in 
both groups were using one or more medications (as high as 14 in the participant 
who had the highest CNP levels). In the case of PD, it would be pertinent to 
evaluate if one class of medications (e.g., dopamine agonists) affect CNP values 
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more than others. Inclusion of drug-naïve PD participants as well as drug-naïve 
controls may circumvent such potential confounding in future studies. 
 
 
3.5   Exosome trial 
 
3.5.1  Background 
 
Extracellular vesicles in general, and exosomes in particular, have recently 
garnered increasing attention in the neuroscientific community due to their 
apparent role as propagation mediators of neurodegeneration (including PD; see 
recent review by Vella, Hill, & Cheng, 2016). This has, in turn, led to 
intensification of research efforts in the area. However, there have been concerns 
with the reliability and validity of methods used to isolate such extracellular 
vesicles (Vogel et al., 2011). The aim of this study, therefore, was to assess the 
repeatability of the tunable resistive pulse sensing (TRPS) method in human 
biofluid samples, as well as to examine the simple characteristics of exosomes in 
our PD participants. 
 
3.5.2  Methods 
 
3.5.2.1 Pre-analysis sample processing 
 
CSF and plasma sample acquisition and pre-analysis treatment have been 
described in the previous Chapter. Sample analysis was undertaken by Izon 






3.5.2.2 Sample centrifugation 
 
To remove any freeze-thaw aggregates, samples were spun (at 10 000 g for CSF 
and 3 000 g for plasma) for a duration of 10 minutes. The supernatant was then 
retained without disturbing the pellet. For CSF, 140 µl of each sample was 
pipetted into microcentrifuge tubes to serve as raw reference samples; this left 
approximately 450 µl of fluid to be purified as described below. 
 
3.5.2.3 Sample purification 
 
Biological samples tend to contain a mix of free proteins and other molecules that 
may cause fouling of equipment surfaces, as well as contaminating any 
subsequent analysis of vesicular content (Saugstad et al., 2014). Izon’s 
proprietary separation column—the “qEV”—was utilised in order to remove 
such contaminants whilst retaining the majority of particles above 70 nm in 
diameter (Saugstad et al., 2014). Each sample was topped with 5 ml of phosphate 
buffered saline; the first 3 ml of the fluid was then discarded, leaving the “hot” 
fractions (i.e., containing exosomes) for subsequent analysis. 
 
3.5.2.4 Quantification of exosomes 
 
The present trial TRPS technology. In brief, a tunable sub-micron-sized pore 
separates two fluid cells: one containing the sample to be analysed, the other an 
electrolyte solution (Sowerby, Broom, & Petersen, 2007). An electric current 
between the cells is disrupted when a particle passes through the pore causing a 
translocation event, the magnitude of which is proportional to the volume of the 
particle traversing the pore (Roberts et al., 2010; Sowerby et al., 2007), and the 
blockade rate directly related with the particle concentration (Roberts et al., 
2012). Calibration of the system with standard particles enables accurate 
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measurement of the concentration and size distribution of particles in solution 
(Roberts et al., 2012; Vogel et al., 2011). Often concentration measurement 
techniques only evaluate the ‘total’ particle concentration, which will crucially 
depend upon the smallest detected size of the technique used (van der Pol, 
Coumans, Gardiner, et al., 2014). In order to enable comparable exosome 
quantification, a particle concentration over a suitable size range is applied.  
 
3.5.2.5 qNano system measurements 
 
Samples were analysed on Izon’s qNano systems using NP150- (plasma only) 
and NP200- (CSF and plasma) sized nanopores. Izon’s EV reagent kit, which 
contains 200 nm calibration particles and a coating reagent to prevent non-
specific binding of particles to the nanopore, was also utilised. 
 
3.5.2.6 Further CSF sample processing 
 
Raw CSF samples were diluted in PBS by 10x. A trial of ultracentrifugation (at 
100 000 g) of a small volume of purified CSF samples was attempted in order to 
concentrate exosomes. This, however, resulted in tube damage and it was, 
therefore, not possible to obtain additional measurements of the CSF samples. 
 
3.5.2.7 Further plasma sample processing 
 
A concentration fraction, which refers to the concentration of particles in a 
sample always being quoted across a defined particle size-range, was utilised. 
This allowed for comparison of a set size-range between different samples. Due 
to time constraints, only half of the samples were measured under multiple 
pressures. Multi-pressure measurement is necessary to establish an accurate 
absolute concentration of particles (Vogel et al., 2011). See Table 3-10 for details. 
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Table 3-10. Summary of plasma sample-specific methods for exosome analysis. 




Participant samples 1, 2, 3, 4, 5 and 7 6, 8, 9, 10 and 11 
Concentration 
fraction 
90 – 300 nm 150 – 300 nm 
Particle 
concentration 
Absolute Relative to the least 
concentrated sample 
 
3.5.3  Results 
 
3.5.3.1 CSF samples 
 
A total of six CSF samples (i.e., paired samples, pre- and post- blackcurrant 
therapy, from three PD participants) were analysed.  Both samples of one 
participant revealed slow particle rates, such that reliable measurements were 
precluded. Vesicle elution profiles revealed adequate purification process (B 
Glossop, personal communication, October 16, 2015). Findings from the other 
two participants are summarised in Table 3-11. 
 
Table 3-11. Analysis of exosome diameter and concentrations in two PD participants. 
 Participant 1 Participant 2 
Diameter (nm)  Pre-BC 
treatment 
Mean 132 151 
SD 52.6 43.4 




Mean 183 155 
SD 58.2 36.5 
Mode 135 135 
 
Mean C80-400 (particles/ml) 
Pre-BC treatment 5.4 x108 3.9 x108 
Post-BC treatment 3.6 x108 2.6 x108 
 
Mean C80-180 (particles/ml) Pre-BC treatment 4.4 x10
8 3.2 x108 
Post-BC treatment 2.0 x108 2.1 x108 
BC = blackcurrant; C80-400 = concentration of exosomes between 80 and 400 nm 





Given the insufficient data, statistical analyses were not carried. Analysis of most 
raw samples did not reveal significant discrepancies. 
 
3.5.3.2 Plasma samples 
 
Nineteen plasma samples (i.e., paired samples from nine PD participants and a 
single sample from the tenth participant) were available for analysis. Analysis of 
three samples, namely the paired samples of Participant 7 and the single sample 
of Participant 5, revealed only a small fraction of detectable particles at 90 nm. 
For these samples a larger nanopore was therefore used. Whereas this allowed 
for more accurate analysis of exosome size, cautious direct comparison with 
other samples analysed using the smaller nanopore is necessary. Results of 
multi-pressure analysis are shown in Table 3-12. 
 









Small Participant 1 2.6 x1010 1.6 x1010 
Participant 2 4.4 x109 4.0 x109 
Participant 3 6.1 x1010 7.3 x1010 
Participant 4 8.5 x109 6.2 x109 
Large Participant 5 8.4 x109  
Participant 7 8.3 x109 6.0 x109 
BC = blackcurrant; C90-300 = concentration of exosomes between 90 and 300 
nm; ID = identification number. 
 
Single-pressure analysis, which yields values relative to the least concentrated 






Table 3-13. Single-pressure analysis results before and after blackcurrant treatment. 
ID C150-300 before BC-treatment C150-300 after BC-treatment 
Participant 8 1.0* 1.3 
Participant 9 1.3 1.5 
Participant 10 17.7 14.3 
Participant 11 1.3 1.2 
* = The least concentrated sample; BC = blackcurrant; C150-300 = concentration 
of exosomes between 150 and 300 nm; ID = identification number. 
 
3.5.4  Discussion 
 
3.5.4.1 CSF samples 
 
Characteristics (i.e., diameter and concentration) of exosomes found in purified 
CSF samples of the two PD participants were generally in keeping with those 
found in pooled CSF of 14 PD patients (Saugstad et al., 2014). A small peak of 
exosome concentration at around 200 nm was noted; this is likely to be a “carry-
over” effect of the calibration particles from prior measurements. Using the C80-180 
(instead of C80-400) has accordingly reduced the measured exosome concentrations 
in the present study. 
 
Comparing the size profile of exosomes detected in the two PD participants with 
ovine CSF reveals a far broader range in the latter (Glossop, unpublished). The 
ovine CSF was extracted from brainstems of sheep shortly after death, which 
may explain the difference (e.g., presence of other vesicular particles). 
 
Analysis of the CSF samples reveals two anomalies; exosome characteristics were 
unable to be collected from the third PD participant’s samples. This was due to 
slow particle rates, the reason of which remains unknown. Furthermore, the 
much higher concentrations of exosomes in Participant 2’s raw samples are 
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unexpected. A plausible explanation of this observation is that the thawed 
sample was not homogeneously mixed prior to centrifugation. 
 
3.5.4.2 Plasma samples 
 
Analysis of plasma content of exosomes failed to reveal any correlation between 
blackcurrant treatment and exosome characteristics; in some participants the 
measured concentrations marginally increased, and in others it slightly 
decreased. 
 
Regardless of the effect of blackcurrant therapy, however, two patterns seem to 
emerge. First, the exosome concentrations for any single participant remain more 
or less stable. This is observed in spite of having samples being stored in 
different freezers, thawed and collected at different times and analyses 
performed on different nanopores using different techniques. Whether this is 
due to the short interval between collecting the two samples (i.e., 28 days 
between commencing and ceasing blackcurrant treatment) remains to be 
elucidated. The pattern, however, provides compelling evidence that a 
perturbation to sample collection, storage, preparation or analysis processes is 
unlikely. 
 
The second observation is that some PD participants seem to have more 
exosomes in their plasma than others. To probe this observation further, clinical 
details of participants were re-examined post hoc. Participants with the highest 
plasma concentrations (namely, Participants 1, 3 and 10; see Figure 3-2) were 





Figure 3-2. The relative concentrations of exosomes detected in 11 participants are shown, with samples 
from participants 1, 3 and 10 exhibiting the highest concentrations. 
 
The observation we describe here is intriguing (Alamri, Vogel, MacAskill, & 
Anderson, 2016), but the study is insufficiently powered to draw definitive 
answers. Correlations between CSF exosome concentrations and cognitive 
impairment could not be examined since CSF samples were not obtained from all 
patients (including none of the three patients with the lowest MoCA scores). 
However, correlates using plasma, much more easily accessible than CSF, may 
be more appealing in clinical applications. 
 
In a recent study by Stuendl et al, PD patients were have significantly elevated 
exosome concentrations in CSF compared with DLB and progressive 
supranuclear palsy (PSP) patients (2016). Unlike the Biological Markers study, 
the study by Stuendl and colleagues employed nanoparticle tracking analysis 
(NTA) to quantify exosomes, and the range of particle diameter was not 




The quantification of extracellular vesicles has presented several challenges 
despite the availability of several biophysical techniques, including NTA and 
TRPS (Izon Science, Ltd.). These challenges are mainly due to the small size and 
polydispersity of exosomes, and the lack of a standardised methodology for 
measuring exosomes which allows results from different days, users and 
instruments to be compared. The main advantages of TRPS over other 
technologies include its very limited dependence on instrument settings and its 
versatility in available measurement tools, such as the simultaneous 
determination of size, concentration and zeta potential of a given sample 
(Eldridge, Willmott, Anderson, & Vogel, 2014; Kozak et al., 2012; Kozak, 
Anderson, Vogel, & Trau, 2011; Vogel, Anderson, Eldridge, Glossop, & Willmott, 
2012).   
 
Characteristics of our sample and that of Stuendl et al’s (2016) are comparable 
(see Table 3-14). Perhaps most striking was the difference in the proportion of 
female PD patients. In the original report describing the Kassel cohort 
(Mollenhauer et al., 2011), almost two thirds of the patients were male—much 
more aligned with clinical experience in PD patients (Moisan et al., 2015). 
Regardless of this, however, no sex-based difference in exosome biological 
characteristics has been reported to date, and is therefore unlikely to significantly 










Table 3-14. Demographics of patients in the present study vs. the study by Stuendl and colleagues 
(2016). 
Mean ± standard 
deviation (range) 
Exosome trial Kassel cohort* 
Numbers 10 37 
Age (years) 66 ± 11.5 (48-80) 73 ± 7.9 (51-84) 
Sex (% female) 0 70 
Disease duration 
(months) 
70 ± 30 (11-122) 77 ± 71 (10-300) 
Hoehn and Yahr stage 2.2 ± 0.2 (1-3) 3.9 ± 1.2 (1-5) 
MoCA score 25.6 ± 2.6 (22-30) Not performed 
*As reported by Stuendl et al (2016); MoCA = Montreal Cognitive 
Assessment. 
 
In another recent study, Winston and colleagues examined the exosome profile 
in plasma samples of a group of participants with normal cognition, MCI (both 
stable and deteriorating) and AD (2016). Using NTA technology, exosome 
concentrations were not significantly different between the study groups. 
Analysis on exosome content, however, revealed significantly different levels of 
proteins in deteriorating MCI and AD participants, compared with participants 
with normal cognition or stable MCI (Winston et al., 2016); some proteins were 
significantly higher in the former two groups (e.g., Aβ1-42), whereas others were 
significantly higher in the latter two groups (e.g., neurogranin). 
 
Whether a similar pattern to our observation would be seen in CSF exosomes, 
and implications thereof, remains to be answered. Ridder et al have recently 
reported increased transfer of genetic material, via exosomes, between murine 
haematopoietic cells and Purkinje neurons in states of neuro-inflammation 
(Ridder et al., 2014). This could afford a potential explanation for the higher 
plasma exosome concentration in PD patients with mild cognitive impairment 
(defined as MoCA score of 21-25 by Dalrymple-Alford et al., 2010) compared 




3.5.4.3 Other remarks 
 
The initial results, whilst intriguing, raise more questions than they answer (see 
discussion below). This is because exosome research is still young, and 
standardised methods to isolate and identify these vesicles are still being 
developed and optimised (Colombo, Raposo, & Thery, 2014). Of particular 
relevance to the biological markers trial was the accurate determination of 
exosome size and concentration, and whether these variables provided 
meaningful, if any, clinical correlations. Tunable resistive pulse sensing, 
employed by Izon’s qNano system, was recently found to be the most accurate 
(van der Pol, Coumans, Grootemaat, et al., 2014) and reproducible (Coumans et 
al., 2014) out of the five most commonly utilised methods to detect single 
extracellular vesicles. 
 
A potentially problematic issue specifically pertaining to the exosome analysis 
was the ‘freeze-thaw’ effect and its ramifications on the quality of the samples. 
Immediately after the 2011 Christchurch earthquake, power was temporarily lost 
to the laboratory freezers; and even though back-up generators had restored 
power shortly thereafter, interval warming of frozen samples (estimated up to -
60 C from -80 C, at most) cannot be excluded. This slight increase in temperature 
is unlikely to have caused significant damage to the frozen samples, even for 
species as temperamental as exosomes (Zhou et al., 2006). However, to err on the 
side of caution, only previously-unthawed samples that were placed in freezers 
least affected by the power cuts were used for exosome analysis; hence, the lower 
number of samples available. This, whilst preserving methodological rigour, 






3.5.4.4 Future directions 
 
Future research ought to focus on several aspects. Current protocols should be 
optimised further in order to allow for low-concentration-sample analysis. 
Vesicular particles below 80 nm could be investigated in future studies using 
smaller nanopores. Finally, the samples utilised in this study had been stored in 
the freezer for over three years; characterising exosomes in freshly collected CSF 
may offer different insights into the disease process, as well as establish the 
extent of the ‘freeze-thaw’ effect on exosomes in biofluids. Finally, larger studies 
that examine CSF and plasma concentrations of exosomes in PD patients 






























































4.1   Participants 
 
The protocol of this study was approved by the Upper South B Regional Ethics 
Committee, New Zealand (reference URB/11/06/010). Prior to the commencement of 
any study-related procedures, all participants gave written informed consent. This 
study stretched over a period of four years. The start date was 31/10/2011 and the stop 
date was 01/02/2015. 
 
The study population was divided into three groups: PD-N group, PD-MCI group 
and a healthy control (NC) group. PD participants were aged 40 years or older, and 
met the UK Brain Bank criteria for idiopathic PD as confirmed by a movement 
disorders neurologist (TA). All PD patients were required to have had a normal brain 
scan (CT or MRI) within the previous five years, as well as having a normal 
neurological examination (apart from PD). Diagnostic criteria by Litvan et al (2012) 
were used to define mild cognitive impairment in PD-MCI participants. Control 
participants were matched for age (± 5 years), level of education (± 2 years) and sex. 
Years of education were calculated as the combination of years in primary school, 
years in secondary school (if any; see Table 4-1 for further details) and years in 
tertiary education (if any; see Table 4-2 for further details). 
 
Table 4-1. Types of NZ secondary school qualifications and associated total years of education. 
Secondary school qualification Total years of education 
No qualifications 10 years 
School Certificate/NCEA 11 years 
Sixth Form Certificate/University 
Entrance/ NCEA Level 2 
12 years 
Bursary/Scholarship/Higher School 
Certificate/NCEA Level 3 
13 years 













years of education 
Trade Certificate +1 or 2 years 15 years 
Teaching or Nursing 
Diploma/Technician’s 
Certificate/Undergraduate Certificate 
+1 or 2 years 15 years 
Polytechnic Bachelor’s Degree +3 years 16 years 
University Diploma +1 year 14 years 
University Bachelor’s Degree +3 years 16 years 
University Master’s Degree +5 years 18 years 
University Doctorate Degree +6 years 19 years 
 
All participants were recruited from the Van der Veer Movement Disorders Clinic 
and the NZBRI volunteer database, and were initially approached by the primary 
researcher (YA). Exclusion criteria included any other explanation for parkinsonism, 
history of CNS disorders (except for mild TBI) and major cervical spine pathology. 
Patients were also excluded if they had major depression or a major psychiatric 
disorder, did not speak or read English or were younger than 40 years of age. 
 
 
4.2   Study setting 
 
4.2.1  Study design 
 
The study was designed as a case-control study. The study involved a single visit to 
the NZBRI. The session lasted about two hours and was made up of three parts. 
 
4.2.2  Part one 
 
This entailed ensuring all participants had understood what the study involved, and 
that they agreed to participate. An informed consent form was provided for all 
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participants to sign; a photocopy of the form was supplied to the participant upon 
request. Information pertaining to ethnicity and previous medical history was 
directly sought from the participants. Next, the participants underwent several 
general health and cognitive assessments. These included HADS (Zigmond & Snaith, 
1983), Edinburgh Handedness Inventory (Oldfield, 1971), UPDRS parts II, III and IV 
(for PD participants only; Goetz et al., 2007) and uncorrected visual acuity 
examination; a Snellen chart at 6 m was used for distant evaluation, and the N-
notation chart (Collins, 1999) at arm’s length (range from 30-35 cm) for near 
evaluation. 
 
4.2.3  Part two 
 
Laboratory-based saccadic function was then assessed in the Eye Movement 
Laboratory at NZBRI. The tasks presented, in order, were: animal identification task 
of the MoCA, JLO, MR, Where’s Wally?™ and Jeddah map search. This part took 
about 60 minutes. 
 
4.2.4  Part three 
 
Participants were given a short break, and then taken to the MoVELab at NZBRI 
where real-life saccadic function was assessed. The tasks performed by participants, 
in order, were: SDMT1, SDMT2 and tea-making tasks. Most participants completed the 









4.3   Equipment and software used in the study 
 
4.3.1  iViewX™ Hi-Speed 
 
The iViewX™ Hi-Speed system (SMI, Teltow, Germany) is a stationary non-invasive 
eye-tracker system. The manufacturer’s specifications include accuracy of 0.25o – 
0.50o, monocular sampling rate of 1 250 Hz and tracking resolution of < 0.01o (SMI, 
2010b). The device is composed of an eye-tracking column with adjustable ergonomic 
chin rest and forehead rest, a built-in infra-red eye camera and a see-through glass 
piece. The system is connected to a personal computer. Participants were seated with 
their chin on the chin rest and forehead against the forehead rest, while looking 
through the see-through glass piece at the presented stimulus. Stimuli were presented 
onto an 877 mm x 1 514 mm (width x height) screen via a DLP projector with a refresh 
rate of 100 Hz and a resolution of 1 280 x 720 pixels. The screen was 1 649 mm in front 
of the eye-tracking column. This system was used to obtain eye movement data in the 
Eye Movement Laboratory from lab-based tasks. 
 
4.3.2  iViewX™ HED 
 
The iViewX™ HED system (SMI, Teltow, Germany) is a mobile lightweight head-
mounted eye-tracker system. This system was used to compile eye movement data in 
the MoVELab from real-life tasks. It is made up of two video cameras (eye camera 
and scene camera), both of which are mounted to a modified baseball cap (total 
weight < 80 g, SMI, 2010a) and connected by a USB cable to a laptop. This setup 
allowed for simultaneous recording of eye movements and the scene environment 
while allowing the participant to respond to tasks naturally. The manufacturer’s 
specifications include accuracy of 0.50o – 1.00o, sampling rate of 200 Hz and tracking 
resolution of < 0.01o monocularly (SMI, 2010a). Focal length of the scene camera was 




4.3.3  PsychoPy 
 
PsychoPy is an open-source application for stimulus presentation and data collection 
(Peirce, 2007). It was used to command the beginning and end of each task, and 
control audio-response and video-clip recordings and stimulus target presentation. 
 
4.3.4  BeGaze™ 
 
BeGaze™ is a behavioural and gaze analysis software produced by SensoMotor 
Instruments (SMI; Teltow, Germany). This eye-tracking software was utilised to 
extract eye movement data obtained by the iViewX™ Hi-Speed eye-tracker, as well as 
the iViewX™ HED system. 
 
4.3.5  Audacity® 
 
Audacity® (Mazzoni & Dannenberg, 2014) is free open-source software used for 
audio recording and editing. It was primarily used during analysis to play recorded 
voice responses as well as visualise the generated sound waves. Thus, a two-tier 
method was used to identify the start time of a voice response. A voice response was 
defined as the sound of the first letter of a word (e.g., the sound of the letter ‘H’ in 
hippopotamus) or stuttering of the first letter/syllable (e.g., hip hip hip hippopotamus). 
Use of indefinite articles (e.g., a hippopotamus) and conjunctions (e.g., hippopotamus 
and lion) were not considered proper voice responses based upon which start times 
ought to be documented. Start times were calculated twice by the same rater using 






4.4   Statistical analysis 
 
Statistical analysis was performed using the SPSS Statistics® software package (SPSS 
Inc., 2013) and R software environment (Ihaka & Gentleman, 2015). Where reported, 
mean values and standard deviations (SD) are given as mean (± SD). Due to the 
expected performance progression of the three study groups, significant results from 
analyses of variance (ANOVA) were followed by a rather permissive post-hoc 
analysis, Fisher’s least significant difference. Statistical significance was determined if 
Type I error rate was < 0.05. 
 
As the behavioural markers study was intended to be exploratory, numerous 
statistical tests were performed. As mentioned earlier, the emphasis was to obtain an 
in-depth evaluation of novel eye movement-performance associations; given the 
small sample size, an exploratory approach was taken. Therefore, corrections of 
family-wise error rates were not performed. To gain confidence in the results of 
individual findings, further research ought to be carried out in order to exclude the 





































5.1   Introductory remarks 
 
5.1.1  Study aims and hypotheses 
 
Exploring the relevant literature reveals an early interest in the interplay between 
manifest PD and disordered oculomotor control. This is evident by the early 
attempts of eye movement quantification in the 1960s (Anderson & MacAskill, 
2013). A brief background on eye movement research in PD and the effects of the 
disease on oculomotor control has already been described earlier in this thesis. The 
aim was to better understand each group’s patterns of performance and 
impairment. This was achieved by an in-depth evaluation of novel eye movement-
performance associations. 
 
Based on reviewing published literature, I hypothesised that cognitive and eye 
movement deficits are highly likely to correlate to the disease state—motor and 
cognitive impairment in particular—of PD patients. I further hypothesised that a 
detailed assessment of saccadic function with laboratory-based as well as more 
natural tasks may assist in gaining greater insight into effect of PD on the 
behavioural aspect of eye movement control. Because of the novelty of this 
approach, it is hoped to reveal potentially useful markers for PD, some of which 
may even prove easy to adapt for use in clinical settings as well as future studies. 
 
5.1.2  Laboratory settings 
 
5.1.2.1 Settings in the Eye Movement Laboratory 
 
The ergonomic chin and forehead rests were cleaned with 70% isopropyl alcohol 
swabs (Medi-Swab™, Smith & Nephew, London, UK) prior to and at the end of 
each participant’s session in the Eye Movement Laboratory. Comfort of seated 
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participants was ensured at all times, which occasionally necessitated placing a 
pillow between the participant’s back and the chair’s back-rest. 
 
Recordings from the left eye (i.e., tracking the left pupil) were the default. 
Recordings from the right eye, however, were necessary for two participants in 
whom conditions, such as unilateral cataract surgery and trichiasis, precluded 
adequate recordings from the left eye. The iViewX™ Hi-Speed eye-tracker allows 
for recordings from either eye with no compromise of data quality (SMI, 2010). 
Participants were permitted to wear unifocal spectacles if desired; bifocal 
spectacles, however, interfered with proper tracking of the pupils, and 
participants needing to use them were excluded. The lights in the Eye Movement 
Laboratory were dimmed such that the only light was that projected onto the 
screen from the projector. The size and resolution of the objects depicted in the 
images were such that participants could perform all tasks comfortably. 
 
5.1.2.2 Calibration protocol 
 
After adequate positioning of the participant, and before starting tasks, a 
calibration procedure was undertaken. This comprised a semi-automated process 
in which the eye-tracker matched raw pupil and corneal reflection data from each 
participant relative to known fixation positions projected on the screen. Thirteen 
locations on the screen were pre-selected (see Figure 5-1); participants were asked 






Figure 5-1. Calibration targets for the laboratory-based eye movement tasks. 
 
The calibration-targets were distributed to give adequate coverage over an area 
marginally larger than the ±15o (horizontal) by ± 10o (vertical) field in which 
stimuli were presented. These calibration-targets were set well below the 
maximum viewing angle of the iViewX™ Hi-Speed system, which is ± 30o 
(horizontal), +30o (vertical upwards) and -45o (vertical downwards), (SMI, 2010). 
The calibration process was repeated until satisfactory eye-position relative to the 
actual calibration-targets was obtained. Task-specific calibration checks were 
constantly reviewed between trials of the task (see below). 
 
5.1.2.3 BeGaze™ analysis software settings 
 
Automated data on saccadic eye movements were computed by BeGaze™ 
software (SMI, 2013) offline. Relevant to this study were the saccade amplitude 
and the number of saccades made per task. Saccade amplitude was calculated by 
multiplying the mean saccade average velocity by saccade duration (SMI, 2013). A 
task-specific upper limit of saccade amplitude was set to equal the maximum 
angle covered by that task’s calibration check. The minimum saccade duration 
threshold was 22 ms. The saccade velocity detection threshold was 40o /s, and 
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commenced when 20% of a saccade length was attained and ended when 80% was 
reached. Automated data on fixations during task performance were also 
computed by the BeGaze™ software. Relevant to this study were the fixation 
duration and the number of fixations made per task. The minimum fixation 
duration was set at 50 ms. 
 




Forty-eight participants were enrolled in the Behavioural Markers study; they 
were divided equally (n =16 per group) between the NC, PD-N and PD-MCI 
groups. The mean age of participants was 68 years (± 9.8), with a mean of 12.9 
years (± 2.8) of education (see Table 5-1 for group-specific data). Most participants 
were male (NC = 88%, PD-N = 81% and PD-MCI = 81%). All participants identified 
as Pākehā, except one PD-MCI participant who identified as Māori. Three 
participants (one from each group) could not continue to be involved in the study 
beyond the initial meeting due to poor health or change of social circumstances; 
their demographic data have been included for completeness. 
 






Mean (year) SD Mean (year) SD 
NC 16 69.0 10.1 12.9 3.1 
PD-N 16 66.2 9.8 13.4 2.9 
PD-MCI 16 68.7 9.9 12.5 2.4 
Total 48 68.0 9.8 12.9 2.8 
 
Disease duration data (for PD participants) were available for all participants. 
Differences between both groups were not statistically significant (see Table 5-2 
below for details). 
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Table 5-2. PD duration according to subjective report of symptoms and diagnosis by a clinician. 
 PD-N PD-MCI T-test p 
Duration since 
symptom onset 
Mean (years) 9.3 8.6 t29 = -
0.02 
0.71 
SD 5.2 4.1 
Duration since 
diagnosis  
Mean (years) 7.3 6.9 t29 = -
0.19 
0.82 




Mean (years) 2.0 1.8 t29 = -
.83 
0.44 
SD 1.0 0.9 
 
Disease durations calculated from the time of diagnosis were similar between the 
study’s two PD groups (i.e., PD-N and PD-MCI). The reported rates of PD-MCI at 
time of diagnosis are 21.6% in the Norwegian ParkWest study (Pedersen, Larsen, 
Tysnes, & Alves, 2013), 35% in a study by Broeders et al (2013) and 42.5% in the 
ICICLE-PD study (Yarnall et al., 2014). The discrepancy in the observed rates is 
probably reflective of differences in the populations studied (clinic- vs. 
population- based) and the MDS-testing level diagnoses (level 1 vs. level 2 
category diagnoses). 
 
The lag between symptom onset and diagnosis in this study’s sample is consistent 
with that reported in the literature (Cervantes Arriaga et al., 2014; Kraus, 1996; and 
see review by Meissner, 2012). Male sex and presenting with appendicular motor 
complaints (e.g., hand tremor; Breen, Evans, Farrell, Brayne, & Barker, 2013; 
Cervantes Arriaga et al., 2014) have been reported as independent risk factors for 
delayed presentation to a doctor. Female sex, on the other hand, is associated with 
delayed referral to a movement disorder specialist once a diagnosis is made or 
suspected (Saunders-Pullman, Wang, Stanley, & Bressman, 2011). This study, 
however, was not sufficiently powered to detect sex influences on the time of 






5.1.3.2 Anthropometric measurements 
 
Utilising the Edinburgh Handedness Inventory (Oldfield, 1971), participant 
handedness was assessed. All participants were right-handed except three: two 
NC participants were left-handed and one PD-MCI participant was ambidextrous. 
 
All participants had a distant corrected visual acuity (cVA) of 6/12 -2 or better in 
the better eye, with the exception of one participant whose distant cVA was 6/18 in 
the better eye. Moreover, all participants had a near cVA of N. 14 or better in the 
better eye, except one participant whose near cVA was N. 24 in the better eye. 
 
Scores of the HADS were available from 45 participants. The mean scores ranged 
from 7.2 to 9.5. As a whole, participants with PD scored higher than NC 
participants, although not reaching statistical significance (see Table 5-3 for further 
information). 
 
Table 5-3. HADS scores in the NC, PD-N and PD-MCI groups. 
 
 
5.1.3.3 Clinical staging 
 
Clinical staging of participants with PD was performed using parts II, III and IV of 
the UPDRS (Goetz et al., 2007). Clinical assessments generally occurred mid-
morning during which period all PD participants were in their “on” stage. Part IV 
of the assessment incorporates the modified Hoehn and Yahr scale (Goetz et al., 
2004). No statistically significant differences were observed in motor function 
Group N Mean score SD ANOVA p 
NC 15 7.2 4.5 F2,44 = 1.0 0.38 
PD-N 15 9.5 5.9 
PD-MCI 15 9.5 5.2 
Total 45 8.8 5.2   
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between participants in PD-N and PD-MCI groups. Table 5-4 lists the mean scores 
of the various UPDRS components. 
 
Table 5-4. Mean scores of the PD-N vs. PD-MCI participants on elements of the UPDRS. 
 PD-N PD-MCI T-test p 
 
UPDRS II 
N 15 14 t28 = 1.3 0.22 
Mean score 17.8 14.1 
SD 8.3 7.1 
 
UPDRS III 
N 15 15 t29 = 0.34 0.73 
Mean score 36.6 35.0 
SD 13.1 12.4 
 
mH&Y* 
N 15 15 t29 = 0.58 0.57 
Mean stage 2.2 2.0 
SD 0.6 0.6 
* = modified Hoehn and Yahr 
 
Which side was more affected was also assessed in PD participants; disease 
laterality was almost perfectly balanced between the right and left sides. In the 
PD-N group, more participants (n = 8) had right-sided symptoms compared with 
left-sided symptoms (n = 7). A similar trend was observed in PD-MCI participants 
where eight participants had right-sided symptoms, six had left-sided symptoms 
and one did not have this information recorded. 
 
 
5.2   MoCA animal identification task 
 
5.2.1  Background 
 
PD patients have been shown to perform worse on confrontational naming tasks 
compared with matched controls (Hong et al., 2014). In PD, deficits in language 
have been described. Three aspects of language appear to be particularly affected 
in PD patients: comprehension, naming and verbal fluency (Bodis-Wollner & Jo, 
2006). Impairments of comprehension and fluency have been attributed to 
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abnormal dynamics between the pre-frontal cortex and the basal ganglia (i.e., the 
“phonological loop”). Naming, on the other hand, appears to place less demand 
on executive processing (Bodis-Wollner & Jo, 2006). Tracking eye-movements 
while participants perform a naming task could potentially reveal (or confirm an 
absence of) any connection between naming and executive function (viewed as 
oculomotor planning in this case). 
 




The task instructions were explained verbally before the start of the task. Brief 
written instructions (“say the names of the following three animals”) were also 
projected onto the screen prior to the start of each trial. The three MoCA versions 
were always presented in the same order across participants. Participants were not 
specifically instructed as to which animal should be named first (i.e., all three 




The MoCA animal identification task was made up of three trials; each trial 
represented a MoCA version (see Figure 5-2). There were three side-by-side 
animals per trial (i.e., a total of nine animals to name). The first animal named by 
the participant was considered to be the first animal in that trial, regardless of its 





Figure 5-2. A visual representation of the order in which the trials 
were presented, corresponding to the three alternate forms of the 
MoCA test (Nasreddine et al., 2005). 
 
5.2.2.3 Task-specific calibration check 
 
Immediately prior to the presentation of each trial’s stimulus, participants were 
asked to fixate on six pre-selected targets which were presented one-at-a-time. The 
targets were distributed to give adequate coverage over an area marginally larger 
than the field in which stimuli were presented (30o horizontally by 12o vertically). 
The last calibration-check target (referred to as the ‘neutral point’), immediately 
prior to stimulus presentation, was located above the middle animal. The targets 
were presented quasi-randomly; the last target was always the (0o, 7o) target (i.e., 
the neutral point), while the first five targets appeared in random order. See 








Figure 5-3. Animals of MoCA Trial 2 with overlaid calibration-check targets. 
The circled target was always the last to be presented (i.e., the neutral point). 
 
5.2.2.4 Time to trial completion 
 
The start of the trial occurred 250 ms after the onset of the neutral point. This 
consisted of the presentation of the stimulus and a simultaneous 400 ms A-note 
beep (which was used as a reference when recorded voice responses were played 
back in Audacity® for analysis). The trial ended when the researcher pressed any 
keyboard button after the participant uttered the name of the third animal. The 
total duration of the trial was measured, regardless of the need to prompt the 




Participant responses were evaluated twice; notes were taken during task 
performance and recorded voice responses were evaluated once all data were 
collected. Acceptable responses, according to trial, were: (1) lion, rhinoceros and 
camel/dromedary; (2) giraffe, (polar) bear and hippopotamus; and (3) 
donkey/(jack)ass,  pig/swine and kangaroo. Participants were allowed to self-
correct. However, no hints were provided. Participants scored one point for 




5.2.2.6 Saccade and fixation data 
 
An upper limit of 32.3o (maximum angular extent of the calibration area) was 
applied to saccade amplitude. This provided complete coverage of the area in 
which the MoCA task was presented. The number of fixations, rather than 
saccades, was chosen to be reported here as it was thought to be more reflective of 
the cognitive process of trying to identify the animal and recall its name 
(Martinez-Conde, Macknik, & Hubel, 2004). This is different to the methodology 
of Matsumoto et al (2011) who used the number of saccades when comparing 
visual scanning in PD patients. 
 
5.2.2.7 Areas of fixation interest 
 
Individual fixation locations were isolated using BeGaze™ (see Figure 5-4(a) for 
an example). Next, a rectangular background was specified as an area of interest 
(AOI) for each animal within a MoCA trial (see Figure 5-4(b)). Fixation points 
falling outside the AOI were excluded. Using Microsoft Paint, the “area of fixation 
interest” was depicted by connecting the outermost fixation points (see Figure 5-
4(c)). Patterns in the areas of fixation interest were compared across trials between 
the three study groups. The method was adopted from (Matsumoto et al., 2011), 
although a quantitative scanning area was not calculated. 
 
5.2.2.8 Latency to first animal fixation 
 
This parameter refers to the time it took each participant to make a meaningful 
fixation (i.e., fixate on the first animal figure and not the surrounding white space), 
from the start of the trial. Because the starting location was the neutral point, this 
meant one or more saccades needed to be made before the eyes could fixate on 
any animal. Any interruption to eye-tracking (e.g., blinks or loss of tracking) 
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before the first meaningful fixation resulted in excluding that particular trial from 
analysis. 
 
Figure 5-4. Step-wise illustration of creating areas of fixation interest around the MoCA animal stimuli. 
Individual fixation points, from all participants, were obtained (a). Rectangular areas of interest were 
specified for each animal (b). Areas of fixation interest were created by connecting the outermost fixation 
points (c). The red circle in panel (a) represents the neutral point location. 
 
5.2.2.9 Latency to the first fixation per animal 
 
This was the time taken to make the first fixation on each animal within a trial (i.e., 
including the second and third animals). For the first animal, this was as 
previously described (“latency to first animal fixation”). For the second and third 







beginning the fixation upon the next one. Any interruption to eye-tracking 
between animal fixations resulted in excluding that specific trial from analysis. 
 
5.2.2.10 Latency to vocal response 
 
This was defined as the time elapsed between the start of the first fixation on an 
animal and onset of the corresponding vocal response. A vocal response was 
defined as onset of the sound of the first letter of the animal’s name (e.g., the 
sound of the letter ‘H’ in hippopotamus) or stuttering of the first letter/syllable 
(e.g., hip hip hip hippopotamus). Indefinite articles (e.g., a hippopotamus) and 
conjunctions (e.g., hippopotamus and lion) were not considered as the onset of a 
response. Responses for which the participant required prompting were excluded 
from analysis. 
 




Three participants (one PD-N and two PD-MCI) were unable to complete the 
confrontational naming-of-MoCA-animals task due to technical complications or 
physical exhaustion. Thus, 45 participants completed the task; 16 NC, 15 PD-N 
and 14 PD-MCI participants. Several parameters (see below) were recorded, each 
of which had associated quality-assurance criteria. Participants’ data falling short 
of these criteria were discarded. Therefore, depending upon the parameter’s 
criteria, the number of participants in an analysis was not always equal to the total 






5.2.3.2 Time to trial completion 
 
The total time to complete each trial was recorded for every participant. Because 
participants completed each of the three MoCA animal identification trials 
separately, three durations (per participant) were recorded and then meaned. The 
per-group durations reported below represent the overall means of the group’s 
means (see Table 5-5). There was no statistically significant difference between the 
three study groups. 
 
Table 5-5. Time to trial completion according to group. 
Group N Mean (s) SD ANOVA p 
NC 16 5.5 1.4 F2,42 = 
0.68 
0.51 
PD-N 15 5.4 1.4 
PD-MCI 14 6.0 1.6 




Most participants were able to correctly identify all nine animals: 98% for NC, 96% 
for PD-N and 94% for PD-MCI. Of the erroneous responses, confusing the 
rhinoceros for a hippopotamus (30%) and vice versa (25%) were the most 
common. 
 
5.2.3.4 Saccade amplitude 
 
Mean saccade amplitudes are presented in Table 5-6. NC participants made 







Table 5-6. Saccade amplitudes across the study groups. 
 N Mean (o) SD ANOVA p 
NC 16 5.9 0.8 F2,42 = 3.0 0.061 
PD-N 15 5.1 1.0 
PD-MCI 14 5.2 1.1 
Total 45 5.4 1.0   
 
5.2.3.5 Number of fixations and their duration 
 
Although two trends emerged, in that NC participants made fewer, but longer, 
fixations and the opposite for PD-MCI participants, neither trend reached 
statistical significance. See Table 5-7 below for details. 
 





N Fixation number Fixation duration 
Mean 
(n) 
SD ANOVA p Mean 
(ms) 
SD ANOVA p 
NC 16 17.3 3.9 F2,42 = 1.5 0.23 237 55 F2,42 = 
0.31 
0.74 
PD-N 15 18.1 4.4 223 54 
PD-
MCI 
14 20.6 7.6 220 81 
Total 45 18.6 5.5   227 63   
 
5.2.3.6 Areas of fixation interest 
 
Visual inspection of the generated areas of fixation interest did not reveal any 
group-specific patterns (see Figure 5-5 for an example of MoCA trial 3). The head 
of the animal was the primary area of fixation interest. The notable exception was 
the giraffe, for which the primary area of fixation was the neck. It is notable that 
‘less distinctive’ animals (e.g., donkey, pig and bear) had relatively larger 
associated areas of fixation interest, compared with ‘more distinctive’ animals 





Figure 5-5. Patterns of the areas of fixation interest across groups for MoCA trial 3. Each participants' 
fixations, within a group, are given a different colour. The red circle represents the neutral point. 
 
5.2.3.7 Latency to first animal fixation 
 
Of a total of 135 individual recordings (i.e., recordings of each of the MoCA trials 









excluded responses was almost equal between the groups: four from the NC 
group, five from the PD-N group and six from the PD-MCI group. 
 
The times taken to fixate on the first animal of each MoCA trial were averaged. 
NC participants took a mean of 559 ms to fixate on the first animal, while 
participants in the PD-N group took 545 ms. PD-MCI participants, on the other 
hand, took the longest, with a mean of 727 ms. The difference did not reach 
statistical significance (F2, 40 = 2.7, p = 0.08). 
 
To examine any learning effect as participants progressed through the task (i.e., 
first animal in MoCA trial 1 → first animal in MoCA trial 2 → first animal in 
MoCA trial 3), a linear mixed-effects model was applied (see Table 5-8 for details). 
 
Table 5-8. Linear mixed-effects model fit by REML for latency to first animal fixation as a function of 
group. The mean latency for NC participants in trial 1 was utilised as the intercept (i.e., all subsequent 
latency values are relative to the intercept value). 
 Latency (ms) Standard error df t-value p 
NC trial 1 673* 204 70 3.29  
PD-N trial 1 -35 290 41 -0.12 0.90 
PD-MCI trial 1 973 295 41 3.30 0.002 
NC trial 2 -130 239 70 -0.55 0.59 
PD-N trial 2 -2 339 70 -0.01 1.00 
PD-MCI trial 2 -859 347 70 -2.48 0.016 
NC trial 3 -196 231 70 -0.85 0.40 
PD-N trial 3 39 334 70 0.12 0.91 
PD-MCI trial 3 -488 350 70 -1.40 0.17 
* = intercept; df = degrees of freedom. 
 
The average latency from trial start to fixating on the first animal in MoCA trial 1 
was 673 ms for NC participants. Performance did not change significantly across 
MoCA trials 2 and 3. Performance of PD-N participants was not dissimilar to that 
of participants in the NC group. PD-MCI participants, on the other hand, were 
significantly slower in MoCA trial 1 (973 ms slower than NC participants, p = 
0.0020). They, however, showed evidence of a learning effect between MoCA trials 
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1 and 2 (p = 0.016), but no significant change thereafter. See Figure 5-6 for the 
trends of per-group performance. 
 
 
Figure 5-6. Mean latencies to fixation on the first animal, per trial of MoCA, stratified according to group. 
 
5.2.3.8 Latency to the first fixation per animal 
 
There were 405 individual recordings for this parameter. Due to unacceptable 
quality, 41 recordings were excluded. Fewer recordings were excluded from the 
NC group (eight recordings) than from either PD group (15 from the PD-N group 
and 18 from the PD-MCI group). 
 
The mean time before fixating on any animal was not significantly different 
between the groups: 1 007 ms for NC participants, 852 ms for PD-N participants 







5.2.3.9 Latency to vocal response 
 
A total of 405 responses were recorded. Forty-three recordings were excluded, the 
details of which (stratified by group) are in Table 5-9 below. 
 
Table 5-9. Classification of excluded recordings from the vocal response parameter. 
 NC PD-N PD-MCI Total 
Technical difficulties 8 15 18 41 
Required prompting 1 0 1 2 
Total 9 15 19 43 
 
The mean latencies to vocal response were 1 252 ms (± 339), 1 092 ms (± 298) and 
1195 ms (± 295) for NC, PD-N and PD-MCI participants, respectively. There was 
no statistically significant difference between the groups. 
 
5.2.4  Discussion 
 
5.2.4.1 Time to trial completion 
 
The time taken to complete the MoCA task was not significantly different between 
the three study groups. Because the task was relatively simple, it may not have 
been sufficiently cognitively-demanding to uncover any difference, if present, 
between the groups (i.e., a ceiling effect of the current task).  
 
PD patients have been shown to demonstrate deficits in naming tasks generally 
(Tröster, Stalp, Paolo, Fields, & Koller, 1995) and confrontational naming tasks 
specifically (Hong et al., 2014). There did not appear to be a significant 
relationship between oculomotor function/planning and performance on the task 
in participants in this study. This is in accordance with findings by Bodis-Wollner 
and Jo who suggested that naming required less executive processing, compared 
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with other language skills such as comprehension and fluency (2006). It would 
perhaps have been helpful to have included a PD-D group in this study to allow 




Most participants correctly identified the names of the nine animals presented. 
The most common errors were confusing the rhinoceros for a hippopotamus and 
vice versa. Stratifying PD participants by cognitive status failed to yield any 
significant differences between either PD-N or PD-MCI and the NC group. In the 
only other published study (Del Brutto & Wright, 2015) that specifically looked at 
animal naming sub-scores of the MoCA, authors found three covariates to 
significantly positively influence the animal naming sub-score: younger age (60-74 
years), sex (men) and higher level of education (more than primary education). 
However, the study population was from rural Latin American communities 
(using the Spanish MoCA), and cognitive status was not controlled for per se. 
 
When Nasreddine and his colleagues designed the MoCA, it was their intention to 
use drawings of “low-familiarity” animals in order to assess language (2005). 
Familiarity, however, is relative to sociocultural context, which ought to be taken 
into consideration when administering such a task. Even so, it is unlikely to 
explain the results found in this study or the pattern of most mistakes (since 
participants equally confused the rhinoceros and hippopotamus, as opposed to 
exclusively being familiar with one but not the other). 
 
5.2.4.3 Saccade amplitude 
 
NC participants made significantly bigger saccades compared with participants in 




Hypometric saccades are characteristic eye movement abnormalities in PD 
patients (Anderson & MacAskill, 2013). PD patients exhibit reduced voluntary 
saccadic amplitudes (particularly when looking upwards) early in the course of 
the disease. As the disease progresses, especially when dementia intervenes, 
hypometric voluntary as well as reflexive saccades become apparent (MacAskill et 
al., 2012). This pattern of aberrant eye movements in early PD is thought to be 
related to basal ganglial loss of dopaminergic neurons (Terao et al., 2011). 
 
5.2.4.4 Number of fixations and their duration 
 
There was no difference in the number of fixations or fixation duration in PD-N 
and PD-MCI participants compared with NC participants. This is partially 
contrary to what Matsumoto and colleagues from Japan found; PD subjects in 
their study took significantly longer to fixate on simple figures compared with 
controls, but this difference was lost when PD subjects fixated on more complex 
figures (2011). 
 
The observed differences between the two studies might, at least in part, be 
ascribed to a number of essential methodological differences. The study by 
Matsumoto et al (2011) did not stratify for cognitive status for PD subjects, and 
subjects were given time-limits and were asked to memorise the figures (i.e., a 
delayed task). The present study, on the other hand, separated PD-N from PD-
MCI participants, was not timed and participants were asked for instantaneous 
responses (i.e., an immediate task). 
 
Methodological differences do not offer a full explanation, however. The 
impression of most participants in this study was that the MoCA animal 
identification task was one of the simplest to perform. Extrapolating findings from 
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the Japanese subjects to this study, one would then expect fixation durations akin 
to those when subjects were shown the simple, rather than the complex, figures. 
That the “low-familiarity” of the MoCA animals added to the task’s difficulty up 
to a level comparable to memorising complex figures seems therefore unlikely. 
 
5.2.4.5 Areas of fixation interest 
 
To our knowledge, this is the first study to examine eye movements in this task. 
Although there were no group-specific patterns in the generated area of fixation 
interest, several observations—upon the performance of the study population as a 
whole—are of interest. First, participants principally focused their fixations on the 
animal’s head, the area perceived to be most informative. The notable exception 
was the giraffe, whose conspicuously-long neck was sufficiently informative for 
most participants to recognise the drawing as that of a giraffe’s. In fact, there were 
almost no fixations below the giraffe’s torso/lower neck (see Figure 5-7).  
 
 
Figure 5-7. Areas of fixation interest, in each group, pertaining to the giraffe of MoCA trial 2. 
 
Extrapolating to other animals with ‘distinctive’ features, another pattern emerged 
(see Figure 5-8). Animals with ‘distinctive’ features (e.g., the long neck of the 
giraffe or the long tail and bipedalism of the kangaroo) had relatively smaller 
associated areas of fixation interest. In contrast, animals with less distinctive 
NC PD-N PD-MCI 
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features (e.g., the donkey or pig) had comparatively larger associated areas of 
fixation interest. Participants presumably required more careful oculomotor 
exploring of these animals’ bodies in order to determine at which animal they 
were looking (e.g., donkey vs. horse or cow). 
 
 
Figure 5-8. Areas of fixation interest for a 'less distinctive' animal (upper panel) vs. 'more distinctive' 
animal (lower panel) in each group. 
 
From previous studies, it seems that the familiarity of the animal determines 
whether participants correctly identify it, taking into account the sociocultural 
influence on performance. For example, a common mistake made by elderly 
subjects in rural Ecuador (Del Brutto & Wright, 2015) was mistaking the 
rhinoceros on the Spanish MoCA (equivalent to MoCA trial 1 in this study) for a 
cow (i.e., a much more familiar quadrupedal animal to them). 
 
The animal’s morphology (regardless of familiarity), on the other hand, appears to 
dictate the pattern of fixations (i.e., duration, location and number) when trying to 
correctly identify the animal drawing. The antithesis of this (i.e., restricting the 
time allowed to visually explore two morphologically similar animals) should 
result in decreased accuracy of animal identification. This latter notion has been 
NC PD-N PD-MCI 
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examined in a recent study by Wu and colleagues (2015). In their study, healthy 
subjects sat in front a screen where two stimuli, arranged side-by-side, were 
presented simultaneously for a period of only 400 ms. Participants were asked to 
always look towards the dog. They performed better when the two animals 
presented were morphologically different (e.g., dog vs. bird) than when 
morphologically similar (e.g., dog vs. cat). 
 
Although participants did not necessarily fixate on the unique features of ‘more 
distinctive’ animals, peripheral vision might have contributed to recognising the 
animal, and fixations on the head were perhaps made to confirm that. There is 
compelling evidence in the literature that humans are particularly efficient at 
recognising certain categories of visualised scenes. This observation has been 
confirmed in both behavioural (Thorpe, Fize, & Marlot, 1996) and 
electrophysiological (Rousselet, Mace, Thorpe, & Fabre-Thorpe, 2007) studies. Part 
of the underlying neurophysiology of this phenomenon has been attributed to 
faster eye movements, especially towards “biological stimuli”, such as human 
faces (Crouzet, Kirchner, & Thorpe, 2010) and animals (New, Cosmides, & Tooby, 
2007), as well as a remarkable accuracy of detecting the same object categories 
using extrafoveal (i.e., peripheral) vision (Thorpe, Gegenfurtner, Fabre-Thorpe, & 
Bulthoff, 2001). 
 
Caution is warranted in extrapolating the above observations to those of the 
present study. This is because most of these previous experiments utilised 
coloured photographs of animals in natural scenes whilst monochrome animal 
drawings were used herein. Also, most of these earlier studies did not require 
substantial semantic processing (i.e., participants were asked to look towards the 
animal as opposed to naming it). Furthermore, suggestions made earlier are in 
contrast to findings by Kietzmann and his colleagues (2011). They found 
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participants to have made eye movements (i.e., visual attention) prior to 
recognising what the ambiguous image represented (i.e., object awareness). 
 
It is important to recognise the difference in the methodology between the present 
study and that of Kietzmann and colleagues (2011). Whereas I presented clear 
drawings of animals and asked participants to name them, they showed 
participants ambiguous stimuli and asked participants if they recognised the 
object and later to name it (Kietzmann et al., 2011). To account for this apparent 
discrepancy, I suggest a combined sequence of events that explains findings of 
both studies: fixations precede object recognition; once identified, this is followed 
by confirmatory eye movements to collect further evidence before an answer is 
spoken. 
 
There is also an alternative hypothesis to explain the smaller areas of fixation 
interest for specific animals; the order in which the three animals were seen in the 
MoCA trial appears to affect their associated area of fixation interest. For animals 
seen last, participants may have utilised the luxury of time and peripheral vision 
whilst fixating on the first two animals. Therefore, participants may not have 
needed to fixate on them as much. While perhaps plausible, this hypothesis does 
not explain why the lion (the first animal seen by most participants in MoCA trial 
1; figure not shown) and the giraffe (the first animal seen by most participants in 
MoCA trial 2) had smaller areas of fixation interest compared to the subsequent 









5.3   JLO task 
 
5.3.1  Background 
 
Available literature on the performance on the JLO test by PD patients is largely 
descriptive, and this has been described elsewhere in this thesis (see Chapter 4). 
How PD patients reach their final answers (whether correct or erroneous), for 
instance by analysing available data to unveil any underlying search strategies, 
has seldom been explored (Montse, Pere, Carme, Francesc, & Eduardo, 2001). 
 
Employing eye tracking methods while PD participants attempt several JLO items 
may prove valuable in further characterising error-patterns—potentially shedding 
light on a ‘faulty’ strategy stemming from a higher executive dysfunction common 
in PD. 
 




The JLO task was made up of 15 trials (five Practice and ten Test trials). The 
participant was asked to correctly identify which of the 11 reference lines matched 
the pair of test lines (‘stimuli’). The first stimulus (S1) refers to the left-most line of 
the pair. For analysis, a rectangular region was specified around the stimuli, and 
was referred to as the ‘Working Area’. Another rectangular region was specified 






Figure 5-9. Defining JLO task-related parameters. 




The instructions to the task were explained verbally before the start of the task. All 
trials were chosen from the H form of the JLO, and were presented in the same 
order. Participants were not specifically instructed to start with a specific (S1 vs. S2) 
stimulus. 
 
Immediately prior to the presentation of each trial, participants were asked to 
fixate on six pre-selected calibration-check targets which were presented one-at-a-
time. The targets were distributed to give adequate coverage over an area 
marginally larger than the field in which the trials were presented (19o 
horizontally by 19o vertically). The targets were presented quasi-randomly; the last 
calibration target was always the (0o, 3o) target (i.e., the neutral point), while the 







Figure 5-10. An example JLO trial overlaid with calibration-check target locations. 
The circled target was always the last to be presented (i.e., the neutral point). 
 
Participants were initially shown five consecutive Practice trials, and were asked 
for responses. The stimuli in the Practice trials were a pair of full-length lines. 
Correct responses were affirmed, while incorrect responses were corrected, and 
participants were encouraged to look at the practice trial again to try to identify 
why they originally chose the wrong responses. Once the participant was satisfied 
with the answer, the next Practice trial was presented. The start of each Practice 
trial was researcher-initiated via a keyboard. Eye movements were not recorded 
during Practice trials.  
 
Once the Practice trials were completed, a wireless keyboard was activated, and 
participants were asked to initiate the Test trials by pressing any key. As 
automated via PsychoPy, this lead to the presentation of each Test trial, as well as 
a simultaneous 400 ms A-note beep (which was used as a reference when recorded 
voice responses were played on Audacity® for analysis). The trial was ended by 
the researcher once answers for both stimuli were provided. The ten Task trials 
were chosen as a selected representative subset of trials, in an ascending order of 




The stimuli in the Test trials represent a pair of partial-length lines (only a third of 
the line was shown). The protocol is illustrated diagrammatically in Figure 5-11. 
 




Participant responses were collected twice; notes were taken during task 
performance, and recorded voice responses were evaluated once all data were 
collected. Participants were permitted to self-correct, but no hints were provided. 
Participants scored two points for correctly identifying both stimuli, one point for 





















initiated Test trials 







5.3.2.4 Error analysis 
 
Incorrect responses were analysed using two systems: line location and the Ska 
classification (see Table 1 in Chapter 4). Because stimuli in Test trials were 
presented as partial-length lines, this allowed for each partial-length line location 
to be classified as high, middle or low. 
 
5.3.2.5 Performance on Practice trials 
 
Participant performance on Practice trials was tested for any correlation with 
performance on Test trials. Akin to assessing Test trials, each Practice trial was 
assigned two points for correctly identifying both stimuli without prompting from 
the researcher, one point for correctly identifying one stimulus but not the other, 
and zero points for two incorrect responses. 
 
5.3.2.6 Saccade and fixation data 
 
An upper limit of 26.9o (maximum possible amplitude) was applied to saccade 
amplitude. This provided complete coverage of the area in which the JLO task was 
presented. The number of fixations, rather than saccades, was chosen to be 
reported here as it was thought to be more reflective of the cognitive process of 
trying to correctly identify both stimuli. Each fixation made by each participant 
contributed to the heat map (as shown in a coloured timescale) relative to its 
duration. Heat maps were generated automatically by BeGaze™. Coloured 
timescales (in ms) were manually set to a fixed maximum for all trials in order to 










Acceptable data were available for a total of 43 participants who completed the 
JLO task: 15 NC, 15 PD-N and 13 PD-MCI. Data for one PD-MCI participant were 
only recorded for nine Test trials. Several parameters (see below) were recorded, 
each of which had certain quality-assurance criteria. Participants’ data falling 
short of these criteria were discarded. Therefore, depending upon the parameter’s 
criteria, the number of participants may not always be equal to the total number of 




Only a few participants were able to correctly identify both stimuli in each of the 
ten Test trials. The average correct response rates were still high, nonetheless: 93% 
(± 6) for NC, 88% (± 12) for PD-N and 87% (± 11) for PD-MCI. The difference 
between the groups did not reach statistical significance. Participants made more 
errors in later trials (especially H-27) compared with earlier trials (see Figure 5-12). 





Figure 5-12. The total number of incorrect responses per JLO trial across all participants. Given trials were 
presented in an ascending order of difficulty, it was expected to detect more incorrect responses in later 
trials (R2 = 0.49, p = 0.02). 
 
5.3.3.3 Error type 
 
The overall most common line location associated with erroneous identification 
was low partial-lines. The per-group differences are shown in Table 5-10. Using 
the Ska classification, error types QO1 and QO3 were by far and away the most 
common. PD participants also made a few other error types (see Table 5-10). 
 
Table 5-10. Details of error types made by participants in the JLO task. 
 Line location Ska classification Error total* 
L M H QO1 QO3 QO4 V IQO 
NC 8 7 6 9 12 0 0 0 21 
PD-N 18 7 11 20 9 6 1 0 36 
PD-MCI 13 11 10 20 9 4 0 1 34 
Total 39 25 27 49 24 5 1 1  






























5.3.3.4 Performance on Practice trials 
 
Most participants (86%) correctly identified eight or more out of the ten Practice 
stimuli. A Pearson correlation failed to reveal a significant relationship between 
performance on Practice and Test trials. 
 
5.3.3.5 Saccade amplitude 
 
Mean saccade amplitudes for all participants are presented in Table 5-11. NC 
participants made marginally bigger, albeit not statistically significant, saccades 
compared with PD participants.  
 
Table 5-11. Saccade amplitudes across the study groups 
performing the JLO task. 
 Mean (o) SD ANOVA p 
NC 5.9 0.9 F2,40 = 
0.45 
0.64 
PD-N 5.7 1.1 
PD-MCI 5.5 1.0 
Total 5.7 1.0   
 
5.3.3.6 Heat maps 
 
As a whole, participant fixation patterns were similar across all JLO trials. In the 
Scanning Area, most fixations were made on the distal ends of the reference lines. 
Fixations in the Working Area, on the other hand, appeared to vary between trials. 
These patterns were observed whether the response was correct or incorrect. 
Below are the heat maps of three representative JLO trials: H-3 trial (both stimuli 
identified correctly by all participants), H-27 (trial in which most errors occurred), 
and H-24 (which had a few erroneous responses that were distributed equally 




Figure 5-13 shows the H-3 trial, both stimuli of which were correctly identified by 
all participants. Across all groups, fixations in the Scanning Area are most 
concentrated on the distal ends of the reference lines, whereas fixations in the 
Working Area were more concentrated on the proximal end of S2 (and the distal 
end of S1). 
 
 
Figure 5-13. A heat map of combined fixations of trial H-3. The correct responses were lines 6 and 7. 
 
Figure 5-14(a) and Figure 5-14(b) show fixation densities of the Correct and 
Incorrect subjects, respectively, for the H-27 trial. The pattern of fixations in the 
Scanning Area is similar; participants fixated most on the distal ends of the 
reference lines (albeit the wrong ones in the case of the Incorrect group). Fixations 
in the Working Area were longer (i.e., from the provided time-scale) and more 





Figure 5-14. Trial H-27 as performed by the Correct subjects (a) and Incorrect subjects (b) across all three 
groups. The correct responses were lines 3 and 4. 
 
Finally, heat maps for the Correct and Incorrect subjects of trial H-24 are shown in 
Figure 5-15(a) and Figure 5-15(b), respectively. Erroneous responses from the H-24 
trial, for which acceptable eye movement data were available, were distributed 
equally between the study groups (three responses for each of NC, PD-N and PD-
MCI groups). Similar to trial H-27, participants fixated most on the distal ends of 





in the Working Area were longer (i.e., from the provided time-scale) and more 
diffuse across both stimuli, compared to fixations in the Scanning Area. 
 
 
Figure 5-15. Trial H-24 as performed by the Correct subjects (a) and Incorrect subjects (b) across all three 













The proportion of trials for which acceptable data are available was slightly less 
than that of the MoCA task. This is to be expected, however, as the JLO task was 
harder and involved a higher number of trials. Also, only selected items of the 
actual JLO neuropsychological test were presented in this study. This, in turn, 




As expected, participants made more errors in the later trials, most likely as a 
result of increasing trial difficulty. Although performance slightly worsened going 
from NC, to PD-N and finally to PD-MCI participants, the difference did not reach 
statistical significance (p = 0.21). 
 
Findings here differ from those reported in the literature whereby PD patients 
score significantly lower in the full JLO task, compared to matched controls 
(Hovestadt, de Jong, & Meerwaldt, 1987; Levin et al., 1991; Montse et al., 2001). 
One possible explanation of this discrepancy is that for practical reasons, the JLO 
task in this study only included a few selected trials (10 items), instead of the 
entire task (30 items). This, in turn, could have mitigated an otherwise significant 
difference between the groups had more trials been included. 
 
Owing to the large number of tasks participants were expected to complete in this 
study, only selected items of several neuropsychological tests were utilised. This 
was done with the intention of avoiding participant fatigue and to conserve 
testing time. The JLO alone takes an estimated 21 minutes to be administered in 
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full (Lundin & DeFilippis, 1999), without the additional time required for eye 
movement recording procedures. Recently, Gullett and his colleagues 
demonstrated the reliability of the JLO short forms, OF and EF (15 items each) and 
TF (20 items), in patients with PD (2013). 
 
5.3.4.3 Error types 
 
Two classification systems were employed to categorise erroneous responses in 
the JLO task. The line location classification revealed low partial-lines to be 
associated with many more incorrect responses, compared with middle and high 
partial-lines. 
 
Using the Ska classification (Ska, Poissant, & Joanette, 1990), several patterns 
emerged. The most common error types were QO1 and QO3. QO1 errors were 
predominantly made by PD participants. QO3 errors were slightly more common 
in NC participants than either PD group. Other error types (several QO4, one V 
and one IQO errors) were exclusive to PD participants. These findings are 
generally in keeping with the published literature (Finton, Lucas, Graff-Radford, 
& Uitti, 1998; Montse et al., 2001). The finding by Finton et al that H type errors 
were also common in PD patients (1998) cannot be supported or refuted by 
findings of the present study. This is because my study did not include any 
horizontal Test stimuli (i.e., parallel to reference lines 1 or 11), and therefore, any 
such potential deficits in PD participants could not be ascertained. 
 
5.3.4.4 Heat maps 
 
Close inspection of the fixation heat maps generated for all JLO trials reveals some 
interesting and persistent patterns. Most fixations in the Scanning Area are made 
to the distal ends of the reference lines (i.e., close to the numbers). This is contrary 
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to my hypothesis, whereby most Scanning Area fixations were expected to occur 
more proximally on the reference lines to enable spatial comparison and narrow 
down the choices to three or four possibilities. These results bear similarities to 
findings by Mosimann and colleagues who examined clock reading in a group of 
AD patients (2004). Whereas healthy controls focussed on the distal end of each 
clock hand (i.e., closest to the number), AD patients’ fixations were less organised.  
 
The observed pattern was consistent across the study groups and also across all 
JLO trials (regardless of the position of the Test stimuli: low, middle or high). One 
could contend that participants in fact made more fixations on the choice numbers 
adjacent to the distal ends of the reference lines prior to vocalising their responses. 
However, this is unlikely as participants appeared to make a small number of 
fixations to the number once a decision on the answer(s) had been reached. This 
observation is particularly evident in tasks where the choice numbers are not as 
close as they are in the JLO task (see the MR task next). Perhaps a more plausible 
explanation is that participants subconsciously try to extrapolate a line that 
connects the reference line to the very stimulus in question. This is especially 
apparent in reference line 6 and S1 (see Figure 5-16 below) of task H-3 (in which all 
participants’ responses were correct). A line of fixations can almost be seen 





Figure 5-16. JLO trial H-3: a faded green line (of fixations) can almost be seen connecting the distal end of 
reference line 6 and the proximal part of S1. 
   
The main difference in the heat maps of the Correct and Incorrect groups was the 
fixation density (i.e., a product of both the number of fixations and the duration of 
each fixation) of their respective maps; the Incorrect group had increased density 
heat maps compared with the Correct group (see Figure 5-14 and Figure 5-15). 
 
 
5.4   MR task 
 
5.4.1  Background 
 
The most relevant data to date on the performance in MR by PD patients come 
from a single case-control study from Christchurch, New Zealand. In this study, 
PD patients and matched controls underwent a battery of neuropsychological tests 
among which was the MR. PD patients scored significantly lower on the MR, 
compared with control subjects (McKinlay, Grace, Dalrymple-Alford, & Roger, 
2010). Another more recent, although not directly related, study found MR scores 
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to differentiate PD patients with freezing of gait (lower MR scores) from those 
who do not freeze (Nantel, McDonald, Tan, & Bronte-Stewart, 2012). However, a 
matched control group was lacking in the study. Eye tracking during the MR task 
was included to provide insight into possible strategies utilised by PD participants 
(PD-N vs. PD-MCI) compared with healthy controls. 
 




The MR task was made up of 11 trials. Participants were required to complete the 
visual pattern presented in the 2x2 matrix by selecting the correct option from a 
multiple choice array. Correctly choosing the missing pattern was required to 
score a point and qualify the trial as ‘correct’. For analysis, a rectangular region 
was specified around the 2x2 matrix, and was named the ‘Scanning Area’. Another 
rectangular background was specified around the multiple choice panel, and was 









The task instructions were given verbally before the start of the task. Brief written 
instructions (“Say the number of the correct choice”) were also projected onto the 
screen prior to the start of each trial. Eleven selected trials were presented in an 
increasing level of difficulty (namely, MR-0A, MR-04, MR-05, MR-10, MR-13, MR-
16, MR-19, MR-20, MR-21, MR-23 and MR-24). All trials were presented in the 
same order across subjects. 
 
Immediately prior to the presentation of each trial, participants were asked to 
fixate on six pre-selected calibration targets which were presented one-at-a-time. 
The targets were distributed to give adequate coverage over an area marginally 
larger than the field in which the trials were presented (20o horizontally by 15o 
vertically). The targets were presented quasi-randomly; the last target was always 
the (0o, 9o) target (i.e., the neutral point), while the first five appeared at no 





Figure 5-18. An example MR trial with overlaid calibration-check targets. 
The circled target was always the last to be presented (i.e., the neutral point). 
 
All trials were researcher-initiated by pressing any key on the keyboard. This led 
to the presentation of the trial, as well as a simultaneous 400 ms A-note beep 
(which was used as a reference when recorded voice responses were played on 
Audacity® for analysis). The trial was ended by the researcher once an answer 
was provided. The protocol is illustrated diagrammatically in Figure 5-19. 
 
 



















Participant responses were evaluated twice; notes were taken during task 
performance, and definitive recorded voice responses were evaluated once all data 
were collected. Participants were allowed to self-correct, but no hints were 
provided. Participants scored one point for correct responses and zero points for 
incorrect responses. 
 
5.4.2.4 Saccade and fixation data 
 
An upper limit of 25o (maximum possible amplitude) was applied to saccade 
amplitude. This provided complete coverage of the area in which the MR task was 
presented. The number of fixations, rather than saccades, was chosen to be 
reported here as it was thought to be more reflective of the cognitive process of 
trying to correctly identify the missing pattern. Similar methods to the JLO task 
were used to generate heat maps. 
 




A total of 45 participants completed the MR task: 16 NC, 15 PD-N and 14 PD-MCI. 
Physical fatigue was the most common reason for not completing the MR task. 
Several parameters (see below) were recorded, each of which had certain quality-
assurance criteria. Participants’ data falling short of these criteria were discarded. 
Therefore, depending upon the parameter’s criteria, the number of participants 







Only a few participants were able to correctly identify the missing pattern in each 
of the trials. The average correct response rates were still high, nonetheless: 77% (± 
14) for NC, 78% (± 19) for PD-N and 67% (± 17) for PD-MCI. The difference 
between the groups did not reach statistical significance. Participants made more 
errors in latter trials (especially MR-23 and MR-24) compared with earlier trials 




Figure 5-20. The total number of incorrect responses per MR trial across participants. As with the JLO task, 
trials of the MR task were presented in an ascending order of difficulty, which likely underlies the 
regression line found based on the number of incorrect responses per trial (R2 = 0.86, p < 0.001). 
 
5.4.3.3 Saccade amplitude 
 
Mean saccade amplitude did not significantly differ between study groups: 5.7o (± 



























5.4.3.4 Heat maps 
 
Akin to JLO, general trends of fixation density, across most MR trials, can be 
visualised. Generally, more time was spent fixating on the Scanning Area than on 
the Working Area. Within the Scanning Area, fixations on the visual pattern next 
to the missing one (on the horizontal axis) were longer than fixations on either 
pattern above or below it. These trends persisted regardless of the response given. 
 
Below are the heat maps of three representative MR trials: MR-0A trial (where the 
missing pattern was identified correctly by all participants), MR-24 (the trial in 
which most errors occurred), and MR-21 (which had a few erroneous responses 
that were distributed equally between NC, PD-N and PD-MCI participants). 
 
Figure 5-21 shows the MR-0A trial, the missing pattern of which was correctly 






Figure 5-21. A heat map of trial MR-0A (all participant responses were correct). Owing to the short duration 
in which all participants identified the correct response, this heat map appears ‘less dense’ relative to the 
following heat maps (the colour time-scale has been standardised across all heat maps). 
 
Figure 5-22(a) and Figure 5-22(b) show fixation densities of the Correct and 
Incorrect subjects, respectively, for trial MR-24. Performance on this trial appears 
to conform to the general trends seen elsewhere in this task. Of note, fixations in 
the Working Area appear considerably more focussed (on the correct choice) in 
the Correct subjects compared with the Incorrect subjects. Moreover, almost no 





Figure 5-22. Heat maps of the performance of the Correct (a) and Incorrect (b) subjects in trial MR-24. 
 
Lastly, heat maps of trial MR-21 for the Correct and Incorrect subjects are shown 
in Figure 5-23(a) and Figure 5-23(b), respectively. Erroneous responses from the 
MR-21 trial, for which acceptable eye movement data were available, were 
distributed equally between the groups (four responses for each of NC, PD-N and 
PD-MCI groups). Almost exactly the same fixation patterns, observed in MR-24, 





the visual pattern right of the missing one and fixations by the Incorrect subjects 
were scattered between the possible answers. 
 
 













Differences in the proportions of correctly identified patterns among the three 
study groups did not reach statistical significance. This could be due to a similar 
scenario with the JLO task: the number of MR items used in this study was 
insufficient to reveal any differences between the groups. Supporting this 
explanation are the significantly lower scores of PD patients who performed the 
full MR (McKinlay et al., 2010) and other similar tests, such as Raven’s Coloured 
Progressive Matrices (Bašic et al., 2004). 
 
Furthermore, more erroneous responses were made in the latter trials, compared 
with the earlier trials. In fact, the number of errors in the last three trials (i.e., the 
most difficult trials: MR-21, MR-23 and MR-24) is almost equal to that of all earlier 
trials combined. 
 
5.4.4.2 Heat maps 
 
Certain global patterns of fixations were evident throughout the MR task. These 
patterns were often preserved regardless of study group (NC vs. PD-N vs. PD-
MCI) and response given (correct vs. incorrect). 
 
The proportion of time spent fixating on the Scanning Area was longer than that 
on the Working Area. Within the Scanning Area, participants fixated longer on the 
visual pattern next to the missing one compared with the two visual patterns 




Fixation behaviour on the Working Area differed according to the response given. 
The Correct group fixated on the correct choice the longest, and not much else. 
Fixation durations of the Incorrect group, on the other hand, were divided almost 
equally between two or three choices. Neither long nor more fixations on the 
choice number were required before voicing a response. This observation serves as 
further confirmation that the higher density on the distal ends of references lines 
of JLO’s heat maps represents fixations on the lines and not the choice numbers. 
 
 
5.5   Where’s Wally?™ search task 
 
5.5.1  Background 
 
There is a paucity of published literature on the performance of PD patients on 
search tasks in general. It is known that dynamics (i.e., duration, magnitude, rate 
and velocity) of human saccades and microsaccades are influenced by the 
cognitive and attentional demands of a visual task (Otero-Millan, Troncoso, 
Macknik, Serrano-Pedraza, & Martinez-Conde, 2008). Therefore, the aim of this 
task was to study the pattern(s) of eye movements in a challenging visual search 
task in PD participants with normal and impairment cognition, and compare this 
to the performance of healthy controls. 
 




All participants, but one, were familiar with Where’s Wally?™ prior to the start of 
the task. Verbal instructions to the task were given, nonetheless. Brief instructions 
(“Search for Wally in his red striped top. Press a key when looking at him”) were 
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also projected onto the screen prior to the start of each trial. The four trials were 
always presented in the same order. Participants were not specifically instructed 




The Where’s Wally?™ task was made up of four trials; each trial showed an 
illustration in which many people were depicted at a given location. The last 
calibration-check target, immediately prior to stimulus presentation, was termed 
the ‘neutral point’. 
 
5.5.2.3 Task-specific calibration check 
 
Immediately prior to the presentation of each trial’s stimulus, participants were 
asked to fixate on six pre-selected targets which were presented one-at-a-time. The 
targets were distributed to give adequate coverage over an area marginally 
smaller than the field in which stimuli were presented (36o horizontally by 22o 
vertically). The targets were presented quasi-randomly; the last target was always 
the (0o, 0o) target (i.e., the neutral point), while the first five targets appeared in a 





Figure 5-24. The Airport Trial of Where's Wally?™ with overlaid calibration-check targets. 




The four Task trials were selected from the Where’s Wally?® 2012 Calendar (The 
Ink Group, 2012), and included scenes of a museum,  an underground maze and 
an airport. The choice of the scenes was not arbitrary. The museum scene was 
shown twice (Trial 1 and Trial 4); this was done to evaluate improvements in the 
time to finding Wally and/or trial score. The maze scene (Trial 3) depicted people 
in near horizontal rows in an underground dungeon. Because the scene appeared 
‘orderly’, it was hoped that tracking eye movements may shed some light on any 
difference in the “search strategy” (i.e., eye movement pattern) between the study 
groups. 
 
All trials were initiated by the researcher by pressing any key on the main 
keyboard which led to the presentation of the trial stimulus. A wireless keyboard 
was provided to participants who were instructed to press any key whilst fixating 
on Wally once they were confident they found him. This matched the end of the 
trial. Participants were not told that the task had a time-limit. Each of the Where’s 












Participants’ eye movements were traced on the researcher’s screen in real time 
(visualised as a moving cross atop the background scene). No hints were provided 
for the participant once trials had started.  Participants scored two points for 
correctly identifying Wally, one point for identifying a red herring character (i.e., 
Wilma, Wally’s doppelgänger friend, or Wenda, her identical twin sister). No 
points were awarded for incorrect responses or if time ran out. 
 
5.5.2.6 Search strategy and saccade data 
 
Participants’ search strategy for each trial was observed. This parameter was 
quantified by measuring the saccade directions (in degrees), and determining 







As mentioned earlier, this was of particular interest in the Maze scene where the 
objects and people were drawn largely in horizontal paths. 
 
Due to the nature of the task (up to three minutes in duration, large field of search 
and the small target), it was much more difficult to maintain complete tracking of 
eye movements compared with other tasks. When tracking was lost, the 
participant’s saccade data would not be recorded. To accommodate this, it was 
decided to include saccade rate (i.e., saccades per second) whereby the number of 
recorded saccades was divided by the time during which tracking was available. 
 
Saccade data, rather than fixation data, were thought to be more meaningful to 
measure. Combined with saccade rate, the saccade amplitude was thought to be 
reflective of the participant’s search strategy. An upper limit of 42.2o (maximum 
possible amplitude) was applied to saccade amplitude. This provided near-
complete coverage of the area in which Where’s Wally?™ scenes were presented.  
 




Eleven participants (four NC, three PD-N and four PD-MCI) were unable to 
complete the Where’s Wally?™ task, mainly due to technical complications. This 
left a total of 38 participants who completed the task (12 NC, 14 PD-N and 12 PD-
MCI). Several parameters (see below) were recorded, each of which had quality-
assurance criteria. These criteria, considering the nature of the task (large field of 
search combined with a small target), were relatively stringent; data falling short 
of these criteria (a sizeable amount compared to other tasks’ data) were discarded. 
Thus, depending upon the parameter’s criteria, the total number of participants 




5.5.3.2 Duration to trial completion 
 
Trial duration data were available for all participants completing the task (n = 38). 
The average duration taken to complete each of the four Where’s Wally?™ trials 
was calculated for each participant. The per-group mean durations were: 51.7 
seconds (± 12.3) for NC, 56.3 seconds (± 9.1) for PD-N and 58.3 seconds (± 25.2) for 
PD-MCI. There was no statistically significant difference between the three study 
groups. Only three participants exhausted the three-minute time-limit without 
providing an answer: two PD-N participants (trial 1 for one and trial 3 for the 
other) and one PD-MCI participant (trial 1). 
 
To examine for a learning effect, the difference in duration between completing 
Museum 1 (trial 1) and Museum 2 (trial 4) was calculated. Despite the marked 
difference in the mean duration difference between NC vs. PD-N vs. PD-MCI (18.5 
seconds vs. 11.4 seconds vs. 31.1 seconds, respectively), it did not reach statistical 
significance due to the heterogeneous performance of individuals within each 





Data pertaining to response correctness were available for 37 participants (12 NC, 
14 PD-N and 11 PD-MCI). Each trial in the Where’s Wally?™ task was scored out 
of 2 points (total 8 points). Each participant’s aggregate score was converted to a 
percentage. The mean percentages of correct answers were 30.9% (± 17.2%) for NC 
participants, 24.7% (± 14.8%) for PD-N participants and 13.6% (± 13.8%) for PD-
MCI participants, with a significant difference in between-group performance (p = 
0.036). Post-hoc analysis showed PD-MCI participants scored significantly lower 
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than NC participants (p = 0.011). Scores of PD-N participants were not significantly 
different from NC (p = 0.27) or PD-MCI (p = 0.10). 
 
5.5.3.4 Search strategy and saccade data 
 
Analysis of saccade direction revealed a generally preserved pattern of scene 
search by NC and PD-N participants; most of the saccades were horizontal, which 
fits with the general layout of the Maze trial. PD-MCI participants, on the other 
hand, made more vertical saccades, which appears at odds with the orderly layout 
of the scene (see Figure 5-26). 
 
To quantify the observed difference, values of saccadic directions—which varied 
from 0o to 360o— were transformed to be within a single quadrant (i.e., 0-90o). This 
allowed meaningful calculations of mean saccade directions with regards to 
horizontal or vertical tendencies (i.e., larger mean values indicate a higher 
proportion of vertical saccades). Saccades made by PD-MCI participants deviated 
significantly more from the horizontal (39.7o ± 8.5) in the Maze trial, compared 
with NC (33.2o ± 3.3) and PD-N (31.4o ± 3.2) participants (F2, 18 = 4.4, p = 0.028). 
 






The mean tracking ratio (i.e., the ratio of summed fixation durations—excludes 
blinks—divided by the sampling frequency of BeGaze™; expressed in percent) for 
all 38 participants across the four trials was 84.3% (range, 34-95%). There was no 
significant difference in the mean saccade rate between the study groups: 3.9 /s (± 
0.7) for NC, 4.4 /s (± 2.1) for PD-N and 3.9 /s (± 1.4) for PD-MCI (p = 0.68). 
Moreover, there was no significant difference in the saccade amplitude between 
NC (6.6o ± 1.5), PD-N (5.8o ± 0.9) and PD-MCI (5.6o ± 1.0), (p = 0.12). Saccade peak 
velocity was similar between the study groups: NC 269.6 o/s (± 55.6), PD-N 245.9 
o/s (± 37.3) and PD-MCI 253.2 o/s (± 64.7), (p = 0.72). 
 




The number of participants for whom complete data were available was 
substantially lower compared with other tasks. This could be attributed to several 
reasons. The task was performed towards the end of the first testing session, by 
which time some participants might have been more prone to distraction and 
fatigue. Moreover, the field in which the trials were projected was the largest of all 
tasks’ (36o x 22o), and the target (i.e., Wally) was among the smallest targets of all 
tasks. Finally, the time allowed to complete the task was, in retrospect, too long. 
The initial intention was, by providing ample time, to avoid pressuring 
participants to give a hasty answer (i.e., ultimately disturbing the ‘natural’ search 
pattern). However, this also led to an increased chance of technical lapses when 
eye movements could not be recorded. To circumvent this problem, rate of 
saccades (as opposed to number of saccades) was utilised in an attempt to 





5.5.4.2 Trial duration and correctness 
 
The mean total duration for each trial did not significantly differ between the 
study groups: NC, 51.7 s (± 12.3); PD-N, 56.3 s (± 9.1); PD-MCI, 58.3 s (± 25.2); F2,35 = 
0.5, p = 0.61. As expected, PD-MCI participants scored significantly lower on this 
task than NC participants; PD-N participants did not differ significantly in their 
scores from either group. 
 
What is intriguing is the marked, albeit not statistically significant, duration 
difference between the groups when performing the two Museum trials. PD-MCI 
participants spent an average of 31.1 seconds less on Museum 2 than on Museum 
1. This is compared with 18.5 seconds for NC and 11.4 seconds for PD-N. This may 
be attributed to one of two explanations: a learning effect or increased 
distractibility as participants progressed through trials. 
 
To uncover any possible learning effect, group performance on Museum 1 and 
Museum 2 trials was examined more closely. A learning effect was defined as 
faster location of Wally or Wilma/Wenda in Museum 2 compared with Museum 1, 
or improved score (i.e., finding Wally in Museum 2 after not having found him in 
Museum 1). 
 
Table 5-12. Assessing per-group learning effect based on the difference in their performance in Museum 1 
and Museum 2 trials. 
Group N Duration 
difference 
(s) 




NC 12 - 65.1 F2,35 = 
0.96 
< 0.001 9 +18.1% F2,26 = 1.6 0.001 
PD-N 14 - 62.1 < 0.001 10 +1.3% 0.78 
PD-
MCI 




As shown in Table 5-12, only NC participants showed a significant learning effect 
on score; they located Wally or Wilma/Wenda with more accuracy in Museum 2 
compared with Museum 1. PD participants, on the other hand, while completing 
Museum 2 trial faster, their score did not significantly improve. Therefore, it 
appears as though NC participants had ‘learnt’ from their mistakes in the Museum 
1 trial, whereas PD participants repeated their mistakes. 
 
5.5.4.3 Search strategy and saccade data 
 
There was a stark contrast between the search strategies employed by NC and PD-
N, and the strategy of PD-MCI participants (see Figure 5-27 for representative 




Figure 5-27. Representative scan paths (fixations are represented by circles and saccades are represented by 






(middle) and one from the PD-MCI group (bottom). Note the limited scanning area as well as the different 
search strategy (i.e., more vertical saccades) employed by the PD-MCI participant compared with the NC 
and PD-N participants. 
  
Several factors have been described in the literature as influencers of eye 
movement direction. The effect of cognitive status, however, does not appear to 
have been addressed before. To understand how a person’s cognitive status affects 
the pattern of their eye movements, other factors must be addressed first; these 
will be discussed from most general to more specific. 
 
At the most basic level are biological and evolutionary factors. The human head 
(through motion at the cervical spine) moves more horizontally (i.e., rotation, to 
almost 180o) than it does vertically (i.e., flexion/extension, up to 160o), (Windle, 
1980). These movements substantially enhance the visual field of humans, whose 
two horizontally-arranged eyes are much more restricted vertically (around 90o) 
than horizontally (up to 180o) (Pelz, Hayhoe, & Loeber, 2001; Smeets, Hayhoe, & 
Ballard, 1996). Furthermore, Collewijn and colleagues (1988) have shown that 
vertical and oblique saccades are slower than horizontal saccades, and Becker et al 
demonstrated that vertical saccades are more curved than horizontal saccades 
(1990). It may well be that, over time, we learn to favour horizontal over vertical 
saccades (Petit et al., 1996), as they allow us to maximise the gain (i.e., details seen) 
for a minimum cost (i.e., less time and fewer saccades). This, however, may be 
influenced by other factors described next. 
 
More specific to groups of people are cultural and experiential factors pertaining 
to specific tasks. When presented with non-directional visual patterns (e.g., dots, 
circles or bars), Middle Eastern subjects have shown preference (Abed, 1991) for 
and higher proficiency (Nachshon, Shefler, & Samocha, 1977) in right-to-left 
scanning (since Arabic and Hebrew are read right-to-left). Western subjects were 
more likely to show the opposite pattern. East Asian subjects, who have 
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traditionally read vertically, going from right to left, demonstrated a 1:1 ratio of 
horizontal to vertical saccades. The latter finding is in contradiction to the 2:1 ratio 
observed in Middle Eastern and Western subjects.  
 
Finally, scene-specific factors need to be considered. The rectangular screen onto 
which stimuli from the Behavioural Markers study were projected is wider than it 
is high. Moreover, people depicted in the particular Where’s Wally?™ stimulus 
chosen (i.e., the Maze task) were arranged in horizontal rows. Therefore, more 
information was available on the right and left of the scene (as opposed to above 
and below). Only NC and PD-N participants, however, seem to have taken 
advantage of this.  
 
Taken together, these factors provide a rationale for the bias for horizontal over 
vertical saccades. Since more specific factors (i.e., stimulus-display and cultural 
factors) were the same across the participants, this leaves biological factors as the 
likely explanation of the peculiar pattern of eye movements of PD-MCI 
participants.  
 
The direction of microsaccades (which are generally involuntary and horizontal in 
humans; Cui, Wilke, Logothetis, Leopold, & Liang, 2009; Otero-Millan et al., 2011) 
has been previously shown to be affected by the person’s attention (Engbert, 2006; 
Engbert & Kliegl, 2003) and working memory (Otero-Millan et al., 2008; Valsecchi 
& Turatto, 2009). Moreover, Kapoula and colleagues (2014) have recently shown 
that microsaccades deviated from the horizontal in patients with AD and amnesic 
MCI. The authors point the differences detected in microsaccade direction could 
be related to attentional deficits present in AD (Perry & Hodges, 1999; Riva et al., 
1999) and MCI patients (Belleville, Chertkow, & Gauthier, 2007; Levinoff, Saumier, 
& Chertkow, 2005). They acknowledge, nonetheless, that further research is 
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required to see if changes in microsaccade direction are associated with specific 
attentional deficiencies (Kapoula et al., 2014). 
 
Several differences between Kapoula et al’s study (2014) and the present 
behavioural markers study exist. The studied populations (AD vs. PD), nature of 
involved task (fixating on a stationary cross vs. a search task) and types of eye 
movements (microsaccades vs. reflexive saccades) are all different. Yet the 
‘abnormal’ pattern of eye movements displayed by both MCI—amnesic MCI and 
PD-MCI— groups (assuming microsaccades and saccades are parts of a 
continuum; Martinez-Conde, Macknik, Troncoso, & Hubel, 2009) is similar; MCI 
participants’ eyes move up and down more than eyes of humans with normal 
cognition. Further research to clarify (or dispel) any relationship between our 
findings and those of Kapoula et al’s (2014) is axiomatic. 
 
Despite dissimilar search strategies, performance in the Maze trial was not 
significantly different between the groups. Neither the saccade rate (F2, 24 = 1.1, p = 
0.36) nor trial duration (F2, 24 = 1.6, p = 0.23) was found to be significantly different 
between NC, PD-N and PD-MCI participants. Furthermore, the Maze trial-specific 
score was not significantly different between the study groups. This latter variable, 
however, is probably less likely to be meaningful due to a floor effect. Only three 
participants (two NC and one PD-MCI) were able to locate Wally. 
 
 
5.6   Jeddah map search task 
 
5.6.1  Background 
 
In this task, the subject is shown a map of Jeddah, Saudi Arabia. In it are several 
copies of different symbols (e.g., petrol pump symbol signifying a petrol service 
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station). The subject is instructed to locate as many of the petrol station symbols as 
they can. This is aimed to examine visual selective attention. In essence, this task is 
similar to the familiar Map Search task of the Test of Everyday Attention (TEA; 
Robertson, Ward, Ridgeway, & Nimmo-Smith, 1996). 
 
Among neurological populations, map search tasks have been best described in 
traumatic brain injury (TBI) patients, followed by stroke patients (Lezak, 
Howieson, Bigler, & Tranel, 2012; pp. 426). Performance on the Map search and 
Telephone search subsets (of the Test of Everyday Attention) was the most 
sensitive indicator in differentiating moderate-to-severe TBI patients from normal 
controls (Bate, Mathias, & Crawford, 2001; Chan, 2000). Given the relative scarcity 
of data on map search task performance by PD patients, the Jeddah Map Search 
task was included in order to assess this; simultaneous recording of eye 
movements was hypothesised to enrich the data gathered by providing details on 
the strategy utilised by the searching participant. 
 




None of the participants was familiar with Jeddah’s geography. Participants were 
asked to look for petrol stations. The corresponding symbol (see Figure 5-28) was 
magnified and shown to participants prior to starting the task. Brief instructions 
(“Search for petrol stations. Press a key when looking at each one, and say when 
you have finished”) were also projected onto the screen prior to the start of the 
task. Participants were not told the total number of petrol stations shown in the 





Figure 5-28. The petrol station symbol 




The Jeddah Map Search task was made up of three identical trials. The last 
calibration-check target, immediately prior to stimulus presentation, was termed 
the ‘neutral point’. 
 
5.6.2.3 Task-specific calibration check 
 
Immediately preceding the presentation of each trial’s stimulus, participants were 
asked to fixate on six pre-selected targets which were presented one-at-a-time. The 
targets were distributed to give adequate coverage over an area marginally 
smaller than the field in which stimuli were presented (20o horizontally by 17o 
vertically). The targets were presented quasi-randomly; the last target was always 
the (0o, 9o) target (i.e., the neutral point), while the first five targets appeared at no 





Figure 5-29. The Jeddah Map Search task, with overlaid calibration-c 
heck targets. The circled target was always the last to be presented 




A freely available map of the Southwestern part of the researcher’s hometown in 
Saudi Arabia, Jeddah, was chosen for the last task. This visually cluttered map 
contained the names of streets and suburbs in both Arabic and English, as well as 
symbols for the various amenities (e.g., banks, hospitals, petrol stations, 
restaurants and supermarkets). Participants were asked to localise the petrol 
stations, of which there were six.  
 
All trials were initiated by the researcher by pressing a key on the main keyboard 
which led to the presentation of the trial stimulus. A wireless keyboard was 
provided to participants who were instructed to press any key whilst fixating on 
the petrol station symbol once they were confident they found one. The trial was 
ended by the researcher upon the participant reporting that they could not locate 






Participants’ eye movements were traced on the researcher’s screen in real time. 
No hints were provided for the participant once trials had started. Participants 
scored one point for correctly identifying a petrol station. No points were awarded 
for missed petrol stations. Participants were not penalised for incorrect responses. 
 
5.6.2.6 Trial duration 
 
The time the trial ended was recorded by BeGaze™. A mean duration (across the 
three trials) was calculated for each participant. 
 
5.6.2.7 Saccade data 
 
The Jeddah Map Search task was, in some ways, similar to Where’s Wally?™ in 
that participants had to search a large field for small targets. Therefore, it was 
more difficult to maintain complete tracking of eye movements compared with 
other tasks. When tracking was lost, the participant’s saccade data were not 
recorded. To accommodate this, it was decided to include saccade rate (i.e., 
saccades per second) whereby the number of recorded saccades was divided by 
the time during which tracking was available. 
 
Saccade data, rather than fixation data, were thought to be more meaningful to 
measure. Combined with saccade rate, the saccade amplitude was thought to be 
reflective of the participant’s search strategy. An upper limit of 26.2o (maximum 
possible amplitude) was applied to saccade amplitude. This provided near-









Acceptable data were available for a total of 38 participants: 12 NC, 14 PD-N and 
12 PD-MCI. Physical fatigue and technical difficulties were the two most common 
reasons data were not collected from ten participants. Several parameters (see 
below) were recorded, each of which had certain quality-assurance criteria. 
Participants’ data falling short of these criteria were discarded. Therefore, 
depending upon the parameter’s criteria, the total number of participants may not 
always be equal to the total number of participants completing the task. 
 
5.6.3.2 Correctness and trial duration 
 
In general, NC participants had the highest mean of correct responses and shortest 
mean of trial duration, compared with PD-N and PD-MCI participants. The 
differences between the means, however, were not statistically significant (see 
Table 5-13). In addition, mean aggregate scores for trial 1 (2.6 points ± 1.3), trial 2 
(3.0 points ± 1.2) and trial 3 (2.9 points ± 1.6) were not significantly different (F2, 71 = 
0.64, p = 0.53). 
 
Table 5-13. Comparing trial scores and durations of the study groups. 
 Correctness Trial duration 
NC PD-N PD-MCI NC PD-N PD-MCI 
N 10 13 8 12 14 12 
Mean 3.2 pts 2.5 pts 2.2 pts 34.6 s 36.6 s 53.0 s 
SD 1.3 pts 1.1 pts 1.0 pts 13.1 s 17.5 s 30.0 s 
ANOVA  F2, 28 = 1.8 F2, 35 = 2.8 
p 0.18 0.077 





5.6.3.3 Saccade data 
 
The mean tracking ratio across the three Jeddah Map Search trials was 76.4% 
(range, 24.5-95.3%). There was no significant difference in the mean saccade rate 
between NC (4.4 /s ± 2.4), PD-N (3.9 /s ± 1.5) and PD-MCI (4.2 /s ± 2.2), (F2, 28 = 0.19, 
p = 0.83). Furthermore, there was no statistically significant difference in the 
saccade amplitude between the study groups: 5.0o (± 1.6) for NC, 4.6o (± 0.5) for 
PD-N and 4.3o (± 0.4) for PD-MCI (F2, 28 = 1.1, p = 0.35). 
 




The number of participants for whom complete data were available was 
acceptable, albeit less than most other tasks. The chosen map of Jeddah, although 
conceptually mimicking TEA’s Map search task (Robertson et al., 1996), has no 
standardised performance normative data. The objective of this task was to 
compare performance on a search task between the three study groups, 
acknowledging external applicability may be limited. 
 
5.6.4.2 Correctness and trial duration 
 
Echoing results of other tasks in the behavioural markers study, PD-MCI 
participants trended, albeit non-significantly, towards a worse performance and a 
longer period of time for task completion. Perhaps the addition of a PD-D group 
would have resulted in a significant difference between the study groups; this 




Whilst general improvement in the performance of all participants across the three 
trials was expected, this was not observed. This could be due to a floor effect, since 
none of the participants was able to locate all six stations. Moreover, because 
participants were not given feedback whether their answers were correct or not, 
this may have led some participants to locate six targets but not all of which were 
correct. The latter explanation is less likely given the fact that incorrect responses 
were mostly random targets that differed from the petrol station symbol in shape, 
and sometime colour. 
 
5.6.4.3 Saccade data 
 
Significant between-group differences in saccade rate and saccade amplitude were 




5.7   Chapter summary 
 
This component of the behavioural markers study was conducted using bench-
mounted laboratory eye tracking. In the MoCA animal identification task, PD-MCI 
participants were significantly slower to fixate on the first animal of Trial1 (p = 
0.002) than NC and PD-N participants. The latency to fixating on the first animal 
of Trial2 by PD-MCI participants was significantly shorter (p = 0.016) than Trial1—
indicating a learning effect. This was not observed in Trial3 in PD-MCI 
participants, or in any of the trials by NC and PD-N participants. In addition, PD-
MCI participants scored significantly lower than NC and PD-N participants on the 




The overall results of the laboratory-based eye movement tasks were largely 
similar among the three study groups, however. It is vital to note that PD-MCI 
participants included in this study were selected from a cohort of PD patients who 
in fact fulfilled the diagnostic criteria of mild cognitive impairment as proposed by 
Litvan et al (2012). Inadequate screening of research participants (e.g., just using 
the MMSE) may lead to the potential inclusion of PD-D patients masquerading as 
PD-MCI patients (Fernandez, Crucian, Okun, Price, & Bowers, 2005). This, in turn, 
may exaggerate findings on neuropsychological tests that are otherwise milder or 
absent in PD-MCI participants. 
 
The addition of a PD-D group to this study will give a fuller picture of the 
association between eye movements and performance on neuropsychological tests 
in this disease. Based upon the above findings, it may be the case that PD-MCI 
participants compensate in their performance, only to deteriorate rapidly once 






















































6.1   Introductory remarks 
 
6.1.1  Study aims and hypotheses 
 
Dynamic tracking (i.e., using mobile apparatus) of eye movement abnormalities in PD 
patients—albeit technically more cumbersome and less robust—may in fact be more 
clinically relevant than static laboratory-based measurements. In addition, dynamic 
eye movement-tracking allows a closer investigation of eye movement abnormalities 
during ambulation (Lohnes & Earhart, 2011). The risk of falls in PD patients, 
especially those with gait freezing, is several-fold higher than in healthy age-matched 
controls (Pickering et al., 2007). Insights gained from eye movement analysis, for 
example during the performance of different types of daily activities, may aid in 
uncovering strategies to mitigate the significant morbidity and mortality associated 
with falls in patients with PD. 
 
Since measuring eye movement dynamics is objective, fast and non-invasive, we 
sought to examine the differences in eye movement behaviour in PD patients vs. 
healthy controls during the performance of selected neuropsychological and natural 
tasks. Study hypotheses have been described in the previous chapter. 
 
6.1.2  Laboratory settings 
 
6.1.2.1 Setting in the MoVELab 
 
Participants were seated on a desk chair with no arm rests, in front of a standard 120 
x 59 cm office desk. Tasks were presented to participants in paper-form, resting on a 
wooden board angled at 60o. The angled board was placed on the desk, centred 
horizontally, with the front of the angled board approximately 5 cm from the edge of 
the desk (see Figure 6-1). To accommodate for variations in participant heights, VA 
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and comfortable reading distances, participants could select their own seat location; 
most participants, however, positioned the chair approximately an arm’s length away 
from the angled board. 
 
 
Figure 6-1. Desk setting for the MoVELab tasks, which were presented to participants on the angled 
wooden board (illustration adapted with permission from Toh, 2016). 
 
Once familiarised with the laboratory setting, participants were fitted with the 
modified baseball cap, fitted with the two cameras of the iViewX™ HED system as 
described earlier. Then, participants were again allowed time to acquaint themselves 
with the head-mounted eye-tracker system prior to the onset of any tasks. 
 
Recordings from the left eye (i.e., tracking the left pupil) were the default. Recordings 
from the right eye, however, were necessary for four participants in whom adequate 
recordings from the left eye could not be obtained, despite multiple adjustments and 
calibration attempts. The iViewX™ HED system allows for recordings from either eye 
with no compromise of data quality (SMI, 2010). Participants who could not 
adequately visualise the tasks without spectacles were excluded, as these interfered 










6.1.2.2 Calibration protocol 
 
After adequate positioning of the participant, and prior to task commencement, a 
calibration procedure was undertaken. This comprised a manual process in which the 
eye-tracker was made to match raw eye-position data from each participant relative 
to fixation positions in the environment. Once seated in front of the desk, each 
participant was asked to fixate on verbally specified nine pre-selected targets printed 
on an A3-sized paper (as shown in Figure 6-2). The same calibration-check was 
constantly reviewed, and repeated if necessary, between tasks. Once satisfactory 
tracking was achieved, the calibration sheet was manually lifted by the researcher 
from the top left corner, revealing the task paper underneath. 
 
Figure 6-2. Calibration targets for the dynamic eye movement tasks. 
 
6.1.2.3 BeGaze™ settings 
 
Automated data on saccadic eye movements were computed by the BeGaze™ 
software (SMI, 2013) offline. During analysis, fixations with duration less than 50 ms 
or greater than 1 500 ms were excluded. Saccades with amplitude greater than 25°, or 
duration greater than 150 ms were also excluded. Saccades were filtered to include 
only those with start and end locations within the pixel dimensions of the scene video 
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(752 x 480). Therefore, saccades with a start or end locations less than zero, or greater 
than 752 or 480 for X and Y locations, respectively, were excluded. Saccades with 
locations outside these values represented instances in which eye tracking was lost at 
the start or end of the saccade, producing eye movement data that were invalid. 
Whilst several participants had low tracking rates, their data were included as valid 
information about measures, such as saccade amplitude and fixation duration, were 
still attainable from the period in which valid tracking occurred. 
 
Inability of the iViewX™ HED system to maintain tracking can occur due to a 
number of reasons, such as a high rate of blinking or ptosis of the eyelid of the 
tracked eye. Such conditions obstruct the camera’s view of the pupil, which is used to 
calculate the position of the eye. Participants with a high amount of lost tracking were 
excluded from the task-specific analysis in order to avoid analysing inaccurate 
fixation patterns. 
 
6.1.3  Study sample 
 
From an initial sample of 48 participants for the behavioural markers study, only 37 
participants were included in the dynamic eye tracking part. The most common 
reason for exclusion was the need to wear spectacles or contact lenses during task 
performance (n = 8); other reasons included persistent poor quality of data collected 
in previous tasks (n = 1) and refusal to continue due to physical and mental fatigue (n 
= 2). The remaining sample was made up of 13 NC participants, 12 PD-N participants 
and 12 PD-MCI participants. No significant changes to the previously described 







6.2   SDMT written task 
 
6.2.1  Background 
 
With the help of eye-movement tracking techniques, insights into participants’ 
oculomotor scanning patterns and visuomotor coordination may be gained. 
Additionally, I hypothesised that I would be able to capture more of any 
improvement in task performance (as assessed by trial-scores) upon repeating the 
task twice. Finally, tracking the participant’s eye movements can also allow for a 
deeper analysis of the quality of and the pattern behind a response; data that are not 
obtainable when using the oral version. 
 




The instructions were given verbally before the start of the task. Participants were 
specifically instructed to start with the top left box and proceed horizontally (i.e., left-
to-right) without skipping any boxes; once a row was completed, the participant 
would move on to the next row and so forth. Participants were not told that the task 
had a time-limit. However, only the first 90 s of each video were included in 




The iViewX™ HED eye-tracking system has been described in earlier sections. As 
stated previously, a red plus-sign was superimposed on the scene video to indicate 





Figure 6-3. Scene video from the head-mounted eye-tracker, showing a participant’s gaze position 
(red plus-sign) whilst completing the SDMT. Here, gaze is directed at the number in the Key below 
the symbol the participant is currently attempting to match. The participant is about to write the 
number associated with the given symbol in the Working Area. 
 
The output data was a scene video in which the objects in view could change location 
freely with the movements of the participant’s head. Hence, each fixation from each 
participant’s scene video were mapped onto a static reference image of the SDMT 
form, in order to aggregate the data. Using the BeGaze™ software, locations of 
fixations on the SDMT paper were determined by manually mapping the specific 
location of the gaze cursor to the corresponding location on the reference image. This 
was carried out in BeGaze™ by referring to the gaze location on the scene video and 
using a mouse to click on the location of the given fixation on the SDMT reference 
image. The iViewX™ HD scene video had a resolution of 752 x 480 pixels, whereas 
the reference image of the SDMT paper had a resolution of 1 240 x 1 753 pixels. 
Therefore, fixations were transferred from the landscape-orientated scene video to the 













Figure 6-4. Fixation position image generated in BeGaze™ for one of the 
participants. Circles indicate the locations of fixations, and the diameter of 
each circle indicates the fixation duration. Fixations during the practice phase 
(i.e., the first 10 boxes) were excluded. Image credit: Ms Maddie Pascoe. 
 
6.2.2.3 Definitions and task protocol 
 
The SDMT written task was made up of two identical trials: SDMT1 and SDMT2. A 
period of at least 15 minutes was always allowed between the two trials (see Figure 6-
5). During this period, participants were made to take a break and engage in 
unrelated conversation in order to minimise mental rehearsal of the SDMT task. Only 
data from the SDMT1 trial were used for eye movement analyses. One point was 
allocated to each correctly identified symbol within the 90 s time-frame. Because the 
effect of wearing the head-mounted eye tracker on task performance was unknown, 






Figure 6-5. A visual representation of the order in which the SDMT 
trials were presented. In the intervening time between the two trials, 
participants engaged in other tasks(s) over a period of ≥ 15 minutes 
(adapted SDMT version from Benedict et al., 2012). 
 
6.2.3  Results 
 
6.2.3.1 SDMT scores 
 
Scores for the SDMT1 task (F2,35 = 4.0) were significantly lower in PD-MCI patients 
(25.8 points ± 4.9) compared with NC participants (35.4 points ± 11.5, p = 0.01) and 
PD-N patients (33.4 points ± 7.5, p = 0.04). Significant score improvements between 
the two SDMT trials were observed in NC (t12 = -5.2, p < 0.001), PD-N (t11 = -5.1, p = 
0.001) and PD-MCI participants (t9 = -4.5, p = 0.017). The magnitude of the effect is 











Figure 6-6. The per-group score improvement between SDMT1 and SDMT2 trials: 
NC participants' scores improved by a mean of 7 points, PD-N participants' by 9.8 
points and PD-MCI participants' by 8.9 points. Error bars represent one standard 
deviation above and below the group mean. 
 
6.2.3.2 Correlations between SDMT scores and participant demographics 
 
No difference was found between male vs. female participants. Age was significantly 
negatively associated with SDMT scores (r = -0.55, p < 0.001; see Figure 6-7), whereas 
education was significantly positively associated with the scores (r = 0.45, p < 0.001). 
For PD patients, SDMT scores were correlated with UPDRS-III scores (r = -0.47, p = 





Figure 6-7. The overall significant negative correlation between age and mean SDMT scores was also found 
within each group. 
 
 
Figure 6-8. There was an overall negative correlation between UPDRS-III scores and SDMT scores. When 





6.2.3.3 Eye movement parameters 
 
The mean fixation duration was similar among the three groups: 287 ms ± 77 for NC, 
326 ms ± 75 for PD-N and 289 ms ± 52 for PD-MCI. Saccade amplitudes (NC, 5.3o ± 2; 
PD-N, 3.9o ± 1; PD-MCI, 4.7o ± 2.2) did not differ significantly (F2,33 = 2.1, p = 0.14). The 
mean number of fixations did not differ significantly between the study groups: NC, 
226.1 fixations ± 58.1; PD-N, 227.7 fixations ± 39.9; PD-MCI 212.1 fixations ± 63.9 (F2,33 
= 0.28, p = 0.76). Secondary analyses of location-specific (i.e., Key vs. Working Areas) 
fixation numbers also yielded no significant between-group differences. 
 
6.2.3.4 Correlations between mean SDMT scores and eye movement data 
 
Scores on the SDMT were not correlated with the proportion of fixations on the Key 
Area to the Working Area (r = 0.2, p = 0.28). Additionally, no significant correlation 
was found between the SDMT score and mean fixation duration in the Key Area (r = 
0.1, p = 0.4) or the Working Area (r = 0.1, p = 0.4). 
 
6.2.4  Discussion 
 
6.2.4.1 SDMT performance 
 
The present study investigated the performance of PD participants and matched 
controls on the SDMT while recording eye movements. PD-MCI participants scored 
significantly lower than NC and PD-N participants. Repetition of the task, however, 
resulted in significant score improvements in all three study groups. Eye-movement 





Age and education were found to be significant predictors of performance on the 
SDMT, in accordance with a number of previous findings from healthy (Kiely, 
Butterworth, Watson, & Wooden, 2014) and old MS populations (Charvet, Beekman, 
Amadiume, Belman, & Krupp, 2014; Van Schependom et al., 2014). 
 
The mean SDMT score of the PD-N group was similar to that of the NC group, 
indicating comparable performance on the SDMT, despite PD-related motor deficits. 
This may support the use of the written SDMT early in the course of the disease in 
patients with PD. Among PD participants, higher UPDRS-III scores were associated 
with significantly lower SDMT scores—a finding which could favour the use of the 
verbal SDMT in patients with advanced motor symptoms. However, even with 
similar UPDRS-III scores, PD-MCI participants scored significantly lower on the 
SDMT compared with PD-N participants (see Figure 6-8). This emphasises the 
contribution of cognition—in addition to the general motor ability—to the deficit 
evident in the PD-MCI group, and corroborates previous findings (Beatty, Staton, 
Weir, Monson, & Whitaker, 1989). 
 
6.2.4.2 SDMT repetition and score improvement 
 
Performance on the SDMT significantly improved—as defined by an increase in the 
trial-score—in participants from all study groups. With the novel task design (i.e., 
employing eye movement tracking), we propose an explanation underlying this 
improvement. We posit that the Key is used as ‘external memory’ during the SDMT. 
Rather than expending cognitive energy on learning the symbol-digit pairs, 
participants appear to utilise their ability to use rapid eye movements to seek 
information. We speculate that upon task repetition, participants’ fixations within the 
Key Area became more efficient (i.e., faster to locate symbols within the Key), 
potentially leading to faster completion of task rows with negligible effect on 
accuracy. This fits in part with findings by Denney and colleagues on a computerised 
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version of the SDMT (2015). Working memory could be employed to learn symbol-
digit pairs during the test, but perhaps due to the time-constrained nature of the test, 
saccadic eye movements to the Key Area appear to be favoured as the optimal 
strategy. 
 
6.2.4.3 Eye movement parameters 
 
Despite strong differences in task performance, analysis of eye movement data 
yielded few differences in eye movement measures between the groups. Our eye 
movement findings are different to those reported by Elahipanah and colleagues in a 
group of patients with schizophrenia performing the SDMT (2011). Compared with 
controls, schizophrenia patients were observed to make more visits to the Key Area 
per response, and to spend more time in the Key Area per visit (Elahipanah et al., 
2011). Direct comparison between the two studies, however, may be problematic due 
to two caveats; the pathologies studied (PD vs. schizophrenia) involve distinct 
pathophysiological underpinnings. Moreover, Elahipanah et al used a computerised 
verbal version of the SDMT in which completed responses were immediately 
obscured—therefore, participants could only refer to the Key Area for guidance on 
symbol-digit pairings (2011). In contrast, there was nothing to prevent participants in 
our study from looking at previously completed symbol-digit pairs—rather than the 
Key Area—to retrieve the correct response. 
 
6.2.4.4 Limitations and future research 
 
Participants were required to wear the head-mounted eye tracker which may have 
caused distraction, thus impairing performance—although NC and PD-N 
participants showed similar performance, which may argue against PD participants 
being differentially impacted by such influence. The contribution of other factors, 
such as peripheral vision, on the performance of participants could not be 
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ascertained. Hence, data on the SDMT repetition task must be interpreted with 
caution. More detailed eye movement analyses, perhaps in conjunction with both the 




6.3   Natural task: tea making 
 
6.3.1  Background 
 
6.3.1.1 Domestic tasks 
 
In performing day-to-day tasks, human eye movements require precise coordination 
with, for example, hand movements. In other words, such domestic activities are 
carried out as a series of visually-guided actions, orchestrated together by a higher-
level representation of the task in hand (i.e., a mental “script”; Land, Mennie, & 
Rusted, 1999). 
 
6.3.1.2 Tea-making  
 
Eye movements of human subjects preparing cups of tea were initially intensively 
studied by Michael Land—a fittingly British neurobiologist. With colleagues, he 
examined the pattern of task completion in a number of subjects. The resultant 
patterns were highly consistent among the studies’ subjects (Land et al., 1999). 
Human eyes deal with one object at a time, with the time spent on each object 
approximating that of the duration of object manipulation; a number of fixations 
occur on different parts of the manipulated object. Second, saccadic eye movements 
were almost exclusive to task-relevant objects, despite a plethora of other objects in 




6.3.1.3 The role of eye movements 
 
As demonstrated by Land et al (1999), healthy subjects tend to fixate on objects prior 
to manually operating them. Our group has previously shown that—in pure 
oculomotor laboratory-based tasks—PD patients exhibit anticipatory saccades 
relative to controls; particularly in response to multi-step rhythmical sequences (M. R. 
MacAskill et al., 2012). This is postulated to be a compensatory mechanism for the 
hypometric saccades in PD. No study to date has examined eye-hand coordination in 
PD participants completing a natural task. We sought to examine if the anticipatory 
asynchrony between fixations and hand actions is preserved in our PD participants. 
 
6.3.2  Methods 
 
6.3.2.1 Task protocol 
 
After the completion of the SDMT2 trial, the angled wooden board was removed from 
the desk. A covered tray was then placed on the desk (as shown in Figure 6-9); care 
was taken to avoid making any noise which would have suggested the contents 





Figure 6-9. The covered tray was initially shown to participants prior to commencing the tea-making 
task. The red plus-sign indicates the position of the participant's gaze position. 
 
Prior to unveiling the tray, the quality of the eye-tracking (as shown on the iViewX™ 
HED computer) was visually inspected by the researcher—however, there was no 
formal calibration process per se for this task other than the calibration conducted in 
the immediately preceding task. 
 
Upon revealing the tray, participants were asked to “please make a cup of tea, with 
milk and one sugar”. The blue plastic tray contained all the items required for 
successful completion of the task. These included (starting from the 12-o’clock-
position and moving clockwise): sugar bowl (filled with granulated white sugar to 
around 75% capacity), teapot (filled with lukewarm black tea to about 75% capacity), 
tea cup placed upside-down on a saucer with a teaspoon to its left and a milk jar 
(filled with trim milk to about 50% capacity). 
 
The arrangement of the tray contents was identical for all participants (see Figure 6-
10), except with the two left-handed NC participants, for whom a mirror-image 




Figure 6-10. Contents of the uncovered tray for the tea-making task. The red plus-sign indicates the position of 
the participant's gaze. 
 
6.3.2.2 Task duration 
 
The total duration to task completion was measured; this was regardless of the need 
to prompt the participant at the start or initial hesitations. The end of the task was 
marked by the removal of the teaspoon from the tea cup (after dissolving the sugar) 
and placing the teaspoon on the saucer. 
 
6.3.2.3 Task execution 
 
This does not relate to the old-age question of how the perfect cup of tea is made (as 
this has already been fathomed by experts in the field3). Rather, the time between 
fixating on the cup and the beginning of each substance’s (milk, sugar and tea) pour 
was measured. Positive values indicate that the participant fixated on the spout until 
                                                          
3 Emsley, B. (2014). How to make a Perfect Cup of Tea. News release: Royal Society of Chemistry.  





after the pour began; negative values, on the other hand, designate fixating on the 
cup prior to pouring of the substance. 
 
6.3.3  Results 
 
6.3.3.1 Task duration 
 
NC participants (38.2 s ± 7.3) completed the tea making task significantly faster (F2,35 = 
10.23) than PD-N (51.8 s ± 9.3, p < 0.001) and PD-MCI (50.5 s ± 8.3, p = 0.001) 
participants. There was no statistically significant difference between the two PD 
groups. 
 
6.3.3.2 Task execution 
 
A significant task-effect was found upon task execution (F2,35 = 10.8, p < 0.001), such 
that fixations to the cup preceded sugar-tipping, occurred around the same time milk 
was poured and lagged behind pouring of the tea (see Figure 6-11). Although several 
PD participants (n = 4) were observed to exhibit slight action tremor during task 
execution, this did not adversely affect their performance, and no group difference 





Figure 6-11. Despite a number of participants making markedly early cup fixations, the overall task execution 
pattern was similar among all participants (reproduced with permission from MacAskill, Alamri, Myall, 






Figure 6-12. A strong task-effect is observed: cup fixations occurred prior to sugar-tipping, close to milk-pouring and after tea-pouring. This task organisation was largely 




6.3.4  Discussion 
 
6.3.4.1 Task duration and execution 
 
The finding of slower task performance by PD participants was not unexpected; 
bradykinesia is one of the cardinal symptoms of PD (Cavanaugh et al., 2015). Given 
that the overall task execution strategy was similar between all participants, the 
longer duration to task completion is, therefore, unlikely to have been due to task 
organisation differences. 
 
The rationale behind the differential, albeit consistent, fixation times vis-à-vis 
substance pouring remains speculative. We propose two hypotheses: the poured 
volume of tea is generally much larger than those of milk and sugar, and thus, a 
person spends more time performing this sub-task; the eyes consequently fixate on 
the spout until such time that the end of the pour nears, at which point a saccade is 
then made to the cup. A second hypothesis—although not necessarily mutually 
exclusive to the first—is that the person realises the more ominous consequences of 
spilling a hot liquid (compared with cold milk), and hence ensure a ‘closer eye’ is 
kept on the pouring tea. 
 
6.3.4.2 Summary and future research 
 
PD participants generally had preserved task organisation. Some participants (more 
so from the PD groups) made a few very early fixations to the next object in the task 
sequence. We posit this is probably in compensation for the motor slowing related to 
PD. Whether deficits in aspects of cognitive domains—for example, dysfunction of 
forward planning (Ogden, Growdon, & Crorkin, 1990)—have contributed to our 






































7.1   Overview 
 
The aim of this thesis research was to examine biomarkers that reflect progression 
during the course of the disease process in patients with PD. Findings from the 
different biological and behavioural markers are highlighted in the following 
sections. 
 
7.1.1  Findings from the biological markers study 
 
The blackcurrant trial was the first of its kind to investigate the presence of 
blackcurrant anthocyanins in human CSF. The a priori hypothesis was that 
blackcurrant anthocyanins would be detectable in plasma and possibly also in 
CSF. However, we demonstrated that anthocyanin species were not present in CSF 
(or plasma) post-oral ingestion of anthocyanin concentrate extracted from 
blackcurrants. The significant increase in the plasma concentration of a number of 
other metabolic by-products—including EGC and kaempferol—after blackcurrant 
supplementation has not been previously studied in in vivo studies.  
 
Given the lack of blackcurrant anthocyanins in CSF, we then attempted to examine 
for an indirect effect of blackcurrant consumption on the CNS cellular or 
extracellular milieu. One way was by measuring the concentrations of IGF-1 and 
related molecules in CSF and plasma. We found CSF concentrations of cGP (a 
metabolite and regulator of IGF-1) increased significantly after blackcurrant 
supplementation. This is a novel but very preliminary finding. If replicated, such a 
finding may lead to the establishment of a unique biological marker in PD 
research. 
 
We also measured CNP and NTproCNP levels in the available biofluid samples. 
Contrary to our hypothesis, we found PD participants had significantly lower CSF 
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concentrations of NTproCNP (in samples from both pre- and post- blackcurrant 
supplementation) compared with a normal reference range. This was also a novel 
finding, and was concordant with findings from stored samples obtained from the 
original DATATOP study (Espiner, Dalrymple-Alford, Prickett, Alamri, & 
Anderson, 2014). Since the reference group only reported CSF concentrations of 
NTproCNP (Schouten et al., 2011), we were unable to directly compare 
NTproCNP concentrations in plasma—a much more easily accessible biofluid. 
However, head-to-head comparisons of plasma concentrations of CNP and related 
metabolites in PD patients and healthy controls are currently underway (Z. 
Woodward, personal communication, December 20, 2016). 
 
Finally, we characterised the profile of CSF and plasma exosomes in our PD 
participants using TRPS. Using this technique, we describe—for the first time—a 
tentative observation of finding the highest plasma exosome concentrations in the 
three participants with the lowest MoCA scores (Alamri, Vogel, MacAskill, & 
Anderson, 2016). Given the small number of samples, a correlation could not be 
statistically examined, and the result should, therefore, be interpreted with 
caution. 
 
7.1.2  Key findings from the behavioural markers study 
 
There were few differences among the study groups in performance-eye 
movement associations. However, we gained important insights into oculomotor 
behaviour during neuropsychological task completion in both healthy controls 
and PD patients. Such behaviour was generally similar across NC, PD-N and PD-
MCI participants, with a few differences that perhaps reflect the underlying 




In the animal identification task, we showed that most participants, irrespective of 
group, tended to fixate on the animal’s head in order to name it—with the areas of 
fixation interest being smaller for animals with ‘distinctive’ features (e.g., giraffe 
and kangaroo) than those with fewer unique features (e.g., donkey and domestic 
pig).  
 
Examination of the JLO tasks revealed a higher fixation density on the distal ends 
of the Scanning Area lines than the proximal ends—a similar pattern to that 
reported of fixations upon viewing a clock face (Mosimann, Felblinger, Ballinari, 
Hess, & Müri, 2004). On the Where’s Wally?™ Maze task, we found PD-MCI 
participants made significantly more vertical saccades than NC and PD-N 
participants. This may be the first report of such difference in directional visual 
pattern in PD. Whilst such difference in eye movements may be difficult to find in 
the clinic (i.e., as a bedside biomarker), they can be recorded in the laboratory 
setting (i.e., functional biomarker). Kapoula et al found a similar higher proportion 
of vertical microsaccades has been reported in AD and amnesic MCI patients 
(2014), although the underlying mechanism(s) of their findings may be different. 
 
Using the mobile eye movement tracker system, we were uniquely positioned to 
assess eye movement behaviour in relation to the performance of dynamic tasks. 
On the SDMT task, we found PD-MCI participants obtained significantly lower 
points on the task-score than NC and PD-N participants—potentially providing a 
relatively easy-to-administer bedside neurocognitive marker of PD. This task-
score different was despite similar motor (i.e., UPDRS-III) and oculomotor (i.e., 
eye movement parameters) performance among the participants. In the tea-
making task, we found a largely preserved task organisation—albeit slower to 
execute in PD participants—whereby fixations to the cup preceded sugar flow, 
occurred around the same time as milk flow and succeeded tea flow. These 
findings were in accordance of our hypothesis that eye movement analyses would 
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aid in gaining greater insight into the effect of PD on oculomotor control when 
patients attempt neurocognitive tasks. 
 
7.1.3  Other findings 
 
Significant collateral findings—not directly related to the studies’ end-points—
were reported throughout the thesis. The safety and efficacy of research LP 
(Peskind et al., 2005) was reiterated (Chapter 3). In particular, participants 
appreciated the repeated explanation of and reassurance prior to the procedure, 
which may have helped alleviate their anxiety (Alamri, MacAskill, & Anderson, 
2016b). We also found our PD participants scored significantly lower on the HADS 
depression-subscale (Chapter 5) compared with a PD group from Saudi Arabia 
(Alamri, Al-Busaidi, MacAskill, & Anderson, 2015). 
 
 
7.2   Critique of the biomarkers studies 
 
7.2.1  Strengths 
 
The behavioural markers study was designed as a case-control study, and controls 
were matched for age, education and sex. One of the main strengths of the 
behavioural markers study was the inclusion of a well-characterised group of PD-
MCI participants. These were participants who satisfied the current diagnostic 
criteria for PD-MCI (Litvan et al., 2012). 
 
The various components of the two studies targeted a pathophysiological aspect of 
PD at a certain stage of the disease process. Although there is ample literature on 
the need to utilise several PD biomarkers in concert, there is a paucity of studies 
that actually do so. This project not only included biomarkers of different categories 
257 
 
(i.e., progress and monitoring biomarkers), but also of different types (i.e., bedside 
tests, biochemical investigations and laboratory studies), as well as undergoing 
different analyses (i.e., both quantitative and qualitative). 
 
7.2.2  Limitations 
 
The low number of participants in both studies is a potential weakness. For the 
biological markers trials, an upper limit on the number of participants was set by 
the Ethics Committee due to concerns about participant safety and wellbeing in 
relation to the need to have repeated LP. As it happened, feedback from 
participants of the biological markers trials (Chapter 3) supported the safety and 
acceptability of repeated LP for research purposes (Alamri, MacAskill, et al., 
2016b). Owing to the smaller number of enrolled participants, power analysis 
showed a reduction of calculated power from 0.68 to 0.47, with a subsequent 
increase in the chance of a Type II error. 
 
For the behavioural markers study, effective recruitment may have been, in 
retrospect, stymied by two factors—restrictive inclusion criteria and disruptions 
after the 2011 Christchurch earthquake. Matching PD participants with each other 
(i.e., PD-N with PD-MCI), as well as with NC participants—for age, education and 
sex—severely limited the pool of participants available for the study. Moreover, in 
the aftermath of the earthquake in February 2011, potential Christchurch 
participants were probably focussed more on immediate needs (e.g., health, 
family, safe accommodation and getting back to work) than on volunteering to 
participate in the research studies. Closure of buildings for safety inspections 
(including the Van der Veer Clinic and the New Zealand Brain Research Institute) 




The omission of a PD-D group in the behavioural markers study might be 
considered a further limitation. Recruitment of dementia patients in research can 
be challenging even under ideal conditions (Cooper, Ketley, & Livingston, 2014; 
Fargo, Carrillo, Weiner, Potter, & Khachaturian, 2016). The recruitment of 
sufficient numbers of local PD-D participants who satisfied the study’s inclusion 
criteria for age, education and sex would have been challenging and likely not 
feasible. However, adding a group with PD-D in any future studies would 
provide a more picture of eye movement-performance associations in PD. 
 
 
7.3   Implications and future directions 
 
Biomarkers remain an essential element of PD research and a much-needed 
component of the clinical diagnosis, monitoring and management of PD patients. 
With substantial concerted efforts currently under way to uncover new and ‘re-
purposed’ already-available biomarkers for PD, it is difficult to foretell what the 
future beholds (Alamri, MacAskill, & Anderson, 2016a). Akin to the recently 
proposed A(myloid)/T(au)/N(euronal injury) classification of AD biomarkers (Jack 
et al., 2016), it may well be the case that several PD biomarkers—of different 
categories based upon the patho-physiological parameter(s) they measure— need 
to be used in combination to generate a similar descriptive scheme. 
 
The many findings of the two studies comprising this thesis raise a number of 
questions. The underlying mechanism of the putative effects of berry-fruit 
consumption on neuronal health remains unanswered. If anthocyanins do exert a 
neuroprotective effect, this would need to be examined in a sizeable double-blind 
trial—although the absence of anthocyanins in CSF found in the present study 
would suggest that any such benefit might be indirect. If such putative 
neuroprotective effects are instead exerted by other indirect mechanisms, the 
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underlying mediator(s) ought to be further studied. In the case of IGF-1 and 
related molecules, for example, this could include examining samples from PD 
patients with high dietary berry-fruit intake for the interplay between dietary 
habits and intrathecal cGP and IGF-1—and any downstream effect(s) on the 
presumed IGF-1-resistance in PD. 
 
Independent of blackcurrant anthocyanin supplementation, an obvious next step 
for CNP-related research is to directly compare the concentration of NTproCNP in 
plasma—a more easily accessible biofluid than CSF—in PD patients and matched 
healthy controls. If significant differences between healthy controls and PD 
patients are found in plasma concentrations of NTproCNP, this may lead to the 
development of a clinically useful diagnostic biomarker for PD. 
 
Plasma exosome concentrations may be useful to compare in a large sample of PD-
N, PD-MCI and PD-D patients to rigorously assess for any correlations with 
cognitive status. In addition, the technology utilised in the present study did not 
analyse exosome contents. Given the recent findings of a correlation between 
levels of α-synuclein in CSF-derived exosomes and the cognitive status of PD 
patients (Stuendl et al., 2016), examination of a similar correlation with plasma-
derived exosomal contents is warranted. 
 
Detailed quantitative analyses of the several tasks included in the behavioural 
markers study were largely beyond the scope of this thesis, but provide ample 
opportunity for future research. For instance, areas of fixation interest may be 
mathematically calculated in order to quantitate any differences between healthy 
controls and PD patients (or among well-characterised PD-N, PD-MCI and PD-D 
patients). Likewise, utilising eye movements, erroneous answers can be 
categorised and the per-group differences in each category calculated. Such 
further studies would permit a more detailed exploration of oculomotor 
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behaviour in PD, and perhaps thereby provide a greater insight into behavioural 
and cognitive sequelae of this condition. 
 
Closer study of ‘problem-solving’ strategies—for example, by investigating eye 
movements between Scanning/Key and Working Areas—is also warranted. The 
effects of cultural and experiential factors could be studied more closely in relation 
to different neuropsychological tasks. Additional eye movement parameters, such 
as look-ahead fixations (Mennie, Hayhoe, & Sullivan, 2007), could be incorporated 
into investigations of oculomotor behaviour during natural tasks. Finally, 
extending this line of research to encompass other neuropsychological and natural 
tasks in patients with PD (of varying cognitive status) might uncover behavioural 
biomarkers that prove useful in the prognostication of PD—or more usefully—as 
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British spelling was adopted throughout this thesis, except in direct quotes and 
referenced items published in resources that employ the American spelling. 
Likewise, the possessive form of all eponymous diseases (e.g., Parkinson’s disease 
instead of Parkinson disease) was used, with exceptions arising from direct quotes 
and certain references. 
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Supplementary Figure 1. Frequency of year of publication for references cited in this thesis (n = 542). 
References in press have been included in the 2011-2016 period. 
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